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Summary
The generally accepted structure for KS type I has been proposed to be composed of a 
pattern of non-sulphated N-acetyl-lactosamine disaccharides located next to the 
linkage region oligosaccharide, with mono-sulphated N-acetyl-lactosamine in the mid­
regions of the KS GAG chain and disulphated N-acetyl-lactosamine disaccharides 
concentrated towards the non-reducing end of the KS chain (Oeben et al, 1987; 
Stuhlsatz et al., 1989). The generic structure for KS type II has been reported to occur 
with a similar pattern but with a predominance of disulphated and occasional 
interdispersed monosulphated N-acetyl-lactosamine residues present throughout the 
KS glycosaminoglycan chain (Stuhlsatz et al, 1989). A novel KS monoclonal 
antibody (mAb) recognising a keratanase-generated KS ‘stub’ neoepitope was 
developed and used in conjunction with mAb 5D4 (recognising linear sulphated 
motifs) to analyse the sulphation pattern of KS from cornea and cartilage. The results 
of these analyses have demonstrated that KS types I and II chains both contain a 
combination of differentially sulphated (mono- versus di- versus unsulphated) N- 
acetyl-lactosamine domains. In the bovine model different tissue sources of KS most 
likely produce similar varieties of KS disaccharide structures, but that sulphation 
patterns are more randomly located along the KS chain than previously reported.
Two mAbs were also generated to the small leucine rich KS proteoglycans lumican 
and keratocan. They were used in the identification of low and increased levels of 
these ‘comeal associated’ PGs in musculoskeletal tissue locations with pathology. 
Collectively the data challenges the generic structure for KS and proposes a range of 
KS chain structures that are more heterogeneous in nature, even from within the same 
tissue sources, than previously thought. The work also suggests that the expression of 
the KSPGs, lumican and keratocan, may be useful biomarkers to detect cellular 
changes in metabolism that lead to the onset of degenerative joint disease.
Chapter 1 -  Introduction
1.1 Connective Tissues 
Connective tissues are composed of a number of structurally and functionally 
organised extracellular matrix (ECM) components, including water, ground substance 
and matrix fibres that are produced and maintained by specific connective tissue cells. 
These all act together to provide a physiologically stable tissue environment where 
highly specific functions can proceed. Diversity in the amounts and type of the matrix 
molecules produced within a tissue give rise to variations in physical properties of a 
tissue. Traditionally, the ECM was thought of as a stability structure, a scaffold for the 
physical elements of a particular connective tissue. While it does act as such, it also 
assumes a detailed matrix composition where components display an active functional 
role in regulating a variety of developmental and physiological processes.
The major components of connective tissue ECMs include an intricate network of 
twisted collagen fibrils of indefinite length which act as an architectural scaffold to 
trap and position a matrix of highly hydrated proteoglycan molecules and matrix 
glycoproteins. The following subsections will review what is currently known about 
the structure and function of this matrix in different connective tissues with an 
emphasis on cartilage, intervertebral disc and cornea.
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1.2 Connective Tissue Collagens
Collagen is an insoluble extracellular structural protein. It is found in abundance (25% 
of all body protein) through connective tissues of all multi-cellular animals and is an 
essential structural component of many connective tissues such as bone, cartilage, 
cornea, skin, tendon and ligaments. Through tissue specific expression, it functions in 
conjunction with other matrix molecules in providing tensile strength to a tissue. 
Collagen is a heterogeneous population of molecules. Currently there are 27 different 
known collagens (Fitzgerald & Bateman, 2001; Koch et al., 2001 and 2003; 
Hashimoto et a l, 2002; Sato, 2002; Tuckwell, 2002; Boot-Handford et al., 2003) 
(table 1.1) based on the supra-molecular structures of a combination of different a  
chains, which are encoded by a number of genes (Robert et al., 2001; Eyre, 2002; 
Gelse et al., 2003; reviewed by Michelacci, 2003). They are divided into a number of 
classes based on these different molecular structures and assemblies: fibrillar; fibril 
associated collagens with interrupted triple helix (FACITs), network forming 
collagens, basement membrane collagens, microfibrillar collagens, anchoring 
collagens, transmembrane collagens and multiplexins. Despite the differences between 
collagens they all share a characteristic triple helical structure with [Gly-X-Y] repeats, 
where X and Y are often proline and hydroxyproline, respectively (Michelacci, 2003, 
review). The position of the glycine is essential for triple helical structure. Other 
amino acids face outwards and glycine faces inwards and form hydrogen bonds which 
are important in stabilisation of the collagen triple helical structure. Glycosylation 
may also occur on collagens in the endoplasmic reticulum and Golgi complex, 
resulting in a monosaccharide Galactose p - O linkage or a disaccharide Glucosamine 
a l  -  2 Galactose p i - linkage to hydroxylysine with N-glycans linking to asparagine
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in collagen types IV-VI and chondroitin sulphate (CS) attaching to serine in collagen 
types IX, XII and XTV.
Fibril forming collagens include types I, II, III, V, XI and XXTV (table 1.1). Three a  
chains twist into a left handed elongated triple helix through formation of disulphide 
bonds between chains to form a procollagen molecule which assemble into cross- 
striated fibrils, where three quarters of two procollagen molecules overlap, to form 
fibrils of uniform diameter, with each molecule showing displacement of 1/4 of its 
length along the axis relative to the next collagen molecule (reviewed by Kadler et a l , 
1996). These organised structures are characteristic of the ECM and give the tissue its 
characteristic tensile strength.
FACITs do not form fibrils but associate with those that do. They include collagens 
IX, XII, XIV, XVI, XIX, XX, XXI and XXII (table 1.1) (Koch et a l , 2001; Tuckwell, 
2002). They share a common motif and they all have one or two triple helical domains 
separated by non-triple helical domains giving them more flexibility than fibrillar 
collagens. They bind fibrillar collagens and are thought to mediate interactions 
between them and other matrix molecules (reviewed by Gelse et a l , 2003; Shaw & 
Olsen, 1991).
Network forming collagens include types IV, VIII and X. The collagens of this family 
assemble by association at the carboxyl and N-terminus to form two-dimensional 
cross-linked networks, which form stabilised structures.
The following discussion is primarily concerned with collagens which are present in 
cartilage and corneal stroma ECM, a brief description of each is given below.
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Table 1.1
Collagen classification.
Type
Fibril-forming I, II, III, V, XI, XXIV
FACITs EX, XII, XIV, XVI, XIX, XX, XXI
Network forming VIII, X
Anchoring VII
T ransmembrane XIII, XVII, XXV, XXIII
Multiplexins XV, XVIII
Basement membrane IV
Microfibrillar VI
Other XXII, XXVI
Adapted from Gelse et al., 2003
Type I  collagen:
This is a heterotrimer composed of [a l (I) ] 2  and a2 (I) chains. It is a fibril forming 
collagen which accounts for a large portion of comeal collagen where it assembles 
with type V collagen to form single heterotypic fibrils which may be important in the 
regulation of uniform fibril diameter in the cornea which is essential for transparency 
(Birk et al., 1988). It also accounts for 90% of the organic bone mass (reviewed by 
Gelse et al., 2003). It is the major collagen found in large amounts in skin and tendon 
and is a minor component of cartilage where it is enriched in the lamina splendens of 
the superficial zone of articular cartilage (Duance, 1983).
Type II collagen:
This is a fibrillar collagen made up of a homotrimer of the form [a l (II) ] 3  and 
possesses hydroxylysine-linked galactose residues. It is the main cartilage collagens, 
where it forms heterotypic fibres with collagens IX and XI. It is also expressed in the 
vitreous of the eye (Bishop et al., 1994) in the notochord, the developing eye, foetal 
brain and in the developing skeleton where it is essential for endochondral ossification 
(Li et al., 1995). There are only minor amounts of type II collagen found in the
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cornea. Collagen II in non-pathological articular cartilage shows a turnover with a half 
life of over 100 years (Knudson & Knudson, 2001, review). Mutations of this collagen 
cause chondrodysplasia, a disorder characterised by dwarfism, joint and skeletal 
deformities (reviewed by Kuivaniemi et a l , 1997). Electron microscopic analysis 
shows collagen II fibril structures that have become crosslinked through head-to-tail 
hydroxylysyl pyridinoline residues (reviewed by Eyre, 2002).
Type III collagen:
This is a fibril forming collagen composed of 3 identical [a l (III)]3 chains (table 1.1). 
It is the major component of vascular tissues. In cartilage, it is found in low amounts 
(Young et a l , 2000) and the extent to which it is expressed depends on the ECM 
condition surrounding the chondrocyte. An increase is observed in chondrocytes of 
human osteoarthritic cartilage (Aigner et a l, 1993) and in wounded comeal tissue 
(Cintron et al, 1988; BenEzna & Foidart, 1981; reviewed by Steele, 1999) and may be 
made in response to matrix damage and inflammatory responses (Aigner et a l, 1993).
Type V collagen:
Type V collagen is a fibril forming collagen which has a [a l (V)]2 a2 (V) chain form 
(table 1.1). It is found in the comeal stroma where it co-polymerises together with 
collagen I monomers within the same fibril to help regulate fibril diameter, essential 
for transparency in the avian comeal stroma (Birk et a l, 1988).
Type VI collagen:
This is a non-fibrillar network forming collagen with a a l  (VI), a2 (VI) and a3 (VI) 
heterotrimer found in most connective tissues (table 1.1). It is a major component of 
human comeal connective tissue making up 17% of total comeal collagens
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(Zimmermann et al., 1986). It interacts with decorin core protein and other matrix 
proteins where it is thought to anchor cells to PGs and hence may have a role in 
regulating the structural organisation of the ECM (Bidanset et al., 1992). In cartilage it 
forms a disulphide bonded structure involved in providing a fibrillar meshwork which 
surrounds and protects the chondrocytes (Chang & Poole, 1996). It is involved in 
regulation of fibril spacing and corneal transparency (Nakamura et al., 1992). In 
cartilage it is predominantly found in lacunae surrounding the chondrocytes where it 
forms a fibrillar network that protects the chondrocytes from compressive loads.
Type IX  collagen:
This is a FACIT collagen which is composed of three different chains, a l  (IX), a2 
(IX) and a3 (IX) with three triple helical domains (COL 1, 2 and 3) flanked by four 
non-triple helical domains (NC 1, 2, 3 and 4) (Van der Rest et al., 1985; Wu & Eyre, 
1995). There are six possible sites where covalent crosslinks may occur with collagen 
II or collagen XI specifically (Wu et al., 1992). Type IX collagen may also be 
classified as a proteoglycan since it has a chondroitin sulphate/dermatan sulphate 
glycosaminoglycan chain attached to the third non-helical domain (Me Cormick et al., 
1987). Type IX collagen is found in developing avian cartilage (Mendler et al., 1989) 
and in the developing avian corneal stroma (Fitch et al., 1988). Homozygous mice 
with a mutation in collagen a l  (IX) were shown to be viable at birth. However, 
degenerative joint disease similar to OA was observed with age from 4 months and 
older (Fassler et al., 1994). Histological analysis of eyes showed no apparent 
abnormalities even in older animals that had OA pathogenesis. Their results suggest 
that a l  (IX) collagen plays an important role in mechanical stability of articular 
cartilage.
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Type X  collagen:
Type X collagen is a short chain non-fibrillar network forming collagen composed of 
a homotrimer of a l  (X) chains with one triple helical domain and two non-triple 
helical domains. It is present at sites of new bone formation where it is thought to 
influence chondrocyte hypertrophy through a2p l integrin cell-type X collagen 
interactions (Luckman et al., 2003). Type X collagen is expressed in osteoarthritic and 
rheumatoid articular cartilage but not in normal cartilage (Von der Mark, 1992).
Type X I collagen:
This is a fibril forming collagen and a minor constituent of cartilage. It is a 
heterotrimer of three different chains, a l  (XI), a2  (XI) and a3 (XI). It contains two 
collagenous domains (COL 1 and 2) and three non-collagenous domains (NC 1, 2 and 
3). The NC 2 domain forms a kink that produces an angle between COL 1 and COL 2. 
The proteins are cross-linked through head to tail bonds to other type XI collagen 
molecules and form lateral crosslinks to collagen II (Wu & Eyre, 1995; Eyre, 2002). It 
functions to promote nucleation of the cartilage type II collagen fibrils (Blaschke et 
al.f 2000)
Type XII collagen:
Type XII collagen is a FACIT collagen found in articular cartilage and the comeal 
stroma. In the developing avian cornea it has been localised in the subepithelial matrix 
on day 3 of embryonic development, in the primary stroma on days 5 of development 
and thereafter in the sub-epithelial and sub-endothelial matrices of the limbus before 
development of Descemet's and Bowman’s membranes (Akimoto et al., 2002; Young 
et al., 2002).
B. Kerr PhD thesis 2005 1
13. Connective Tissue Proteoglycans 
Properties of connective tissue ECM are dependent largely on protein and 
glycosaminoglycan (GAG) interactions, which together form the proteoglycan, a 
major functional component of connective tissues (Hassell et a l, 1986; reviewed by 
Roughley & Lee, 1994; Iozzo & Murdoch, 1996; Iozzo, 1998). Proteoglycans (PGs) 
are high molecular weight polyanionic elements of extracellular matrices that are 
synthesised and localized in accordance with the specific biological requirements of 
the tissue. They may be as diverse in function as they are in structure. In the ECM 
tissue they contribute to architectural organisation, and functions range from 
modulation of growth factor activities, collagen binding (Bindanset et a l, 1992; Scott, 
1991; Rada et a l, 1993; Nakamura et a l, 1997), collagen fibrillogenesis (Chakravarti 
et al., 1998), neurite outgrowth modulation (Cole & McCabe, 1991; Bovolenta & 
Femaud, 2000), corneal transparency (Chakravarti et a l, 1998; Kao & Liu, 2003) and 
blood vessel elasticity (Bode-Lesniewska et a l , 1996).
In articular cartilage PGs, polyanionic side chains imbibe water and maintain an 
osmotic force in the ECM that allows cartilage to resist compressive deformation 
during movement. In corneal stroma, KS and CS/DS PGs are thought to influence 
comeal transparency by binding collagen fibrils and maintaining uniform fibril 
diameter and spacing (Chakravarti et a l, 1998; Kao & Liu, 2003). These properties 
are all essential for the proper organization and functioning of the ECM and the 
tissues associated with it.
1.3.1. Glycosaminoglycan and oligosaccharide attachments
Proteoglycans are formed from covalent interactions between a core protein and one
or more glycosaminoglycan chains. GAGs are a family of extended linear
polysaccharides and are classified by their characteristic disaccharide repeat structure
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(figure 1.1) which are of variable length and can be classed into either sulphated or 
non-sulphated types. The most common sugar units that occur in GAGs include 
galactose (Gal), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), 
N-sulphated glucosamine (GICNSO4), uronic acid (UA) and iduronic acid (IdUA) with 
fucose (Fuc), mannose (Man) neuraminic acid (Neu) and xylose (Xyl) occurring to a 
lesser extent, mainly at linkage regions and capping structures (table 1.2).
There are six different types of GAG namely; chondroitin sulphate (CS), keratan 
sulphate (KS), dermatan sulphate (DS), heparan sulphate (HS), heparin (Hep) and 
hyaluronic acid (HA) (figure 1.1). CS, DS, KS, HS and Hep are all sulphated forms of 
GAG, which bind to a protein core to form proteoglycans (as described above in 
section 1.3). HA in cartilage and other tissues is an unsulphated GAG, which exists 
freely in the ECM (Hardingham & Muir, 1974; Hascall & Heinegard, 1974). 
Synthesis of HA by cartilage was first described by Gillard et al, (1975).
PG forming GAGs can be bound through either specific O-glycosidic linkages 
between serine hydroxyl groups and Xyl in CS, DS, HS and Hep, through specific O- 
glycosidic linkages between serine or threonine and GalNAc in skeletal KS (Mathews 
& Cifonelli, 1965; Bray et al., 1967), or through specific N-glycosidic linkages 
between asparagine and GlcNAc in comeal KS (Baker et a l , 1969; 1975; Nilsson et 
al., 1983; Nakazawa et al., 1983).
1.3.1.1. Keratan Sulphate
Keratan sulphate was first identified in the cornea by Suzuki in 1939, who established 
that the comeal mucoid contained galactose and glucose in equal amounts, as well as 
acetyl and sulphate groups. Keratosulphate was the name later given to this molecule 
when it was characterised by Meyer et al. in 1953 that we now call keratan sulphate 
(KS).
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Figure 1.1 The disaccharide repeat structures characteristic of the different sulphated 
glycosaminoglycans (adapted from Hardingham & Fosang, 1992).
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GAG Repeat
disaccharidc
Other mono- N-acetyl
groups
O-sulphate
groups
N-suIphate
groups
Disaccharide 
structure (example)saccharide
componentscomponents
Fuc, Man,Corneal KS 1
Neu+ Gal/Skeletal KS II
Xyl, GalGalNAcC-4-S /C-6-S
+ GlcUA/c-o-s
GalNAc Xyl, GalDS o,si
:oo*
+GlclIA/IdUA
ICOCH;
c o t fGlcNAc Xyl, GalHS / Heparin
+GlcUA/IdUA
GlcNAcHA
Table 1.2 The polysaccharide disaccharide structure and other possible monosaccharide/sulphate/acetyl components which occur as side
branches or in the linkage regions (adapted from King, 1996).
Since then it has been further characterised into three types, KS I [corneal], KS II 
[skeletal] (Meyer, 1956) and KS III [brain] (Krusius et al., 1986) all of which have the 
definitive disaccharide repeat units of galactose (Gal) and N-acetylglucosamine 
(GlcNAc) (table 1.2 / figure 1.1) linked through p i -3 and pi-4 glycosidic linkages, 
respectively (reviewed by Funderburgh, 2 0 0 0 ).
KS chains are of variable length and sulphation (Oeben et a l, 1987; Stuhlsatz et al, 
1989; Block et al, 1992; Oguma et a l, 2001). They are sulphated at Carbon- 6  of both 
sugars in a disulphated disaccharide (Choi & Meyer, 1975) but only on GlcNAc of 
monosulphated disaccharides as this monosaccharide becomes sulphated first (Fukuda 
& Matsumra, 1976; Nakazawa et al, 1998). This is supported by the fact that in 
macular corneal dystrophy, where the GlcNAc sulphotransferase enzyme does not 
function, the Gal residue does not become sulphated either and so may require initial 
sulphation of GlcNAc (Akama et a l, 2001), see section 1.4.3 for further details. It has 
been hypothesised that these non-, mono- and di- sulphated disaccharide patterns 
occur sequentially in domains stretching from the linkage region through the centre 
and to the non-reducing end of the chain, respectively (Oeben et a l, 1987; Stuhlsatz et 
al., 1989) and this has been the accepted structure for the comeal KS chain since then. 
However, challenging this generic structure, Dickenson et a l, (1990) have identified a 
6 -sulphated GlcNAc residue occurring attached directly to the GalNAc of the linkage 
region. The extent to which KS sulphation occurs, and chain length proceeds, depends 
on tissue specific factors such as galactosyltransferase, glycosyltransferase and 
sulphotransferase expression (Nakazawa et a l, 1998; Sashima et a l, 2002; Kushe- 
Gullberg & Kjellen, 2003) which differ with specific requirements of the tissue (see 
section 1.4.1.3).
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In vivo functions of KS include organogenesis (e.g. cartilage, heart, gonad, pancreas) 
during chick development (Hemming & Saxod, 1998), possible implications in 
diminishing the motility of lung cancer cells (Seko & Yamashita, 2004), cartilage 
maintenance and metabolism (Scott, 1994; Leroux et a l, 1996; Pratta et a l, 2000) and 
maintenance of comeal transparency (Comuet et al., 1994; Nakazawa et al., 1984). 
KS substitution has been shown to increase with age in a variety of connective tissues 
(Kaplan & Meyer, 1959; Sweet et a l, 1979; Thonar et a l, 1986; Hering et a l, 1997). 
In addition, it has been shown that in the human cartilage KS increases in sulphation 
and molecular size from foetal up to 9 years of age, at which point there is a change in 
molecular size (Brown et a l, 1998).
KS type I (comeal specific), KS type II (skeletal specific) and KS type III (brain 
specific) are distinguished from each other by their different linkage regions, which 
are N- or O-linked (figures 1.2 -  1.5).
Type IK S  (see figure 1.2) is characteristic of the KS found in cornea, but is not tissue 
specific as it has also been found in cartilage on small leucine-rich KSPGs 
(Funderburgh et a l, 1987) where as it is present in its unsulphated polylactosamine 
form. KS type I can also occur N-linked in the hyaluronic acid binding region of 
aggrecan (Barry et a l, 1995) where KS type II is the prevalent KS form in other 
GAG-attachment domains of aggrecan. Recently, Poon et al, (2005) demonstrated 
that N-linked KS substituted onto Asparagine at position 368 in the IGD domain of 
aggrecan facilitated aggrecanase cleavage at the E -  E cleavage site. KS type I 
binds through N-glycosidic linkages from GlcNAc to asparagine residues of an 
Nx(S/T) site on the proteoglycan core protein (figure 1.2) (Choi & Meyer, 1975;
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Figure 1-2 Keratan Sulphate type I structure is N-linked and found attached to SLRPs (Oeben 
et al., 1987; Stuhlsatz etal., 1989; Tai etal., 1996; 1997; Funderburgh, 2000).
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Figure 13 Keratan Sulphate type II A from load bearing tissues such as cartilage and IvD. 
KS II is O linked to serine or threonine (Stuhlsatz et a l 1989; Nieduszynski et al, 1990 B; 
Tai etal., 1996. 1997; Funderburgh, 2000).
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Figure 1.4 Keratan sulphate type II B from non-load bearing tissues such as trachea and nasal 
cartilage and is also O-linked to a core protein through serine or threonine (Nieduszynski et 
a l , 1990 B; Funderburgh, 2000).
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Figure 1.5 Keratan Sulphate type III structure from brain is O-linked through mannose to the 
core protein of nervous tissue KSPGs (U = unknown). It is lower sulphated than KS types I or
n.
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Nilsson et a l , 1983; Stuhlsatz et al., 1989; Plaas et al, 1990) where the presence of 
aromatic residues surrounding the Nx(S/T) sequence appears to be important in the 
attachment of KS at this site (Dunlevy et al, 1998). The KS I chain extends from 
carbon 6  of a linkage region mannose, and it may also have a short capped 
oligosaccharide extending from carbon 3 of the linkage region mannose (Oeben et al, 
1987). Other reports have suggested that this carbon 3 linkage region can also be 
extended as a KS chain to give two KS chains per linkage region (Nilsson et al, 
1983). It has been reported that Swainsonine, which inhibits carbon 6  processing did 
not stop KS formation on corneal KSPG or on frbromodulin (Ziegler & Mersman, 
1984; Plaas & Wong-Palms, 1993), indicating that it can be extended on carbon 3. 
The non reducing terminal of the KS I chain may be capped by any of the following:
• oc(2-6) linked NAc Neuraminic acid -41%
• a(2-3) linked NAc Neuraminic acid -  12%
• oc(2-3) linked Glycosyl Neuraminic acid -  6 %
• a(2-6) linked Glycosyl Neuraminic acid - 6 %
• a ( l  -3) Galactose -  26%
• P(l-3) NAc Galactose - 5%
• P(1 -3) NAc Glucose -  4%
(Tai e ta l ,  1996; 1997).
Type II KS (see figure 1.3/1.4) is characteristic of that found in cartilage aggrecan
(Kalpan & Meyer, 1959). It binds through positions 3 and 6  of an N-acetyl-
galactosamine (GalNAc) residue that is O-glycosidically linked to the hydroxyl group
of serine or threonine on a core protein (figure 1.3/1.4) (Bray et a l , 1967; Choi &
Meyer, 1975; Kikuchi et a l, 1987; reviewed by Stuhlsatz et a l, 1989). The KS II
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chain may be capped by neuraminic acid at C-3 or C- 6  of the terminal GlcNAc 
(Funderburgh, 2000, review). It can have a  (1-3) fucose attachments with levels 
escalating with increasing length of the KS chain. The fucose residues are thought to 
attach to the C-3 of GlcNAc residues throughout the KS chain as these are the only 
sugars within the polylactosamine KS chain that are not already substituted on the C-3 
position (Nieduszynski et a l , 1990 A). Fucose can also be found at the non-reducing 
capping structures of the extended KS chain, which when capped with a  (2-3) linked 
N-acetyl neuraminic acid is a sulphated variant of the Vim-2 differentiation antigen 
(Brown et al., 1996). When found in an unsulphated form, the Vim-2 antigen is 
thought to be an important structure in early cartilage development, whose structure 
may later become sulphated to mask the Vim-2 epitope when its role in development 
is complete. This idea is supported by the fact that fetal cartilage KS is found in an 
undersulphated form and that sulphated isoforms of KS increase dramatically with 
age.
KS II can be subdivided into either KS II A (Articular) or KS II B (Basic) 
(Nieduszynski et a l , 1990 B). Whilst KS II A is found in load bearing tissues such as 
intervertebral disc and articular cartilage, KS II B is found in non-load bearing tissues 
such as tracheal and nasal cartilage. KS II A differs from KS II B as it possesses an 
a  (2 —► 6 ) linked N-acetyl neuraminic acid (NeuNAc) at the non-reducing end of the 
KS chain which extends from the carbon 6  of the linkage region GalNAc. NeuNAc 
also caps the short oligosaccharide extending from carbon 3 of the linkage region 
residue and it also possesses fucose attachments (as described above) while KS II B 
does not (figures 1.3 & 1.4). The functional relevance of the 2 different KS type II 
structures is unknown, but perhaps may be a consequence of the load bearing 
properties of the tissues and fucose / NeuNAc attachments may play a role in binding 
or recognition of other articular cartilage molecules (Nieduszynski et a l, 1990 B).
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Type III KS (see figure 1.5) is characteristic of KS found in the brain (Eronen et a l , 
1985; Krusius et a l, 1986; Papageorgakopoulou et a l, 2001; 2002) where it is found 
attached to proteoglycans such as SV2, Phosphocan or Claustrin, and is thought to be 
involved in the modulation of cell interactions and neurite outgrowth in the 
developing brain (Margolis & Margolis, 1993, review). Its repeat disaccharide 
structure is composed of monosulphated disaccharide units of Gal P (1-4) -  GlcNAc 
6 S -  p (1-3), similar to KS types I and II (figure 1.5). It is lower sulphated than KS 
type I or II (Oguma et a l,  2001). It also differs from KS types I and II through 
differences in its linkage region, here the extended repeat disaccharide chain is O- 
glycosidically linked to serine or threonine of a proteoglycan core protein through 
mannose (figure 1.5). Structural heterogeneity and low concentrations have so far 
limited its isolation and a more detailed characterisation (Papageorgakopoulou et a l, 
2001).
1.3.1.2. Chondroitin Sulphate
Chondroitin sulphate is a component of all connective tissues of the body, found 
primarily in cartilage and IvD. The specific chondroitin sulphate (CS) repeats are 
made up of disaccharide units of glucuronic acid (GlcUA) and GalNAc. Each chain 
consists o f 20-40 disaccharide units (Mw 12-20 kDa), (table 1.2 / figure 1.1) which 
are linked through alternating p(l-3) and P(l-4) glycosidic linkages. Sulphation 
occurs at position 4 or 6  of GalNAc but the significance of these sulphation positions 
are at present unclear, although non-sulphation and / or C-4-sulphation has been 
shown to be more prominent in immature cartilage (Mourao et al., 1976) and in the 
comeal stroma (Hart, 1976; Midura & Hascall, 1989). Sulphation patterns have been 
shown to change with the onset of osteoarthritis and with age (Hardingham, 1995; 
Plaas et al., 1998; Lauder et a l, 2001). Chain length can also vary through embryonic
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development (Thonar & Sweet, 1981). CS biosynthetic attachment is signalled by a 
specific consensus sequence of 2 or 3 acidic amino acids followed by Ser - Gly - X - 
Gly where serine is the specific CS attachment site. Xylose is the initial attachment 
sugar attached through O-glycosidic linkages to the hydroxyl group of serine of the 
core protein (Lindahl & Roden, 1965). It is then followed by 2 galactose residues and 
a GlcUA residue. This Xyl - P (4-1) -Gal - P (3-1) - Gal - P (3-1) - GlcUA linkage 
region is followed by the addition of the characteristic series of repeat GalNAc and 
GlcUA residues. This is all dependent on the availability of specific 
glycosyltransferases and sulphotransferases and the availability of precursors (Telser 
et al., 1965); this is discussed further in section 1.4.2.
1.3.1.3. Dermatan Sulphate
DS is a modified form of CS where it may contain GalNAc, GlcUA and Iduronic acid 
(IdUA) in its repeat disaccharide structure (table 1.2/figure 1.1). The IdUA is formed 
by epimerisation of GlcUA by C-5 uronosyl epimerase (Malmstrom & Aberg, 1982). 
It may have one to all of its glucuronic acids undergo this modification depending 
again upon tissue specific factors. The uronic acid residues undergo sulphation at 
position 2 of IdUA and at position 4 of GalNAc as with CS on GalNAc. It has a 
molecular weight of 15 - 40 kDa. It has been shown to bind collagen type V in vitro 
(Munakata et a l , 1999).
1.3.1.4. Heparan Sulphate
Heparan sulphate (HS) is a complex structure composed of a repeat disaccharide 
structure of GlcNAc (N-acetylated glucosamine) or GICNSO4 (N-sulphated 
glucosamine), iduronic acid (IdUA) and glucuronic acid (GlcUA) (table 1.2) with a 
molecular weight of 50 -100 kDa. Some of the GlcUA residues may undergo
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epimerisation to become IdUA and are attached to a core protein in a similar manner 
to CS and DS (reviewed by Sugahara & Kitagawa, 2002). Sulphation occurs at 
position 6  or 3 of the GICNSO4 but only at the position C6  of GlcNAc and at the 2 
position of IdUA residues, or they may not be sulphated at all, these multiple 
combinations adding to the structural heterogeneity of the HS chains (figure 1.1). HS 
is found mainly on cell surface proteoglycans, on some pericellular matrix 
proteoglycans and in basement membrane proteoglycans where it functions in binding 
cell growth factors such as fibroblast growth factor (FGF) (Imamura & Mitsui, 1987), 
vascular endothelial growth factor (VEGF) (Conrad, 1997 review), hepatocyte growth 
factor (HGF) and interleukins 3 and 7 for signal transduction. Its structure too is 
tightly controlled during the biosynthetic process so that it is also tissue specific.
1.3.1.5. Heparin
Heparin is an extensively modified and over sulphated form of HS (Conrad, 1997, 
review) with a molecular weight of 60 - 100 kDa. It is composed of the same repeat 
disaccharide pattern with GlcNAc and GlcUA or IdUA (table 1.2./figure 1.1) 
connected through a Xyl - P(4-l) -Gal - p(3-l) - Gal - p (3-1) - GlcUA linkage region 
sequence to peptides (reviewed by Sugahara & Kitagawa, 2002). Its synthesis appears 
to be restricted to the mast cell where it is found only in storage granules on serglycin 
proteoglycan. It functions as an anticoagulant of blood by blocking the action of 
thrombin and is widely used as an anticoagulant drug. It also regulates angiogenesis 
(Folkman & Shing, 1992). It has been shown to bind with collagen types V and IX, 
and with fibronectin, laminin and vitronectin in vitro (Munakata et al., 1999).
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1.3.1.6. Hyaluronic Acid
In contrast to other GAGs, hyaluronic acid (HA) is found as a free glycosaminoglycan 
lacking covalent attachment to a protein core (reviewed by Roughley & Lee, 1994). 
HA is synthesised on the internal surface of the cell plasma membrane and the 
polysaccharide chain is then released from the cell free of any protein attachments 
(Prehm, 1984). It is distributed widely through the body, in synovial fluid, vitreous 
humour, loose connective tissue and cartilage. It is made of repeat sugar units of p (1- 
4) GlcUA P(l-3) GlcNAc (table 1.2./figure 1.1) which are unsulphated giving it a 
much less complex structure than the other sulphated GAG. It has a variable 
molecular weight (Mw) ranging from 300 -  2000 kDa depending on the tissue 
function and stage of development. One of HAs most important functions in cartilage 
is its ability to non-covalently bind large numbers of aggrecan molecules to form 
multimolecular aggregates essential for the characteristic structural arrangement 
which is necessary for the normal functioning of articular cartilage (Hardingham & 
Muir, 1974; Hascall & Heinegard, 1974). In this aggregate it also non-covalently 
binds link protein, which stabilise the aggregate structure (Heinegard & Hascall, 
1974; Baker & Caterson, 1979). It also interacts with a number of other proteoglycans 
e.g. versican, neurocan and brevican which all have hyaluronic binding regions 
similar to that found on aggrecan and are discussed further in section 1.3.2.1.
1.3.1.7. N- and O- linked oligosaccharides
Oligosaccharides are carbohydrate complexes which are often found as side chains on 
PG molecules. They attach to serine or threonine through O-glycosidic linkages or to 
asparagine through N-glycosidic linkages (Lohmander et al., 1980). They have similar 
linkage regions to comeal and skeletal KS, but are not variably sulphated as with KS 
chains.
B. Kerr PhD thesis 2005 21
Oligosaccharide attachments to various peptide cores act in modifying peptide 
properties. They impart hydrophilic properties, protect against proteases, play 
essential roles in embryonic development and intramolecular regulation where they 
act as differentiation antigens, they target hormones to specific organs and they cover 
antigenic determinants. It is the N-linked oligosaccharides that become extensively 
modified with mannose, to a complex type oligosaccharide, which can be further 
processed to synthesise KS type II chains (Nilsson et al., 1983; Dunlevy et al., 1998).
1.3.2. Proteoglycans of cartilage and cornea
The general ECM proteoglycan structure consists of several distinct functional 
domains spanning a protein core, which may be variably glycosylated, and of 
different lengths and sequences. Some families may conserve a degree of sequence 
homology (reviewed by Roughley & Lee, 1994; Hardingham & Fosang, 1992; Iozzo, 
1998; 1999). They may be classified into a number of families including the large 
hyaluronic acid binding extracellular proteoglycans and the small leucine rich 
proteoglycans (SLRPs).
1.3.2.1. Large Aggregating Proteoglycans
This group of proteoglycans include aggrecan, versican and the nervous tissue 
proteoglycans, brevican and neurocan (figure 1.6). All of these have a central GAG 
binding domain that is flanked by a hyaluronic acid binding region (HABR) at the N- 
terminal and a lectin binding domain at the C-terminal which led them to being 
termed as hyalectans (Doege et al., 1987; Rauch et al., 1992; Halberg et al., 1988; 
Iozzo & Murdoch, 1996; reviewed by Iozzo, 1998). The general structural features of
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Figure 1.6 Structural domains of the Hyalectans (Adapted from Rauch et al., 1992; Yamada 
e/a/., 1994)
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these proteoglycans allow the formation of large aggregates by interaction with HA 
and link protein. These large macromolecular aggregates are entrapped within the 
collagen fibrils and allow cartilage to resist compressive loading through the action of 
negatively charged sulphated GAG chains attached to the proteoglycan core proteins 
by affording a large osmotic swelling pressure to the tissue. The function of the C- 
type lectin domain is less clear but is thought to be involved in binding ECM 
molecules, allowing for cell-cell, cell-matrix communications and associations 
essential for ECM and tissue functions (Halberg et al., 1988; Rauch et al., 1992; 
Aspberg et al., 1997; Miura et al., 1999). Analysis of the primary sequence of 
aggrecan, versican, neurocan and brevican have revealed a 70% sequence homology 
in the C- and N- terminals of all of these molecules (Yamada et al., 1994).
Aggrecan:
Aggrecan (figure 1.6) is the most abundant proteoglycan of cartilage with a core 
protein size of 225-250 kDa or 2132 amino acids in length (Hardingham & Fosang, 
1992, review). Isolation and analysis of cDNA clones has enabled the sequence of 
aggrecan to be deciphered in a range of species (Doege et al., 1987; 1991; Hering et 
al., 1997). It is the product of a single gene on chromosome 15 (Korenberg et al.,
1993). The protein core can be substituted with up to 150 possible GAG (50 KS and 
100 CS) attachments and a number of N- and O- linked oligosaccharides, although 
this number varies greatly with age and pathology (Lohmander et al., 1980).
Aggrecan protein core structure is comprised of 3 globular domains G l, G2, and G3 
N-terminal to C-terminal direction (figure 1.6). Gl (the HA binding domain) is of 
particular functional importance in the formation of cartilage aggregates. It is through 
this domain that aggrecan monomers bind non-covalently to HA and in non-covalent 
associations with link protein to form the large multimolecular weight aggregates. The
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Gl domain occurs as a protein tandem repeat (PTR) loop with an immunoglobulin 
(Ig) like fold at the N-terminal of the protein core (Perkins et al., 1989). As well as 
interacting with HA, the Gl domain also non-covalently interacts with a small 
glycoprotein termed link protein, which has similar PTR and Ig fold structures. The 
interaction helps stabilise the aggregate and without it HA-aggrecan interaction is 
considerably reduced (Buckwalter et a l, 1984; Tang et a l, 1996).
Adjacent to Gl is a short interglobular domain (IGD) where several N-linked 
oligosaccharide substitutions occur and several protease cleavage sites are found e.g.
“XTX 77AGlu and Ala , a designated aggrecanase cleavage site. Such proteases cause 
truncation of the aggrecan molecule with age and disease (Hering et a l, 1997; Little 
et a l, 2002). Age related changes occur in composition of N- and O-linked 
oligosaccharides and KS substitution in the Gl domain and the IGD of aggrecan 
where KS has been observed in steer but not in calf cartilage (Barry et a l, 1995; 
Hering et a l, 1997). It has been suggested that this age related substitution with KS 
may influence aggrecan catabolism at the aggrecanase cleavage site as its removal 
prevented cleavage (Pratta et a l, 2000; Poon et al, 2005). Therefore, KS may be 
important for the recognition of this site by aggrecanases.
Adjacent to the IGD region is the G2 domain, which is structurally similar to Gl in its 
PTR motifs, but it lacks the Ig motif. The exact function of the G2 domain is yet to be 
determined. Between the G2 and G3 domains a longer GAG attachment region is 
found. At the amino terminal side of this GAG attachment region is a domain 
containing specific sequences for KS type II attachment (Heinegard & Axelsson, 
1977). This is about 113 amino acids in length but can vary between species (Barry et 
a l, 1994). This KS attachment region may contain approximately 30 KS chains but 
this number varies greatly with animal species, development, age and pathology of the 
tissue (Sweet et a l, 1979; Thonar & Sweet, 1981). The amino acid sequence of the
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bovine aggrecan KS attachment region has been determined (Antonsson et a l, 1989). 
It consists of a hexapeptide consecutively repeated 23 times and has 19-20 serine and 
9-10 threonine sites for possible attachment of O-glycosidically linked carbohydrate 
chains, many of which may be further substituted with KS. KS content differs 
considerably between foetal and adult articular cartilage PGs (Sweet et al., 1979; 
Thonar & Sweet, 1981; Inerot & Heinegard, 1983; Thonar et al., 1986; Scott, 1994). 
In the KS domain the sum of O-glycosidically linked oligosaccharides plus KS remain 
constant, however KS content increases with development and age, presumably 
gradually replacing the O-linked oligosaccharides with increasing age (Inerot & 
Heinegard, 1983). The significance of the increase observed in KS substitution and 
the specific changes in sites of substitution at present remains unclear (possibilities 
are discussed in section 1.4.3).
Following the KS attachment region lies another GAG binding region, CS I, which 
possesses primarily CS chains but also some KS (Heinegard & Axelsson, 1977). This 
region is followed by another CS binding region CS n. Collectively, these regions 
may contain up to 100 CS chains. During development, age and disease the number of 
CS chains decreases substantially and the number of KS substitutions also increases 
considerably through the CS I and CS II domains of the protein core (Inerot & 
Heinegard, 1983). This has major functional and structural implications on cartilage 
and is discussed further in section 1.5.
Finally, the G3 domain is located at the C-terminal of the core protein and contains 
two epidermal growth factor (EGF)-like repeats, a complement regulatory protein and 
a lectin-like domain that are characteristic of this hyalectan family (Roughley & Lee,
1994). The G3 domain has been shown to selectively bind to sugars such as fucose or 
galactose with low affinity in a calcium dependent manner and thus can bind the 
galactose residues found on collagen type II (Halberg et a l, 1988; Iozzo & Murdoch,
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1996; Iozzo, 1998). This G3 domain may act to link aggrecan with other cartilage 
ECM components and cells.
Versican:
Versican (figure 1.6) is the largest member of the hyalectan family of proteoglycans 
with a 2,389 amino acid core protein sequence and a molecular weight of 400kD 
(Krusius et al., 1987). It is expressed by fibroblasts. It shares 3 characteristic domains 
with aggrecan, the HABR, the GAG binding region and the lectin binding region 
(Zimmermann & Ruoslahti, 1989). The HABR with an Ig and 2 protein tandem repeat 
motif structures, make it typical of this family allowing it to bind HA through non- 
covalent bonds to form aggregates, which are typically found in blood vessels (Bode- 
Lesniewska et al., 1996) where it is thought to contribute to the elastic properties of 
this tissue allowing it to stretch and relax. It is also found in smooth muscle, fibrous 
and elastic cartilage, the central and peripheral nervous system, the epidermis and 
glandular epithelia (Bode-Lesniewska et al., 1996). The GAG attachment domain is 
subdivided into two regions GAGa and GAGp, respectively, which together contain 
up to 30 CS or DS GAG chains covalently bound to the core protein along with bl­
and O- linked oligosaccharides (review by Iozzo & Murdoch, 1996). At the C- 
terminal end it contains 2 of the common EGF-like repeats, a common C-type lectin 
and a complement regulatory protein motif which acts as it does in aggrecan to allow 
cell-cell and cell-matrix interactions.
Neurocan:
Neurocan, a brain specific proteoglycan, has been cloned and its primary structure 
deduced (Rauch et al., 1992). It has 1,257 amino acids in its core protein sequence 
and has a molecular weight of 136 kDa. It is a member of the hyalectan family and is
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composed of a HABR (Gl domain), a GAG binding region and 2 EGF like repeats 
(figure 1.6). The C-terminal area displays 60% sequence homology with the G3 
domain of the fibroblast and cartilage PGs, versican and aggrecan (Margolis & 
Margolis, 1993, review). The central region of neurocan has no homology with other 
hyalectans. The primary structure (136 kDa) accounts for approximately -60% of 
neurocans' 300 kDa molecular weight (Rauch et al., 1991; 1992). The GAG 
attachment region consists of 3 CS attachments (-20% of total molecular weight) and 
several sites for N- and O- glycosylation (-20% total molecular weight). Friedlander 
et al., (1994) have shown that neurocan binds to cell adhesion molecules N- 
CAM/L1/NILE and Ng-CAM with the CS glycosaminoglycans playing an active role 
in this process, which acts to inhibit neuronal outgrowth, an important occurrence 
during development.
Brevican:
Brevican is another member of the Hyalectan family that has been cloned and 
sequenced (Yamada et al., 1994), and shown to possess 912 amino acid residues in its 
core protein. It possesses a hyaluronic acid binding region (containing an Ig like loop 
and 2 link protein tandem repeats) and lectin like (G3 domain) functional domains 
which are similar to aggrecan and versican. However, it only has one EGF-like repeat 
at the C-terminal region (figure 1.6). As its name suggests it has the shortest GAG 
attachment region where five serine-glycine and glycine-serine dipeptide sequences 
are present which are possible CS/DS attachment sites. It can also be found in the 
brain with no GAG attachments where it has been shown to run to the correct 
molecular weight on SDS-PAGE without prior chondroitinase ABC digestion 
(Yamada et a l , 1994). Brevican shows a high degree of sequence homology -  50 - 
60% (review by Iozzo, 1998) to the other members of this family. Its expression is
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confined to brain and central nervous system tissues and it was not located in bovine 
heart, lung or spleen. It may exist as a free ECM form or as a membrane bound form 
linked through a glycosyl phosphatidylinositol (GPI) moiety (Seidenbecher et al.,
1995). It can be found in processed forms that lack the GAG binding region and the 
N-terminal domain (Yamada et a l , 1995).
This group of large aggregating PGs have similar functional characteristics in that 
they all bind HA through a similar HABR and they also bind carbohydrates through 
their homologous lectin binding region, creating an extracellular network whereby 
HA is linked to cell surfaces through the carbohydrate/lectin binding region of these 
PGs. Although they share these functional capabilities, the differences in the central 
GAG binding regions and GAG attachment possibilities of each of these 
proteoglycans indicate different functional capacities for these regions of the PGs. 
The expression of and compensation for such molecules at different points of 
development or pathogenesis may be important aspects of such processes.
1.3.2.2. Small Leucine Rich Repeat Proteoglycans (SLRPs)
This family of PGs are particularly important in regulation of the collagen network 
assembly and maintenance. They include a series of lower molecular weight 
proteoglycans (25-40 kDa) such as decorin, biglycan, lumican, keratocan, 
fibromodulin and mimecan, which are structurally related but are the products of 
different genes and perform different functions (review by Iozzo, 1999). The amino 
terminal of these molecules may contain chondroitin sulphate or dermatan sulphate 
glycosaminoglycan (GAG) attachments or tyrosine sulphate attachments and N-linked 
oligosaccharides. Also found in this region are 4 conserved cystine repeats which 
form disulphide bonds (figure 1.7). Adjacent to the N-terminal lies a central protein 
core with a highly conserved region rich in a variable number of leucine repeat
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residues (LRR) with the consensus sequence LxxLxLxxN/Cx (where x is any amino 
acid and L can be leucine, valine, isoleucine or phenylalanine). This LLR region may 
be involved in a range of functions such as cell adhesion, DNA repair, RNA 
processing and signal transduction (reviewed by Iozzo, 1999). Keratan sulphate 
GAGs may be found in this region. A further 2 conserved cystine repeats are found at 
the carboxyl terminal of the protein core which form disulphide bonds. The function 
of this region is yet poorly defined.
In general, the SLRPs bind with other ECM molecules to organise the matrix 
architecture. In the cornea, they are localised between collagen fibrils where they 
affect fibril assembly and play an important role in comeal transparency (Scott & 
Haigh, 1988; Funderburgh et a l, 1991 A; Scott, 1992; Rada et a l, 1993; Comuet et 
a l , 1994; Chakravarti et a l , 1998). SLRP sequence alignment demonstrates a high 
degree of homology between this family of proteoglycans (reviews by Iozzo, 1998; 
1999). They may be classed into groups according to the type of GAG attachment 
they possess (e.g. KS or CS / DS) and the degree of sequence homology between 
them (figures. 1.7 & 1.8).
Chondroitin sulphate /  Dermatan sulphate containing SLRPs 
This class of SLRPs contain CS or DS GAG attachments and include decorin 
(Krusius & Rouslahti, 1986) and biglycan (Fisher et a l , 1989). They possess 57% 
sequence homology at the amino acid level (reviewed by Iozzo, 1998). Both of these 
proteoglycans contain an amino terminal propeptide domain (reviewed by Roughley, 
2001) that may be involved in the xylosyltransferase initiation of CS / DS GAG chain 
synthesis to the proteoglycan core protein (figure. 1.7).
Decorin is the product of an 8 exon gene located on chromosome 12 (Danielson et a l , 
1993). Its core protein has 359 amino acids, which contains 10 leucine repeat residues
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Figure 1.7 SLRPs of connective tissues (adapted from Mochizuki et al., 1998)
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--------------------- Fibromodulin: 2-4 KS attachments
----------------  Lumican: 3-4 KS attachments
----------------------------Keratocan: 4-5 KS attachments
__________________ Mimecan: 2-3 KS attachments
Decorin: 1 CS/DS attachment 
----------------------------- Biglycan: 2 CS/DS attachments
Figure 1.8 Sequence homology relationships between SLRPs (Adapted from Corpuz et al.,
1996)
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of 24 amino acids (Krusius & Ruoslahti, 1986). Decorin may contain N-linked 
oligosaccharides (Abramson & Woessner, 1992) and it has one CS/DS GAG 
attachment at Ser11. It controls cell proliferation and so is important in organising and 
maintaining ECM structure. Decorin is thought to be involved in regulating collagen 
fibrillogenesis (Rada et a l, 1993) and fibril diameter. DS is known to associate with 
other DS molecules and the decorin associates with collagen types I and II (Vogel et 
a l , 1984), two of the most abundant collagens of connective tissues, and with type VI 
collagen (Bindaset et al., 1992).
The biglycan gene is located on the long arm of the X chromosome and is also 
composed of 8 exons (Fisher et a l, 1991; reviewed by Hardingham & Fosang, 1992; 
Iozzo, 1999). It, like decorin, has 10 leucine rich repeats of 24 amino acids with 368 
residues in its protein core. The N-terminal is substituted with 2 CS / DS GAG 
attachments on Ser11, Ser17 or Ser5. Biglycan may undergo proteolytic cleavage with 
ageing where the N-terminal GAG bearing region is lost but the functional 
significance of this is as yet unknown (reviewed by Roughley, 2001). Biglycan may 
function in interactions with collagen VI to assist in network formation surrounding 
cells. Both decorin and biglycan bind growth factors (e.g. TGF-P) and thereby 
sequester them in extracellular matrices (Hildebrand et al, 1994).
Keratan Sulphate containing SLRPs:
This family include proteoglycans such as lumican, fibromodulin, osteoglycin /
mimecan and keratocan which all consist of a leucine rich core protein type structure
with KS GAG attachments (figure 1.7) which are linked through N-glycosidic
linkages to asparagine on the sequence Nx(S/T) as described previously in section
1.3.1.1. The presence of sulphated tyrosine on these SLRPs suggests that this may be
an initiation signal for post-translational addition of KS (Corpuz et a l, 1996). They all
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possess 10 repeats of 24 amino acids except for osteoglycin, which has only 6 LRRs 
(Hardingham & Fosang, 1992; Iozzo, 1998). Up to 10% of the mass of KSPGs can be 
attributed to the formation of N-linked mannose containing oligosaccharides on the 
core protein (Midura & Hascall, 1989; Funderburgh & Conrad, 1990).
Fibromodulin is expressed in many connective tissues with high levels in cartilage, it 
is also found in tendon and the sclera of the eye (Saamanen et al., 2001). It is 
structurally related to other SLRPs and is composed of 4 N-terminal and 2 C-terminal 
cystines and a central region of 10 LLRs (Antonsson et al, 1993). Its N-terminal 
domain is rich in tyrosine residues some of which may be sulphated (Antonsson et a l, 
1991). It has type I KS GAG attachments which are N-glycosidically linked to Asn109, 
Asn147, Asn182 or Asn272 residues on bovine fibromodulin protein sequences (Plaas et 
a l, 1990). The unsulphated form of KS can also be found on fibromodulin. It 
associates with collagen types I and II and inhibits collagen fibril formation (Hedbom 
& Heinegard, 1989). Fibromodulin deficient mice have abnormal collagen fibrils in 
tendon (Svensson et a l, 1999). Lumican and fibromodulin bind to the same region of 
collagen type I indicating similar functions in collagen fibrillogenesis. This is 
supported by observations that lumican levels are increased in fibromodulin deficient 
mice and osteoarthritis is prevalent with age due to collagen disorganisation (Gill et 
a l, 2002).
Three different corneal PGs (two with a 37 kDa Mw core protein, and one with a 25 
kDa Mw core protein) which have specific KS attachments, have been identified and 
cloned (Funderburgh & Conrad, 1990; Funderburgh et al, 1991 A; 1997 A; Corpuz et 
a l, 1996). Lumican (Blochberger et a l, 1992) is a 37 kDa core protein that closely 
resembles fibromodulin with 48% sequence homology (figure 1.8). It has 4 - 5  
potential KS attachment sites depending on species (Dunlevy et a l, 1998). In the 
avian cornea only half the potential sites are substituted with KS at Asn 165, Asn 91 and
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Asn 257, while the rest have complex N-linked oligosaccharides, one out of four sites 
are substituted on bovine lumican (Funderburgh et a l, 1991 A). Lumican has been 
found at low levels with low-sulphated or un-sulphated KS depending on cytokines 
present (Melching & Roughley, 1999) in cartilaginous tissues (Grovner et al., 1995; 
Melching et al, 1997; Young et al, 2005 A) and also in aorta, skin, skeletal muscle, 
lung, kidney, bone and IvD (Funderburgh et al, 1987; 1991 B; Corpuz et al, 1996; 
Chakravard et al, 1998; Raouf et al, 2002; Yeh et al, 2005; Young et al, 2005 A). 
But it mainly occurs in a highly sulphated form in cornea where it is thought to have 
an important role in regulating collagen assembly by developing and maintaining 
comeal ECM ultrastructure. It has been identified as being an important molecule in 
inhibiting collagen fibrillogenesis (Rada et a l, 1993; Chakravarti et a l, 1998). 
Lumican deficient mice display comeal opacity and loose dermis with disrupted 
collagen organisation (discussed further in section 1.7).
Keratocan (Corpuz et a l, 1996) also has a 37 kDa core protein which has 4-5 possible 
KS attachment sites (figure 1.7) which are species dependent (Dunlevy et a l, 1998). 
Three of five possible sites are substituted with KS in bovine comeal keratocan 
(Midura & Hascall, 1989) and in chick cornea at Asn , Asn , Asn and possibly 
Asn 299. Keratocan expression has mainly been confined to the cornea to date where it 
is found with highly sulphated KS attachments, although it has been identified at the 
molecular level in some ocular and non-ocular tissues during early chick development 
(Conrad & Conrad, 2003). It may have a sulphated tyrosine residue at amino acid 27 
in bovine comeal keratocan (Corpuz et a l, 1996). Sequence and distribution classify 
it as different from lumican. Keratocan knockout mice have larger collagen fibril 
diameters and loosely organised collagen fibrils (Liu et a l, 2003), this is discussed 
further in section 1.7.
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Mimecan (Funderburgh et al., 1997 A) is another typical leucine rich repeat 
proteoglycan which has characteristic sulphated KS attachments in comeal tissues 
where one out of four sites is substituted with KS in bovine mimecan (Funderburgh et 
al., 1991 A; Dunlevy et al., 1998). It is a full-length translation product of the 
osteoglycin producing gene and is synthesised by keratocytes in a 25 kDa Mw 
proteoglycan form (Funderburgh & Conrad, 1990). Osteoglycin is a small 12 kDa 
glycoprotein found in bone, which is also a product of the mimecan gene and appears 
to result from in situ proteolytic processing and / or alternative splicing of mRNA 
(Funderburgh et al., 1997 A).
These groups of both large aggregating and small leucine rich proteoglycans show the 
enormous diversity in protein core sequence and length and in the type of GAG 
attachments that occur within this large family of macromolecules. The difference in 
core protein structures is clearly a gene related occurrence. However, post- 
translational modification associated changes in GAG types, amount, length and 
degree of sulphation, is dependent on various tissue specific factors and the relative 
functional requirements of the tissues and can change with development, age and 
pathological condition.
The degree to which these post-translational modifications occur and their 
implications on the healthy functioning of the tissues with which they are associated is 
therefore an important area of current research. In order to assess the modifications 
that occur with changing tissue needs, it is important to first understand the 
biosynthetic pathways and mechanisms by which they come about.
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1.4. Proteoglycan Biosynthesis
1.4.1 General Overview
Proteoglycan biosynthesis begins when mRNA is transcribed from DNA and used to 
translate a specific core protein in the endoplasmic reticulum (ER) of the connective 
tissue cell. Through the synthetic process extensive co- and post-translational 
modifications occur. Major changes involve GAG substitution, N- and O- linked 
glycosylation, proteolytic processing and crosslinking, and each biosynthetic process 
requires one or more enzymes to regulate turnover. Length, sulphation patterns, 
number and type of GAG chain present (e.g. CS vs. KS) can vary with the changing 
biological requirements and enzyme expression of the tissue. Translation of the core 
protein and N-linked oligosaccharide formation and attachment to the precursor 
protein proceeds in the ER lumen and continues after the protein is transported to the 
Golgi apparatus (Hassell et al., 1986; Vertel et a l , 1993). The specific protein 
initiation sequence for N-linked oligosaccharide formation is Asn-x-Thr/Ser where x 
may be any amino acid except proline or aspartic acid and aromatic residues (e.g. 
phenylalanine) are located in close proximity to the attachment sequence (Dunlevy et 
a l , 1998). The majority of post-translational modifications however occur as 
processes of the medial- and trans- Golgi apparatus (Vertel et al., 1993) where the 
protein precursor is converted into a proteoglycan. This process may involve the 
posttranslational modification of the core protein with N- or O- linked 
oligosaccharides to asparagine or serine / threonine, respectively. The N-linked 
oligosaccharides maybe further processed to more complex forms. There may also be 
possible removal of peptide portions of the core protein, see figure 1.9 (Hassell et al, 
1986).
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Figure 1.9 Proteoglycan biosynthesis - pathway through the cell to the ECM (adapted from 
Hassell etal., 1986).
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1.4.2. Uronic acid GAG biosynthesis
CS, DS HS (Hep) and HA are all GAGs that contain uronic acid as one component of 
their repeating disaccharide units. CS, DS and HS are all covalently bound through a 
tetra-saccharide linkage region [GlcUA-Gal-Gal-Xyl] to a serine within a consensus 
core protein sequence of Glu/Asp-x-Ser-Gly [figure 1.10] (Lindahl & Roden, 1965). 
Their biosynthesis begins with the transfer of xylose from UDP-Xylose to a hydroxyl 
group of a specific serine in a preformed protein late in the ER and in the Golgi by the 
enzyme xylose-transferase (Lindahl & Roden, 1965; Telser, et a l , 1965; Schwartz & 
Roden, 1974; Lohmander et a l, 1986; Vertel et a l, 1993). This process is followed by 
the transfer of 2 galactose residues by galactosyltransferase I and II. A glucuronic acid 
residue is then attached as the initial GAG residue transferred by a 
glucuronyltransferase, giving a 4GlcUA p(l-3) Gal P(l-3) Gal p(l-4) Xyl pi-O - Ser 
linkage region structure (figure 1.10). Further elongation allows addition of the GAG 
specific repeat disaccharide (hexosamine and uronic acid) and their sulphate groups 
which allow classification of each separate GAG type. This process relies on the 
action of specific glycotransferases and sulphotransferases (Sato et al, 2003; Kushe- 
Gullberg & Kjellen, 2003). Because the linkage region tetra-saccharide is identical for 
all of the uronic acid type GAG chains, it is probable that the initiation enzyme for 
each GAG type compete for the tetra-saccharide substrate and may therefore play an 
important role in determining which GAG type will be produced on various PGs.
In contrast HA is synthesised at the plasma membrane (Prehm, 1984) by specific HA 
biosynthetic enzymes (HAS 1, HAS 2 and HAS 3). UDP-GlcNAc and UDP-GlcUA 
substrates are produced inside the cell and continuously transferred to the growing 
HA chain so that it is extruded into the extracellular space. Unlike the other uronic 
acid GAGs, its synthesis does not require a protein core for attachment.
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Figure 1.10 Structure of the linkage region of uronic acid containing GAGs which attach 
through O -glycosidic linkages to serine on the protein core, e.g. CS, DS, HS and Heparin 
(adapted from King, 1996).
B.Kerr PhD thesis 2005 40
1.4.3 KS GAG biosynthesis
KS biosynthesis differs from all other GAG synthesis as it may occur through either 
N-glycosidic linkages between GlcNAc and asparagine, as with KS type I (Seno et 
al, 1965; Choi & Meyer, 1975; Plaas et a l, 1990), or through O-glycosidic linkages 
between GalNAc and serine/threonine, as with KS type II (Bray et a l 1967; Choi & 
Meyer, 1975; Kikuchi et al, 1987), discussed in section 1.3.1.1.
The KS type I biosynthetic process begins in the ER, with dolichol phosphate on the 
ER membrane acting as a glycosyl acceptor for the GlcNAc residue and subsequent 
formation of a high mannose N-linked oligosaccharide chain which is then transferred 
to the protein core (Nakazawa et a l, 1983; Ziegler & Mersmann, 1984). The complex 
is then transferred to the Golgi where it may be modified to become an N-linked KS 
chain if the specific KS signals, i.e. glycosyltransferases and sulphotransferases, are 
present along with adequate substrate donor molecules and 3’-phosphoadenosine 5’- 
phosphosulphate (PAPS) for sulphation (Dunlevy et a l, 1998; Akama et a l, 2001; 
Kushe-Gullberg & Kjellen, 2003). If this pathway is not favoured the N-linked 
structure may be further processed to become a complex form N-linked 
oligosaccharide (Hassell et a l, 1986; Dunlevy et a l, 1998).
In contrast, KS type II linkage region biosynthesis and subsequent attachment of sugar 
units to the non-reducing end does not begin until the proteoglycan protein precursor 
reaches the Golgi apparatus (Hassell et al, 1986). As with KS type I, chain elongation 
depends on the expression of glycosyltransferase and sulphotransferases and the 
availability of the UDP-sugar donors.
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1.4.3.1 Glycosyltransferases and sulphotransferases 
Galactosyltransferases:
Glycosyltransferases are responsible for the sequential addition of alternative Gal and 
GlcNAc monomers to the growing KS chain (reviewed by Funderburgh, 2000). So 
far, several families of galactosyltransferases (Gal-T) have been identified (Amado et 
al., 1999) and two are important to the biosynthetic addition of Gal monomers to KS. 
p4 GalT-1 catalyses the UDP-Gal linkage to a non-reducing terminal GlcNAc 
acceptor, generating a p i-4 glycosidic linkage. It is involved in the production of non- 
sulphated poly-N-acetyllactosamine domains which comprise the basic unit of the KS 
molecule (Brew et al., 1968; Schanbacher & Ebner., 1970; Ujita et al., 1999). p4 
GalT-1 activity is upregulated in the developing chick cornea and this coincides with 
KS biosynthetic events (Cai et al., 1996). Another Gal-T enzyme, P4 GalT-4, has 
been shown to be the only Gal-T enzyme responsible for the p linkage of Gal to a 
non-reducing terminal GlcNAc-6-sulphate (Seko et al., 2003). It is therefore essential 
for the production of mono- and di-sulphated disaccharide KS domains.
N-acetylglucosaminyltransferases:
To date, seven different p i, 3-N-acetylglucosaminyltransferase (p3 Gn-T) enzymes 
have been identified (p3 Gn-Tl, -T2, -T3, -T4, -T5, -T6 and -T7). They act by 
catalysing the addition of GlcNAc by p glycosidic linkages to the C-3 position of a 
non-reducing terminal Gal or GalNAc (Seko & Yamashita, 2004). A number of these 
are thought to influence KS biosynthesis. P3 GnT or iGnT is a polylactosamine 
producing enzyme has been cloned and its substrate specificity identified (Sasaki et 
al., 1997; Zhou et al., 1999; Shiraishi et al., 2001). Until recently, it was unclear 
which of these enzymes was responsible for the addition of GlcNAc to sulphated
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forms of KS. Seko & Yamashita, 2004, characterised the enzymatic activity of P3 
GnT7. They found that it acts efficiently on Gaipi - 4(S03‘ - 6) GlcNAcpi - 3Gaipi - 
4(S03‘- 6) GlcNAc and Gaipi - 4(S03‘ - 6) GlcNAcpi - 3(S03’ - 6) Gaipi -  4(S03' - 
6) GlcNAc, both of which are partial structures of KS, with 100% and 72% relative 
activity, respectively. P3 GnT7 had a much lower activity (5%) with substrates that 
lacked sulphation on the internal non-reducing end GlcNAc and where the non­
reducing Gal was 6-sulphated reactivity was also reduced (3%) indicating that it 
catalyses the addition of GlcNAc to the non-reducing terminal of monosulphated 
disaccharides (Gal - 6SGlcNAc).
Sulphotransferases:
Sulphotransferase activity is responsible for the transfer of sulphate groups from 3’- 
phosphoadenosine 5’-phosphosulphate (PAPS) to position 6 of Gal or GlcNAc of KS. 
A number have so far been reported (Ruter & Kresse, 1984; Fukuta et a l , 1997; 
Uchimura et al., 1998; Akama et a l , 2001). Two enzymes have been identified that 
are responsible for transferring sulphate groups specifically to KS. Gal-6- 
sulphotransferase (KSGal6ST) transfers sulphate groups to C6 of Gal and GlcNAc-6- 
sulphotransferase (GlcNAc6ST) transfers sulphate to the C6 of GlcNAc. Another 
enzyme (chondroitin sulphate sulphotransferase (C6ST)) catalyses the addition of a 
sulphate group to GalNAc of CS, but also to Gal of KS in both cartilage and cornea 
(Habuchi et a l , 1996). Five GlcNAc-6-sulphotransferase genes have been identified 
(Seko et a l, 2003). It is GlcNAc6ST-5 that is involved in the addition of sulphate to 
the non-reducing terminal GlcNAc of KS and this proceeds as the KS chain is being 
synthesised in both human (Akama et a l , 2001) and mouse tissues (Uchimura et a l, 
1998).
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Fukuta et al, (1997), have cloned and characterised a Gal sulphotransferase enzyme 
(KSGal6ST), that catalyses the addition of sulphate to an internal Gal residue within 
the KS chain. It is specific for KS and comparison of the coding sequence of the two 
KS Gal sulphating enzymes KSGalST and C6ST (CS/KSGalT) reveals a 37% identity 
at the amino acid level (Fukuta et al., 1997). Incorporation of sulphate groups into Gal 
of unsulphated disaccharides is much lower than that of disaccharides in which the 
GlcNAc is already sulphated, suggesting that GlcNAc sulphation precedes and may 
be a prerequisite for Gal sulphation during KS synthesis. The disulphated disaccharide 
unit of KS has been synthesised in vitro (Akama et al., 2002) and sulphation of Gal 
residues is thought to signal an end to KS chain elongation (reviewed by Kushe- 
Gullberg & Kjellen, 2003). From the research described, it is apparent that KS is 
synthesised by the sequential actions of a number of KS specific enzymes p3GnT, 
GlcNAc6ST, p4GalT 4 and KSGal6ST. The proposed sequence of events is depicted 
in figure 1.11 (Seko & Yamashita., 2004).
1,4.4 Factors that effect GAG type generation -  the role of enzymes and energy
There are a number of factors that are involved in selective biosynthesis of different
glycosaminoglycans and what length of chains and sulphation patterns are produced
by a cell of a particular tissue. These include UDP-xylose concentration of the cell
and the NAD/NADH ratio (reviewed by Balduini et al., 1989).
UDP-xylose is present in all connective tissues but at significantly different
concentrations (Handley & Phelps, 1992) based on tissue specific factors. Xylose is
required for the initial step in uronic acid type GAG linkage to serine residues on the
core protein. In tissues where there is a high concentration of xylose-transferase, the
UDP-molecule is moved to the protein core resulting in a subsequent decrease in free
cytoplasmic UDP-xylose. High levels of cytoplasmic UDP-xylose act to block the
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GlcNAcpi — L.R. —
1. GlcNAc6ST-5 (Akama et al, 2001)
S 0 3-
\GlcNAcpi — L.R. —
UDP-Gal
2. p4GalT-4 (Seko et al., 2003)
so3- 
\
G aipi-46GlcNAcp1 -
UDP-GlcNAc
-  L.R. —
, , 3. p3GnT-7 (Seko et al., 2004)
so3- 
\
GlcNAc(31-3Gal(31-46GlcNAcp1 --  L.R.
repeating 1, 2 and 3
S 0 3-
\
(Galp1-4 6GlcNAcpi-3)n — L.R.
4. KSGal6ST (Fukuta ef 1997)
>^ 3- S<^ 3- SC^ r-
(6Gaipi-4 sGlcNAcpi-3)n-(Gaipi-4 6GlcNAcpi-3)„ — L.R. —
Figure 1.11 The proposed sequence of events in the KS biosynthetic pathway [L.R. =linkage region; 
C.P. = core protein] (Adapted from Seko et al., 2004).
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UDP-glc-dehydrogenase activity of converting UDP-glucose to UDP-glucuronic acid. 
And low levels of cytoplasmic UDP-xylose, resulting from xylose transferase activity 
of transferring xylose to the protein core, allows the UDP-glucose present to be 
converted to UDP-glucuronic acid by UDP-glc-dehydrogenase. This provides the cell 
with the main uronic acid GAG type sugar substrates (e.g. CS/DS/HS), favouring this 
type of GAG formation as observed in immature cartilage proteoglycans.
However, in some cases tissue specific factors in development, ageing or disease 
regulates a decrease in enzyme expression (e.g. xylose transferase) or the core protein 
sequence may be modified resulting in a decreased number of serine residues for 
GAG attachment (Wolf et a l , 1982; Balduini et al., 1989). This results in an increase 
in cytoplasmic UDP-xylose levels. The accumulation of UDP-xylose inhibits UDP- 
glc-dehydrogenase activity, blocking UDP-glucuronic acid formation, thereby 
maintaining a high cytoplasmic concentration of UDP-glucose. Glc-4’epimerase can 
then catalyse the conversion of UDP-glucose to UDP-galactose. In this way the main 
KS substrate sugars, UDP-glucose and UDP-galactose are readily available for KS 
formation as opposed to uronic acid GAG formation. Higher cytoplasmic xylose 
levels are detected in the cornea compared to cartilage and subsequently KS formation 
is preferred to that of CS in contrast to young cartilage. Efficient CS biosynthesis such 
as that in young cartilage actively inhibits KS formation and when CS formation is 
effected by altered enzyme expression/protein modifications with age and disease, KS 
biosynthesis is increased to ‘stand in’ for CS formation (Scott & Haigh, 1988, 
reviewed by Balduini et a l, 1989), a reason for the observed increase in KS 
substitution on the core protein with ageing (Kaplan & Meyer, 1959; Sweet et al, 
1979; Thonar & Sweet, 1981; Sorrell & Caterson, 1989), this is discussed further in 
section 1.5.1.
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A second factor that affects selective GAG type biosynthesis in the cell is NAD / 
NADH concentrations. CS / DS is plentiful in many different tissues, however, KS 
concentrations increase in a range of tissues which are avascular in nature e.g. corneal 
stroma, ageing articular cartilage and IvD, where oxygen supply is acquired by 
diffusion from neighbouring tissues (Scott, 1994), this will be discussed further in 
sections 1.5 and 1.7. It is argued that KS is the choice ‘reserve’ polysaccharide in 
tissues where oxygen is lacking (Scott & Haigh, 1988) where it acts as a functional 
substitute for CS. This is because under aerobic conditions the ratio of NAD / NADH 
is plentiful in the cell and formation of UDP-glucuronic acid for CS, DS and HS is 
allowed to proceed under such conditions (Scott, 1991). Epimerisation of UDP-N- 
acetyl-glucosamine for KS formation is also readily allowed. However, as the specific 
uronic acid GAG sugar substrates are available the formation of such GAGs is 
possible and favoured depending on the availability of serine, xylose transferase and 
resulting cellular concentrations of UDP-xylose as described above. However, the 
UDP-glc-dehydrogenase step (UDP-Glc to UDP-GlcUA) is an oxidising reaction that 
requires NAD+ as a substrate, releasing NADH and lowering cytoplasmic NAD 
levels. This step is sensitive to changes in NAD/NADH ratios of the cell. The 
anerobic glycolysis pathway is an alternative method for producing energy essential 
for cell survival in cases where oxygen levels are low. This pathway is dependent on 
NAD concentrations of the cell and so competes for NAD with CS biosynthesis. 
Therefore under anerobic conditions, tissues such as the cornea require any available 
cytoplasmic NAD concentrations for the production of energy essential for the basic 
metabolic processes of the cell. Its utilisation for CS formation under anaerobic 
conditions could jeopardise cell survival (Scott, 1991). Under similar conditions the 
epimerisation reaction of UDP-Glc to UDP-Gal for KS formation is not dependant on 
using up NAD stores. Therefore it has been suggested that under such anaerobic
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conditions, familiar in cornea and ageing cartilage, KS formation is again favoured as 
a functional substitute for CS (Scott & Haigh, 1988; Scott, 1994). In this way the cells 
NAD supply is reserved for the more essential processes to the cells survival.
In full, the above factors, i.e. the protein core sequence, availability of initiating UDP- 
xylose, oxygen supply, expression of glycosyltransferase and sulphotransferase 
enzymes and subsequent UDP-sugar donor formation and sulphation, all contribute to 
the type of GAG modification which becomes substituted to the protein core 
precursor.
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1.5. Cartilage ECM composition
Cartilage is commonly divided into fibrocartilage, elastic cartilage or hyaline cartilage 
based on its morphologic appearance and ECM composition. Fibrocartilage comprises 
of parallel bundles of collagen fibrils which provide this cartilage with its strength and 
rigidity and is the strongest of the three. Fibrocartilage interacts with dense fibrous 
tissues or hyaline cartilage e.g. intervertebral disc (IvD).
Elastic cartilage comprises proteoglycans collagen and elastic fibres. It is found in 
tissues requiring a great deal of flexibility where shape is important to its function e.g. 
the ear, the epiglottis and cuneiform of the larynx.
Hyaline cartilage is composed of chondrocytes housed in lacunae, proteoglycans and 
collagen. It is the most abundant cartilage in the body found predominantly at 
articular surfaces of movable joints where it is referred to as articular cartilage and is 
an important contributor to synovial joint function. It is also found in IvD (e.g. 
cartilage endplate), another load bearing tissue of the body (see section 1.6).
Articular cartilage is a wear resistant, load bearing surface tissue that protects bones at 
diarthrodal joints by transmitting applied loads at pressures that components of the 
joint can tolerate. It allows flexibility and support, absorbs shock by deforming under 
mechanical load and provides a smooth surface to permit low friction movement of 
the joint. It is composed mainly of a dense avascular, aneural, hypocellular ECM 
where 70% wet weight is composed of water, 7% of proteoglycans which are 
enmeshed in a rich collagen fibril network comprising 20% wet weight of the tissue 
(figure 1.12). Approximately 1% accounts for other matrix proteins. The overall 
composition does vary with species, developmental stage, age and pathology.
The chondrocytes are the only cell type present in articular cartilage and responsible 
for the production and maintenance of the ECM components. They make up less than 
5% of the volume of adult articular cartilage. In healthy tissue, cartilage can be
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Figure 1.12 Aggrecan and collagen function in cartilage hydration. The load bearing 
properties of cartilage is provided by the tensile strength of the collagen fibre network and 
osmotic swelling pressure afforded by the high concentration of negatively charged aggrecan. 
The aggrecan is immobilised within the matrix by forming supramolecular aggregates with 
hyaluronic acid and link protein. (Hardingham 1998)
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divided into four zones. The superficial zone is a layer of flattened cells and collagen 
found at the surface of cartilage giving it a greater tensile strength. The mid zone is a 
zone of randomly placed rounded cells. It has a much higher PG content than the 
superficial zone. The deep zone is a region of large cells that are aligned in vertical 
columns and grouped in lacunae. It has the highest PG content and lowest collagen 
content. Finally the zone of calcified cartilage rests on the subchondral bone. Crystals 
of calcium salts are found in the matrix here.
Chondrocytes from these different cartilage zones differ in size, morphology and 
metabolic activity. Each contains the organelles essential for matrix synthesis. The 
cells are spread throughout the matrix and cell - cell contact is not possible 
(Buckwalter & Hunziker, 1999). They must therefore rely on the surrounding ECM to 
transmit information regarding mechanical changes allowing the cell to regulate 
synthesis in response to physical changes.
Collagens of articular cartilage include type I, II, III, VI, IX, X, XI, XII and XIV 
(reviewed by Eyre, 2002). Types II, EX and XI are the main articular cartilage 
collagens. Types I, II, III and XI are fibril forming collagens which form the fibrillar 
meshwork that give the tissue its tensile properties. Non-fibrillar collagens include 
type X, a short chain network forming collagen associated with calcifying cartilage 
that is over expressed in OA and RA cartilage (Aigner et al., 1993). Type VI collagen 
is usually found as a pericellular network surrounding the chondrocyte in lacunae. 
Fibril associated collagens of articular cartilage include type IX, XII and XIV (Robert 
et a l , 2001). Deletion of the Col 9al chain (Fassler et al, 1994) has established type 
IX collagen as an important collagen of cartilage as mice developed degenerative joint 
disease within 4 months of age.
PGs including aggrecan, versican, decorin, biglycan, lumican and fibromodulin bind 
with or become sequestered in the rich collagen network of articular cartilage.
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Together these molecules form a highly hydrated structure which can resist the 
compressive forces applied to it during movement (figure 1.12).
1.5.1 Changes in articular cartilage with development, ageing and disease 
Developing cartilage is highly cellular compared to mature cartilage and retains the 
capacity to obtain nutrients and oxygen from the blood vessels of the underlying 
subchondral bone. On reaching early adulthood, bone growth ceases and growth plate 
closure results in the inability of cartilage chondrocytes to access nutrients from the 
subchondral bone. Diffusion via the synovial fluid from the blood vessels of the 
synovial capsule becomes the sole source of nutrients and oxygen to the cartilage 
chondrocytes and this diffusion is assisted by the action of compression and relaxation 
of the joint during movement.
During skeletal development and into maturity, the functions and activities of articular 
cartilage chondrocytes change. Growing chondrocytes produce new matrix 
components to build and remodel the articular surface. However, once mature and 
fully formed and when cartilage becomes damaged through use, chondrocytes no 
longer change the volume of the tissue but, instead, replace degraded matrix 
macromolecules, playing a role in remodelling the articular surface (Buckwalter, 
1995). A decrease in chondrocyte metabolism occurs with increasing age. 
Proteoglycan metabolism, expression and modifications vary greatly within cartilage 
during a lifetime. Genes are differentially expressed, for example aggrecan and 
biglycan become down regulated while decorin is upregulated with age (reviewed by 
Roughley & Lee, 1994; Melching et al., 1997) and disease (Young et al, 2005 A). 
Post-translational modifications responsible for functional hydration and structural 
variability have been shown to alter greatly with age. During embryonic and early 
development, aggrecan core protein is highly substituted with C-4-S GAG chains.
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However, during adulthood, C-4-S is largely replaced by sulphation at position 6 
(Bayliss et a l, 1999; Calabro et al, 2001). In addition, with age CS chain length and 
the number of attachments decrease (Sweet et a l , 1979; Thonar et al, 1986). 
Concomitantly KS chain length and sulphation levels increase (Calabro et al, 2001), 
as do the number of chain attachments through KS, CS I and CS II attachment regions 
of aggrecan (figure 1.13) where they possibly attach through O-linked 
oligosaccharides at CS attachment sites (Kaplan & Meyer, 1959; Sweet et al, 1979; 
Thonar & Sweet, 1981; Sorrell & Caterson, 1989). This replacement of CS with KS 
chains appears to occur in tissues where oxygen supply is reduced as tissues develop 
and enlarge and anaerobic glycolysis is required for energy production as described 
previously in section 1.4.4 (Scott, 1991, 1994; Scott & Haigh, 1988). This hypothesis 
is supported by the regional localization of KS containing proteoglycans. Articular 
cartilage and is an avascular tissue and ultrastructural examination has found that as it 
grows and enlarges, KS becomes more prevalent with increasing distance from the 
tissues oxygen supply. When the subchondral blood supply is cut off, as bone growth 
ceases, the KS content of cartilage in regions nearest the bone increases substantially 
(Stockwell, 1970). This may help to explain the increase observed in KS substitution 
with development and ageing, though the extent of its significance is still to be 
determined and heterogeneity observed in KS structure such as length and sulphation 
pattern structure may be due to expression differences of glycosyltransferases and 
sulphotransferases (see section 1.4).
Structural changes also occur in other proteoglycans with ageing and development. 
The GAG attachments on decorin and biglycan decrease in length and content of 
Iduronic acid increases (reviewed by Roughley & Lee, 1994). This may effect 
association capabilities with other molecules and hence the structural integrity of the 
cartilage ECM. ECM environment and cell behaviour trigger changes in expression of
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Figure 1.13 Increase in KS and decrease in CS substitution in cartilage aggrecan observed 
with increasing age and disease.
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proteases and growth factors leading to degradation of the matrix structure, a common 
pathological feature of cartilage arthropathies.
1.5.1.1 Osteoarthritis
With an increasingly ageing population, osteoarthritis (OA) is quickly becoming one 
of the most common diseases to affect the elderly of the Western world with a 
prevalence that is second only to ischemic heart disease affecting a very large 
proportion of the population. OA is a degenerative, debilitating joint disease involving 
the protective layer of articular cartilage overlaying bone. It is associated with ageing, 
and is initiated through several factors including mechanical stress, trauma, metabolic 
or genetic factors and is thought to be caused by an alteration in the balance between 
synthesis and breakdown of the cartilage matrix macromolecules.
Articular cartilage degeneration progresses from early proteoglycan depletion in 
histologically intact tissue through to breakdown of collagen type II (Hollander et al., 
1995), fibrillation and finally late stage erosion of the tissue down to subchondral 
bone (Mankin et al., 1971). OA is thought to progress as altered mechanical stresses 
transmit to the chondrocyte which cause them to produce inflammatory cytokines e.g. 
interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-a). These cytokines then 
trigger further expression of matrix proteases which when secreted and activated act 
to hydrolyse proteoglycans and collagens of cartilage at specific peptide bonds 
resulting in degradation of the structural support system of the tissue (Caterson et al, 
2000). Cleavage of aggrecan results in a loss of the negatively charged GAGs into the 
synovial fluid which diminishes the water binding capability of the tissue and hence 
reduces the compressive protective function of the cartilage. Later stage cleavage of 
collagen causes fibrillation and the combined loss of these molecules is responsible 
for the exposure of bone at the surface and is thought to represent irreversible
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cartilage damage. Bone surfaces are exposed resulting in outgrowths called 
osteophytes and thickening of the subcondral plate (Martel-Pelletier, 1999). For the 
individual all of this leads to clinically disabling symptoms of joint pain, 
inflammation and limited movement.
1.5.1.2. Rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune, inflammatory disease. 
Infectious and genetic events are thought to be the initiating factors associated with 
RA. It occurs as a consequence of chronic inflammation of synovial joints 
(predominantly hands, wrists and feet) where blood specific inflammatory cells 
appear in the normally acellular synovial fluid and synovial membrane (reviewed by 
Feldmann et al., 1996). This causes swelling, inflammation, and the characteristic 
pain associated with RA. Inflammatory cytokines cause activation of the matrix 
proteases responsible for matrix degradation leading to cartilage destruction (Chu et 
al., 1992). In addition the cartilage becomes eroded and the synovial membrane 
thickens. Fibrous tissue then forms in the joint resulting in limited movement 
capabilities and crippling clinical symptoms associated with this disorder.
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1.6 Intervertebral disc composition
Intervertebral disc (IvD) is a soft tissue that separates and cushions each vertebra from 
the next. Some of its component tissues resemble articular cartilage in both their 
biochemical composition and by having few blood vessels, nerves and cells. As with 
articular cartilage it also functions in mechanical loading. It allows flexibility 
associated with movement and therefore must be able to deal with compressive 
deformation caused by body weight and muscle activity, as does articular cartilage 
(reviewed by Urban & Roberts, 2003). The IvD consists of three distinct regions 
(figure 1.14), an inner highly hydrated region known as the nucleus pulposus, an outer 
collagenous anulous fibrosis consisting of 15-20 circular lamellae that surround the 
nucleus with elastic fibres which help the disc return to its original structure following 
movement. The disc region is separated from vertebrate bodies by a thin layer of 
hyaline cartilage called the cartilaginous endplate. Chondroycte like cells are 
responsible for synthesis of new matrix molecules to balance turnover caused by 
proteases such as matrix metalloproteinases (MMPs) and aggrecanases. The most 
important molecules of IvD include aggrecan and fibrillar collagens. Aggrecan 
attracts water into the matrix imparting a high osmotic pressure on the tissue and 
maintains a highly hydrated tissue as it does in articular cartilage. The nucleus has the 
highest concentration of aggrecan in the IvD and a lower concentration of collagen 
(figure 1.14). Type II collagen is the major collagen type found in the nucleus, while 
types I and II collagens are found in high levels in the annulus fibrosis (Eyre & Muir, 
1977). Collagens afford tensile strength to the tissue. The nucleus also contains minor 
amounts of collagen types III, V, VI, IX, X, XI, XII and XTV as well as the SLRPs 
decorin, biglycan, lumican and fibromodulin which are thought to be involved in 
forming cross links with collagens (Cs-Sazbo, et al., 2002; Strolovics et al., 1999 A).
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Figure 1.14 The IvD is a highly hydrated tissue that consists of three distinct regions, the 
nucleus pulposus, the anulous fibrosis and the cartilage endplate. The nucleus pulposus 
contains the highest concentration of proteoglycans and the lowest level of collagens (Roberts 
& Urban)
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Other matrix proteins such as fibronectin are also present. Although IvD resembles 
cartilage in many ways, certain aspects of its composition is also unique to disc. For 
example, aggrecan of IvD is much more highly substituted with KS than aggrecan 
from articular cartilage. There is also a higher concentration of versican in the IvD 
compared to articular cartilage, particularly in the nucleus pulposus. The G1 domain 
of the versican present here is more detectable after keratanase treatment, suggesting 
that it is substituted with KS in IvD tissues (Sztrolovics et al, 2002) while it is 
substituted only with CS / DS when found in articular cartilage.
1.6.1 Changes in IvD with ageing and disease
IvD degeneration arises when the damaged matrix can no longer be properly repaired 
or regenerated. IvD tissue has a very low cell composition, perhaps due to the 
avascular nature of the tissue. Because of this it may be more difficult for this tissue to 
synthesise new matrix molecules to balance turnover caused by the proteolytic 
activity of enzymes such as aggrecanases. Fibronectin levels are increased and it 
appears in fragmented form that is involved in the down-regulation of aggrecan 
synthesis and an up-regulation of MMPs (Johnson et al., 2000). Therefore aggrecan 
and GAG content of the tissue decrease dramatically with age and disease and 
subsequently so does hydration and functional integrity of the tissue. Collagen levels 
increase and the tissue becomes more fibrotic. There is an increase in levels of decorin 
and biglycan in degenerate IvD (Inkinen et al, 1998). Blood vessels and nerves 
appear more frequently with degeneration (reviewed by Urban & Roberts, 2003). 
Apoptosis increases significantly with 50% cell necrosis. Boundaries between the 
nucleus and annulus become less defined with age and degeneration. Discs tend to 
degenerate more quickly than other tissues and these degenerate discs inadequately 
carry load leading to chronic painful and disabling conditions.
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1.7. Corneal ECM components
The biochemical composition and highly organised arrangement of the corneal stroma 
(500pm) provide comeal tissue with its essential physical property as the main 
refractive lens of the eye (Meek & Fullwood, 2001). It is an avascular transparent 
coat, with an appropriate curvature that helps with the initial transmission and 
focusing of light into the eye. It is composed of five main layers, the epithelium, 
Bowman’s layer, stroma, Descemet’s membrane and the endothelium (figure 1.15). 
The epithelium is the outer protective layer of the eye, consisting of several layers of 
cells that regenerate every 48 hours. After wounding the cells migrate quickly inwards 
to close the wound (reviewed by Steele, 1999). Lumican has recently been implicated 
in playing an important role in promoting this epithelial healing (Yeh et al, 2005; 
Chakravarti et al, 2005; Kao et al, 2005).
The epithelium is anchored to the underlying Bowman’s membrane by adhesion 
complexes called anchoring complexes (Linsenmayer et a l , 1986 review) involving 
collagen types IV, VI, VII and XVII. Evaporation of water from the surface of the 
epithelium allows for nutrient diffusion through the avascular stroma from the 
aqueous humour.
The Bowman’s layer is an acellular matrix region that lays beside the basement 
membrane underlying the epithelium. The avian Bowman’s layer has smaller collagen 
fibril diameters (1 8 -2 2  nm) than those in the corneal stroma (Hay & Revel, 1969). It 
acts as a barrier to micro organisms and the corneal stroma.
The Stroma accounts for 90% of the comeal tissue (Maurice, 1957). Collagens present
here are primarily types I and VI, and to a lesser extent types II, III, IV, V, VII, VIII,
IX, XII and XVII (Newsome et a l , 1982). Type III collagen becomes more prevalent
during inflammation and healing processes (reviewed by Robert et a l , 2001). The
stroma of the cornea is rich in collagen VI (Zimmerman et al., 1986) which becomes
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Figure 1.15 The cornea is a highly hydrated tissue that can be divided into 5 distinct regions, 
the outermost epithelium, the Bowman’s layer, the stroma, Descemet’s membrane and the 
inner endothelium.
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detectible at the point of mesenchyme cell invasion (see section 1.7.1 below) of the 
primary stroma (Linsenmayer et al, 1986). The stroma also consists of a staggered 
collagen fibril assembly of type I and type V collagen of remarkably uniform diameter 
of 25 nm and intrafibrillar spacing of 66 nm (Birk et a l , 1990; Linesnmayer et al., 
1986). The uniform diameter and organised packing arrangement of the collagen 
fibrils have been shown to be essential to the refractive capabilities of the cornea 
(Scott & Bosworth, 1990; Scott, 1991; Comeut et al, 1994; Chakravarti et a l , 2000; 
Quantock et a l , 2001). This arrangement is thought to be regulated by corneal 
proteoglycans. Proteoglycans associated with the corneal stroma include keratan 
sulphate containing proteoglycans, lumican (Blochberger et a l, 1992; Funderburgh et 
a l, 1993), keratocan (Corpuz et a l, 1996) and mimecan (Funderburgh et a l, 1997 A) 
and typical CS / DS proteoglycans such as decorin and biglycan (Iozzo & Murdoch, 
1996, review; Iozzo, 1998, review), see section 1.3.2.2. The corneal molecules are all 
synthesised by keratocytes, which are present throughout the corneal stroma.
The proteoglycans of the cornea have a multi-functional property in that the protein 
core can bind collagen fibrils and the polyanionic glycosaminoglycan attachments 
provide the cornea with high hydrophilic properties, attracting water into the matrix 
assembly allowing tissue swelling. This influences collagen fibril arrangement and 
light scattering allowing the maintenance of transparency, an essential property for 
normal visionary processing. The cornea is covered on the inner surface by 
Descemet’s membrane and the endothelium which help maintain proper hydration of 
the tissue.
1.7.1. Changes in cornea with development, ageing and disease
The epithelium is responsible for initial synthesis and assembly of the primary corneal
stroma in the embryonic chick, it is composed of heterotypic type I and II collagen
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fibrils which are only one or two layers thick and FACIT collagen type IX. This 
primary stroma acts as a template for the mature version of the cornea, the secondary 
stroma (Linsenmayer et a l, 1986, review). Secondary stroma development is 
activated when the primary stroma becomes swollen and invaded by presumptive 
fibroblasts (Hay & Revel, 1969). The presence of HA is responsible for an osmotic 
pressure in the stroma that causes the transitional swelling associated with comeal 
developmental maturation. The swelling effect is thought to be triggered by cleavage 
or removal of FACIT collagen type EX from the primary stroma by type EX specific 
enzymes, as it inhibits swelling in the primary stroma by forming crosslinks with 
other collagen molecules and it has been observed to disappear rapidly after comeal 
swelling (Linsenmayer et a l, 1986). The invading mesenchyme cells differentiate into 
stromal fibroblasts and they begin to produce the specific comeal ECM components 
of the mature stroma (described in section 1.7). Finally, the secondary stroma 
becomes compact (Hay & Revel, 1969, review). Its thickness is halved and 
transparency develops which is thought to be a direct result of the appearance of 
sulphated KS and its affect on collagen fibrillogenesis (Comeut et a l, 1994; 
Chakravarti et a l, 2000; Dunlevy et a l, 2000).
Like cartilage and IVD, the cornea is another example of an avascular tissue that 
relies on receiving its oxygen and nutrient supply by diffusion from a different source, 
specifically the aqueous humour of the eye. The major proteoglycan of comeal stroma 
is the KSPG lumican whose KS content increases with increasing distance from the 
vascular supply (Scott & Haigh, 1988; reviewed by Scott, 1992; 1994). Interestingly, 
in mouse cornea where tissue is much thinner and consequently has a shorter diffusion 
distance from nutrient supplies than larger animals (e.g. rat and rabbit), the KS 
sulphation has been shown to be much lower based on light microscopy and electron 
microscopy (Scott & Haigh, 1988; Young et al, 2005B). The ratio of KS to total
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GAG appears to increase with increasing size of cornea from different species. DS to 
CS ratios are increased in mouse cornea, observed after its partial resistance to 
chondroitinase AC (Scott & Haigh, 1988). Their methods were sensitive but not 
quantitative, leaving the possibility for low levels of low sulphated KS to be present in 
mouse cornea which were below levels of immunochemical detection. However, the 
results emphasised the relationship between tissue thickness with increasing distances 
from oxygen supply and a concomitant increase in KS content that occurs during 
tissue development and expansion.
The generation and maintenance of the transparency of the corneal stroma, is a 
primary function of the SLRPs, namely decorin, biglycan, lumican, keratocan and 
mimecan (Comeut et a l, 1994; Dunlevy et a l, 2000) and is vitally important to the 
functioning of the whole eye. Dunlevy et a l, (2000) showed that expression of 
various SLRP mRNAs, especially lumican, and resulting production of KS-SLRP 
proteins with unsulphated KS post-translational modifications, was particularly high 
prior to key transparency development times during chick corneal development days 
9-12. As transparency develops, in days 12-15, so to does the appearance of sulphated 
KS chains on the lumican core protein (Comeut et a l, 1994). Comeal stromal ECM 
development activates tissue specific factors, which signal for these post-translational 
modifications to occur to allow transparency to develop. As collagen fibril diameter is 
much the same in the partially transparent cornea with the poly-N-acetyl-lactosamine 
form of lumican in early developmental days 9-12, the lumican core protein is thought 
to regulate this fibril diameter. It is the accumulation of sulphated KS that brings 
organised spacing of the collagen fibrils which allows transparency to proceed in days 
12-15 (Comeut et al, 1994). This indicates that the development of the sulphated form 
of KS on lumican is essential to visual function.
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The above results have been supported by work carried out on KSPG knockout mouse 
models generated via gene targeting. Mice with lumican null mutations have been 
shown to have thicker collagen fibrils, a 40% reduction in stromal thickness and 
disordered fibril spacing (Chakravarti et al., 2000). This is due to its lack of lumican 
core protein to regulate fibril thickness and a 25% reduction of KS content 
(Chakravarti, 2001 review) to keep stroma hydrated and thereby maintain thickness 
and keep an organised arrangement of collagen fibrils. These knockout (-/-) mice 
develop opaque corneas where the disorganised structure backscatters light by 
disrupting its passage through the cornea. This has been shown effectively to be the 
case with structural information obtained using X-ray diffraction studies (Quantock et 
al., 2001), which allows fine detailed examination of comeal ultrastructure as near to 
the natural state as possible without the artefacts which can be caused by electron 
microscopy fixation methods.
A keratocan knockout mouse model has also been generated (Liu et al., 2003). In 
humans, mutations of the keratocan gene cause cornea plana (CNA2) where the 
convex curvature of the cornea becomes flat. This affects the light refractive 
capabilities of the cornea and is associated with reduced visual activities, thinner and 
flatter cornea and comeal opacities (Liu et al., 2003). Keratocan knockout mice 
revealed larger collagen fibril diameters and a reduction in organised packing; 
however this was not as severe as that observed in lumican knockout mice. Lumican, 
decorin, fibromodulin and mimecan expression were not affected by the knockout 
model.
Studies involving Mimecan knockout mice did not display a pathological phenotype 
compared to the wild type mice (Tasheva et al., 2002). Comeal clarity and thickness 
also appeared to be unaffected. There was a reduction in skin tensile strength where 
475g of force loaded caused rupture of skin samples in knockout mice compared to
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74 lg in wild type mice. Ultrastructural EM examination of comeal fibrils revealed an 
increase in diameter in both comeal and dermal collagen fibril diameters (31.84 +/- 
0.322 nm in knockout cornea compared to 22.4 +/- 0.269 nm in wild type cornea and 
130.33 +/- 1.769 nm in knockout skin dermis samples compared to 78.82 +/- 1.157 
nm in wild type skin dermis samples). In addition, fibrils were more loosely packed 
in knockout compared to wild type mice tissues indicating it has a role to play in 
collagen fibrillogenesis in vivo. Tasheva et al., (2002) observed no significant 
abnormalities in bone structure in mutant mice by X-ray analysis.
CS/DS GAG also play an important role in comeal development and pathogenesis. C- 
0-S levels decline and C-4-S to C-6-S ratios increase significantly as comeal 
development proceeds, peaking on day 14 of avian comeal development at a key stage 
of the onset of transparency (Hart, 1976; Midura & Hascall, 1989). Hep/HS levels 
peak on day 5 of development prior to primary stromal swelling and fall to low levels 
by day 20 of development when transparency is complete. Studies focusing on the p- 
D-xylosidase disruption of the addition of xylose through O-glycosidic linkages to 
decorin in CS/DS PGs during chick comeal development revealed a disruption in 
lamellar organisation, while the collagen fibril diameters remained unaltered 
suggesting an important role for CS/DS PGs in intrafibrillar spacing during 
development (Hahn & Birk, 1992; reviewed by Michelacci, 2003). In macular comeal 
dystrophy, (see below) the structure of CS or DS changes. The chains become shorter 
(15 disaccharides compared to 40 disaccharides) and content of C-4-S to C-6-S 
increases indicating differences in efficiency of GAG chain substitution in such 
disorders (Plaas et al., 2001).
Macular comeal dystrophies (MCD) are a group of autosomal recessive inherited 
disorders, which prove the critical role of sulphated forms of KS on KSPGs in vivo. 
They are reported to be a result of a systemic defect in KS sulphotransferases (Fukuta
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et a l , 1997; Akama et a l, 2001; Seko et a l, 2003; Seko & Yamashita, 2004) causing 
defective sulphated KS synthesis (Nakazawa et a l, 1984). This affects vision by 
altering the normal ordered structural arrangement of the cornea by disrupting the 
passage of light through the eye. Individuals who suffer from this disorder develop 
opaque corneas and progressive loss of vision during adolescence and can be blind by 
the age of 20 (Plaas et a l, 2001). Activity of both KS sulphotransferases (Gal6ST and 
GlcNAc6ST) has been measured in corneas from patients affected with macular 
comeal dystrophy, keratoconus and from normal human corneas (Hasegawa et al, 
2000). Gal6ST activity in MCD corneas was shown to be the same as that of 
keratoconus and normal corneas. However, GlcNAc6ST activity was much lower in 
MCD corneas than of normal or keratoconus corneas indicating that it is a defect in 
the transfer of sulphate to the GlcNAc residue of KS that results in low or unsulphated 
KS and comeal opacity associated with this disease. KS from MCD corneas are found 
mainly in an unsulphated form indicating that not only is sulphation of GlcNAc 
obstructed, but so too is sulphation of Gal, even though Gal6ST levels appear to be 
present at normal levels. This supports the idea that GlcNAc is sulphated first in the 
KS biosynthetic pathway (see section 1.4.3) and that sulphation of GlcNAc is required 
for Gal6ST sulphation of the KS Gal residue to proceed (Hasegawa et a l, 2000). KS 
from patients with MCD is also significantly shorter (3-4 disaccharides compared to 
-14 disaccharides) than that of normal corneas (Plaas et al, 2001).
MCD is not restricted to the cornea as it has been shown that sulphated KS is absent 
in serum from patients with MCD type I where it is found usually resulting from 
normal cartilage turnover (Thonar et a l, 1985). A mutation in the coding region of the 
CHST6 gene responsible for the GlcNAc6ST enzyme, causes MCD type I (Akama et 
a l , 2000). This may cause production of an inactive enzyme or mislocalisation of the 
enzyme that is produced.
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In contrast, unsulphated KS is found in the comeal epithelium of MCD type II cases 
but normal sulphated KS is found in serum and comeal stroma of these patients. MCD 
type II patients show mutations in the upstream region of the same CHST6 gene 
coding for GlcNAc6ST (Akama et al., 2000; Abbruzzese et al., 2004). No significant 
difference in the in GlcNAc6ST activity in serum of normal human patients compared 
to MCD patients suggests that the GlcNAc6ST responsible for KS sulphation in 
cartilage of MCD type II patients may be different from that found in the comeal 
epithelium from the same patients (Hasegawa et al., 1999), or that the upstream 
region of CHST6 affected by mutation may be a regulatory component which affects 
GlcNAc6ST expression only in comeal areas but not in cartilage (Akama et al., 2000; 
Abbruzzese et al., 2004).
Overall, the altering composition of synthesised GAG during comeal development has 
a direct affect on ensuing transparency in a number of ways. Firstly it provides the 
cornea with an osmotic pressure that attracts water into the stroma. It may also 
prevent vascularisation of the cornea and it regulates the fibrillogenesis, intrafibrillar 
spacing and architectural composition of the stroma, all essential qualities for normal 
comeal transparency (Hart, 1976).
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1.8. Aims of this project
The aims of the project were:
• To produce mAbs that recognise keratanase or keratanase II generated 
neoepitope ‘stubs’ on corneal and skeletal KS.
• To characterise the epitopes and use these mAbs to investigate KS GAG 
structure.
• To produce mAbs to linear protein epitopes on corneal KSPGs.
• To investigate KSPG metabolism in “normal” and degenerate joint and 
intervertebral disc tissues.
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Chapter 2 - Production and characterisation of monoclonal antibodies 
recognising keratanase-generated KS ‘stub9 neoepitopes
2.1 Introduction
Antibodies are immune system molecules which are produced in response to invasion 
by foreign antigens in the form of proteins, carbohydrates, glycolipids or nucleic acids. 
Foreign antigens are recognised by circulating macrophages which act with helper T 
cells to induce B lymphocytes to produce immunoglobulins (antibodies), with specific 
antigen (Ag) recognition capabilities. The antibody (Ab) binds to the invading antigen 
complex to mark it for destruction. One lymphocyte recognises and produces 
antibodies to one antigen and the immune system as a whole may respond specifically 
to millions of different molecules.
Although there are 5 different Immunoglobulin classes, Abs have the same basic 
primary structure, 2 identical heavy chains (~50 kDa) and 2 identical light chains (~25 
kDa), which are bound together by disulphide bonds (figure 2.1). The basic structure 
of the Ab can be divided into 2 functional groups, the specificity function and the 
effector function. Papain digestion of an Ig cuts it into three parts. Two identical parts 
contain all of the light chain and part of the heavy chain with variable amino acid 
sequences at the N-terminal. These parts were shown to possess the Ag binding 
specificity function and are therefore known as the Fab region (Fragment -  antigen 
binding). The antibody is therefore divalent. The remaining fragment is composed of 
the remaining heavy chains and is known as the Fc region (Fragment -  crystalline) as 
it is easily crystallised. This region is responsible for effector function, where the 
binding of an Ig to an Ag allows the Fc region to mediate the hosts’ immune response 
by marking the Ag and initiating its elimination.
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variable
light chain
heavy chain
Figure 2.1 - Immunoglobulin structure
(http://www.biologv.arizona.edu/immunologv/tutorials/antibodv/structure.htmn
Differences in the sequence of the constant region of the heavy chains (Ch) code for 
five different Ig classes (IgG, IgA, IgD, IgE and IgM [table 2.1]). Small differences 
within the sequences of heavy chain of a single class results in different subclasses e.g. 
IgGi, IgG2, IgG3, IgG4 or subtypes, e.g. kappa light chains and lambda light chains. 
IgG, IgE, and IgD occur as monomers of the basic structural unit described and 
illustrated in figure 2.1, with two heavy chains and two light chains. IgA can occur as a 
dimer which is joined by a J chain. IgM occurs most commonly as a pentamer of 5 
basic structural units joined together by a J chain.
Classes of Igs Approximate 
molecular size
Heavy chain 
Isotype
Carbohydrate 
by weight (%)
Concentration 
in serum (mg 
per 100ml-l)
IgG 150,000 Y 53,000 2-3 600-1800
IgA 170,000-720,000 a  64,000 7-12 90-120
IgD 160,000 5 58,000 0.3-40
IgE 190,000 8 75,000 10-12 0.01-0.10
IgM 950,000 p 70,000 10-12 50-190
Table 2.1 - Ig classification (Devlin, 1997) 
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The antibody-antigen recognition process has had far reaching implications in the 
scientific world. Antibodies and antigens may be designed and produced for a variety 
of applications in the research, clinical and industrial areas (reviewed by Jackson et al., 
1999). Such antibodies are valuable research tools in the immunodetection assays 
described in this report, such as enzyme linked-immunosorbant assays (ELISAs) and 
Western blotting.
Antibodies used in research may be obtained from one of two sources. Polyclonal 
antibodies are mixtures of antibodies which are produced through repeat immunisation 
of experimental animals with a selected antigen. The antibodies are produced in a 
variety of B-cells and are subsequently obtained from the blood of the animal. Large 
quantities of high affinity polyclonal antibodies (~10 mg/ml) may be produced from 
the blood serum. However, this method does not immortalise the antibody producing 
B-cells and therefore repeat immunisation of numerous animals are required to 
replenish stock of antibodies. In 1975 Kohler & Milstein succeeded in producing cell 
lines that were capable of producing a single antibody species -  the monoclonal 
antibody (mAb), by fusing the specific harvested antibody producing B-cell with an 
immortal mouse myeloma cell line using polyethylene glycol (PEG). Utilising 
myeloma cells that had a defect in the salvage pathway for nucleic acid biosynthesis, 
hypoxanthine, aminopterin and thymidine (HAT) selection in specific growth medium 
ensured that only myeloma cells that had fused with B-cells survived. The myeloma 
cell line provided the properties essential for cell division, while the antibody-secreting 
cells provided the immunoglobulin secreting genes.
Supernatant from these fused hybridomas may be analysed by a variety of
immunodetection methods, e.g. ELISA or SDS-PAGE and Western blotting, to
determine if the resulting cell line contained the desired antibody specificity. Selected
cell lines were then grown and cloned to limiting dilution to ensure that each mAb cell
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line had been derived from a single cell. Monoclonal antibody stocks can be obtained 
from culture media of hybridoma cells. MAb hybridomas are advantageous over 
polyclonal Abs as, due to their unique specificity of binding and their immortal nature, 
they may be cryo-frozen, thawed and recultured in vitro allowing for a continuous, 
renewable source of the antibody, without the need to immunise more animals.
Many connective tissue molecules have been shown to be antigenic, and as such 
numerous monoclonal antibodies have been generated that are specific for antigenic 
determinants on many matrix molecules. They have proved to be invaluable tools in 
analysis o f PG and GAG structure, abundance, sulphation patterns, and may be used as 
early markers of the degeneration of cartilage in arthritic disease amongst many other 
applications.
Immunisation using enzymatically generated neoepitope antigens from structures 
within the PG molecule, such as chondroitinase ABC digested aggrecan (Caterson et 
al, 1985), have been used to cause pronounced antibody response in mice with 
resultant generation of monoclonal antibodies (table 2.2). These antibodies have been 
invaluable for studying PG distribution and structure within cartilage. By 
enzymatically removing the chondroitin sulphate (CS) chain, not only are the 
neoepitopes created, but this also removes the space filling CS chain, making the 
matrix more easily penetrated by antibodies. Antibodies have also been generated and 
characterised (table 2.2) to undigested full length KS and CS chains (Christner et a l , 
1980; Caterson et a l, 1983; Couchman et a l , 1984; Mehmet et a l, 1986) and to 
protein core epitopes and protease-generated neoepitopes (Calabro et al, 1992; 
Hughes et al, 1995).
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Antibody Epitope recognised
2B6 Chondroitinase ABC and AC II generated chondroitin-4-sulphate (C-4-S) stubs 
and chondroitinase B-generated C-4-S in dermatan sulphate
3B3+ Chondroitinase ABC and AC II-generated chondroitin-6-sulphate (C-6-S) stubs
1B5 Chondroitinase ABC and AC II-generated chondroitin-O-sulphate (C-O-S) stubs
3B3- Chondroitin-6-sulphate (C-0-6) at the non-reducing terminal
5D4 KS linear epitope -  pentasulphated hexasaccharide
1B4 KS linear epitope -  tetrasulphated hexasaccharide
4D1 Sulphated linear poly-N-acetyllactosamine epitope
2D3 Highly sulphated linear poly-N-acetyllactosamine epitope
Table 2.2 - Monoclonal antibodies and their epitopes (Christner et al., 1980; Caterson et al, 
1983; Couchman et al., 1984; Caterson et al, 1985; Mehmet et al., 1986).
The objective of the research described in this chapter was to develop a novel 
monoclonal antibody that would recognise a keratanase-generated neoepitope 
produced following exposure of KS GAG chains to the KS degrading enzyme 
keratanase from Pseudomonas sp. (EC 3.2.103). In order to produce the mAb, which 
could be used for studying KS substitution and sulphation patterns in a range of 
connective tissues, an antigen was required that would induce an immune response to 
raise the specific antibodies. In brief, trypsin generated bovine aggrecan KS-peptides 
(Heinegard & Axelsson, 1977) digested with keratanase (Pseudomonas Sp) were used 
in this study to induce antibody production in a mouse. For purposes of both 
immunisation and screening of subsequent hybridoma cell lines for antigen specificity, 
it was important that the antigen of interest was relatively pure and defined in form. 
Therefore, antigens were prepared by extraction of cartilage aggrecan from bovine 
nasal cartilage, and purification from other components in the connective tissue 
matrices through a series of density gradient centrifugation and chromatographic steps.
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2.2 Materials
2.2,1 Stock solutions
Solutions and their components required for practical work are listed in table 2.3. 
Ethanol, acetic acid, hydrochloric acid, sodium hydroxide and methanol were all 
obtained from Fisher Scientific.
Buffer solution Components
Dimethylmethylene Blue 32 mg DMMB; 1% (v/v) ethanol; 2.05% (v/v) 1 M NaOH; 
0.35% (v/v) 98% formic acid; made up to 2 L Milli Q™ 
water.
TPCK-Trypsin buffer 0.1 M tris, pH 7.3,0.1 M sodium acetate buffer
Keratanase buffer 10 mM tris-HCl, pH 7.4
Keratanase II buffer 10 mM sodium acetate, pH 6.8
Endo-P-galactosidase buffer 0.2 M sodium acetate, pH 5.8, containing 2 mg/ml BSA
Chondroitinase / keratanase / 
keratanase II buffer
0.1 M tris acetate, pH 6.8
2 x SDS PAGE sample buffer 0.125 M tris-HCl, pH 6.8, containing 4% (w/v) SDS; 20% 
(w/v) glycerol; 0.01% (w/v) bromophenol blue
SDS PAGE running buffer 25 mM trizma; pH 8.4 192 mM glycine; 0.01% (w/v) SDS.
SDS transfer buffer 25 mM trizma; pH 8.1-8.4; 192 mM glycine; 20% (v/v) 
methanol.
Tris buffered saline with azide 
(TSA)
50 mM trizma; pH 7.4 with HC1; 200 mM NaCl; 0.02% 
(v/w) NaN3
Alkaline phosphatase substrate 
buffer (AP buffer)
100 mM trizma; pH 9.55; 100 mM NaCl; 5mM MgCl2
NBT: nitro blue tetrazolium 50 mg/ml in 70 % dimethylformamide
BCIP: 5-bromo-4-chloro-3- 
indoylphosphate
50 mg/ml in dimethylamide
Lectin buffer TSA, pH 7.5; 1 mM MgCl2, 1 mM MnCl2, 1 mM CaCl2
Anion exchange 
chromatography equilibration 
buffer
0.05 M tris, pH 6.8
Anion exchange 
chromatography elution buffer
2 M NaCl, pH 6.8,0.05 M Tris
Size exclusion chromatography 
equilibration buffer
0.1 M sodium sulphate, pH 6.5-7.5
ELISA coating buffer 20 mM sodium carbonate, pH 9.6
DEA substrate buffer 0.126 mM MgCl2; pH to 9.8 with HC1; 48 ml 
Diethanolamine in 452 ml Milli Q™ water
Proteoglycan extraction buffer 4 M guanidine HC1, pH 5.8-6.8; 0.05 M sodium acetate, 10 
mM Na2EDTA, 0.1 M 6-amino hexanoic acid, 5 mM 
benzamidine, 0.5 mM PMSF
Table 2 3  Buffer solutions and their components 
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2.2.2 Dimethylmethylene Blue materials
Dimethylmethylene Blue (DMMB) dye (table 2.3) was used to measure sulphated 
glycosaminoglycan (S-GAG) in a sample. It works by binding to the negatively 
charged sulphate and carboxyl groups on the GAG chains forming a complex which 
produces a metachromatic shift in the absorbance maxima (Famdale et al, 1986). The 
dye was made by dissolving 32 mg DMMB in 20 ml ethanol overnight with rotation at
TMroom temperature. 1.5 L Milli Q water was added to a 2 L cylinder along with 59 ml 
1 M NaOH and 7 ml 98% formic acid. The dissolved DMMB solution was then added
TMto this solution and made up to 2 L with Milli Q water and stirred for an additional 2
TMhours. The absorbance of the DMMB solution was checked against Milli Q water as 
a blank at 525 nm and 592 nm. This gave absorbance readings of approximately 0.3 
and 1.4, respectively if sufficient dye was dissolved. The solution was stored in a light 
proof container.
Chondroitin sulphate C, sodium salt from shark cartilage was purchased from Sigma, a 
0.5 mg/ml solution was routinely used to make a linear standard curve between 0 and 
40 pg/ml GAG for DMMB analysis to calculate the concentration of sulphated GAG 
in unknown samples. 96 well flat bottom ELA microtitre plates were purchased from 
Elkay, UK. A labsystems multiscan MS plate reader was used to read the plates at a 
wavelength of 525 nm.
2.2.3 Keratan sulphate, chondroitin sulphate and protein degrading enzymes
L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK) treated trypsin from
bovine pancreas was purchased from Sigma. The keratan sulphate degrading enzymes,
keratanase from Pseudomonas sp EC 3.2.103, keratanase II from Bacillus sp Ks 36 and
endo-p-galactosidase from Escherichia freundii, were obtained from MP Biomedical.
Chondroitinase ABC was obtained from Sigma-Aldrich, UK.
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2.2.4 Immunisation, cellfusion and tissue culture materials
All monoclonal cell lines were cultured in RPMI-complete (RPMI-C) media consisting 
of RPMI 1640 media supplemented with 15% (v/v) foetal bovine serum, 2 mM L- 
glutamine, penicillin (100 U/ml), streptomycin (100 pg/ml), fungizone (0.25 pg/ml) 
and 0.5 mM p-mercaptoethanol. RPMI 1640 media, fetal bovine serum (FBS), PBS 
Dulbecco’s, L-glutamine and penicillin streptomycin, fungizone (PSF) were all 
purchased from Gibco Brl (now Invitrogen). p-mercaptoethanol was from Sigma. All 
tissue culture and plastic plates were purchased from Coming Costar. 0.22 pm filter 
units were from Millipore. All complete culture media was filtered through the 0.22 
pm filter units before use.
For immunisation and fusion, Freunds complete adjuvant and Freunds incomplete 
adjuvant were purchased from Gibco Brl (now Invitrogen). The X 63 Ag 8.563 (Ag8) 
myeloma cell line was obtained from stock cell lines frozen at -80 °C in the lab. 16 and
27.5 gauge needles were from Becton Dickenson. Polyethylene glycol (PEG), 
molecular weight 3,000 -  3,700, was from Sigma and hypoxanthine (100 pM), 
aminopterin (0.4 pm), thymidine (1.6 pm) [HAT] was purchased from Gibco Brl (now 
Invitrogen). 2 pM Hypoxanthine, 0.008 pM aminopterin and 0.032 pM thymidine 
were supplemented to RPMI-complete media (see above) for initial culture of newly 
fused monoclonal cell lines.
Cryoprotective media was made of 90% (v/v) fetal bovine serum, 10% (v/v) dimethyl 
sulphoxide (DMSO) [Hybri-Max obtained from Sigma-Aldrich, UK]. Cells were 
resuspended in this media and stocks maintained by freezing at -80 °C and in liquid 
nitrogen.
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2.2.5 SDS-PAGE and Western blotting materials
4 - 12% and 4 - 20% pre-cast Tris glycine gradient gels were purchased from 
Invitrogen. Slab gels of required percentages (12% or 15%) were prepared using 
acrylagel and bisacrylagel from National Diagnostics. The electrophoresis tank was 
purchased from Invitrogen. Transfer tanks, power packs and molecular weight protein 
standards were all from Bio-Rad. p-mercaptoethanol was from Sigma-Aldrich. 0.22 
pm Protran BA 83 nitrocellulose membrane designed for high binding capacity with 
low background interference was obtained from Schleicher & Schuell Bioscience. All 
of the monoclonal antibodies used in this investigation were obtained from stocks 
maintained in our laboratories. Antibody culture media was used at a 1:100 dilution 
and antibody ascities was used at a 1:5000 dilution. Anti-mouse IgG (H+L) alkaline 
phosphatase conjugated secondary antibody was from Promega, UK. Blots were 
developed in an alkaline phosphatase substrate made from 0.33 mg/ml nitro blue 
tetrazolium (NBT) and 0.165 mg/ml 5-bromo-4-chloro-3-indoylphosphate (BCEP) 
which were also purchased from Promega.
2.2.6 Lectin affinity blotting materials
A digoxigenin (DIG) glycan differentiation kit was obtained from Roche and was used 
in accordance with the manufacturers protocol. Lectins used include peanut agglutinin 
(PNA) which is specific for the core disaccharide Gal(3(l-3)GalNAc present in O- 
linked oligosaccharides and galanthus nivalis agglutinin (GNA) specific for terminal 
mannose a(l-3), a(l-6) or a(l-2) linked to mannose, identifying high mannose N- 
linked oligosaccharides. These specific lectins were used to analyse for various 
oligosaccharides and different KS type I and II linkage regions exposed after 
enzymatic deglycosylation of the KS chain with various keratanases.
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2.3 Methods
2.3.1 Deglycosylation (degradation) o f keratan sulphate chains
Structural analysis of KS types I and II was aided by the use of different enzymes 
including keratanase purified from culture media of Pseudomonas sp EC 3.2.103, 
endo-P-galactosidase from Escherichia freundii and keratanase II from Bacillus sp Ks 
36. Keratanase hydrolyses the internal p (1-4) galactosidic linkage between galactose 
and N-acetylglucosamine where the linking N-acetylglucosamine residue must be 
sulphated at position 6 and where the participating galactose residue remains 
unsulphated (Nakazawa et al., 1975; Nakazawa & Suzuki, 1975; Nakazawa et al., 
1989; reviewed by Calabro et al., 2001). Fucosylation at GlcNAc-6-S or proximate 
sialic acid groups can hamper the action of this enzyme.
Endo-p-galactosidase also specifically cleaves P (1-4) galactosidic linkages between 
galactose and N-acetylglucosamine (Fukuda & Matsumura, 1976). It favours digestion 
of KS GAG where the N-acetyl-lactosamine disaccharide is un-sulphated. However, it 
will cleave at the same monosulphated cleavage site as keratanase but at a much lower 
reaction rate, releasing oligosaccharides of various sizes (Fukuda & Matsumura, 1976). 
Keratanase II specifically cleaves the p (1-3) glucosaminidic linkage of N- 
acetylglucosamine-6-sulphate to galactose, irrespective of sulphation at galactose 
residues (Oguma et al., 2001; Yamagishi et al., 2003).
The cleavage sites of these enzymes on KS are as follows:
Endo-p-galactosidase
Keratanase II Keratanase II Keratanase Endo-p-galactosidase
1 1 1  1—GlcNAc6SP l--3Gal6SP 1—4GlcNAc6SP l--3Gaipr--4GlcNAc6SP l--3Gaip l--4GlcNAc p l~3Gaip 1—
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2.3.1.1 Quantification o f GAG using the DMMB assay
GAG concentration of trypsin digested BNC A1D1 KS peptide fragments (provided by 
Professor Bruce Caterson, Cardiff University, see section 2.3.2 below) and bovine 
corneal KSPGs (purified as described in chapter 4) were determined using DMMB 
analysis. This assay works when the DMMB dye (section 2.2.2) binds to sulphate 
groups on GAG chains causing a shift in colour absorbance. 40 pi of a linear standard 
curve ranging from 0-40 pg/ml are applied to a 96 well multiplate along with 40 pi of 
appropriately diluted unknown samples. 200 pi of DMMB dye (section 2.2.2, table
2.3) was applied to each sample and standard and the absorbance read at 525 nm using
a Lab Systems plate reader. All GAG quoted concentrations were calculated using this 
assay.
2.3.1.2 Determination o f  optimal enzyme conditions for keratanase, keratanase Hand  
endo-fi-galactosidase digestion
A volume equal to 400 pg GAG (as determined using the DMMB assay) of BNC 
A1D1 was digested using 100 mU of chondroitinase ABC per mg GAG for 24 hours at 
37 °C, followed by dialysis to Milli Q™ water and lyophilisation. Four test aliquots 
containing 100 pg GAG were initially digested with keratanase, keratanase II or endo- 
p-galactosidase and a keratanase/keratanase II/endo-p-galactosidase mixture in their 
respective digestion buffers (see table 2.3) as follows:
1) Keratanase -  20 mU per mg GAG
2) Keratanase II -  2 mU per mg GAG
3) Endo-P-galactosidase -  2 mU per mg GAG
4) Keratanase/keratanase II/endo-p-galactosidase -  20 mU + 2 mU + 2 mU 
per mg GAG, respectively.
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Samples were digested for 24 hours at 37 °C at which time an aliquot was taken for 
analysis using the DMMB assay. At 24 hours a further 20 mU of keratanase per mg 
GAG, 2 mU keratanase II per mg GAG, 2 mU endo-p-galactosidase per mg GAG and 
a mixture of 20 mU keratanase/2 mU keratanase II/2 mU endo-P-galactosidase II per 
mg GAG was added to each respective sample and digested for a further 24 hours at 37 
°C followed by DMMB analysis. This process was repeated at 48, 72, 96 and 120 
hours or until no further reduction in S-GAG could be detected by DMMB analysis. 
The results for optimal enzyme conditions for corneal and skeletal KS (types I and II) 
has been summarised in tables 2.4 and 2.5, respectively. Optimal digestion of both 
corneal and skeletal KS with either keratanase, keratanase II or endo-p-galactosidase 
was accomplished after the addition of 80 mU, 6 mU and 8 mU of each enzyme, 
respectively per mg GAG for a minimum of 24 hours (figures 2.2 and 2.3; A, B & C, 
respectively). It was not possible to reduce S-GAG dye-binding by 100% using either 
keratanase or endo-P-galactosidase in either comeal or skeletal KS. This indicated that 
there were disulphated disaccharide domain motifs on KS towards the linkage region 
that could not be removed by keratanase or endo-P-galactosidase suggesting that 
disulphated disaccharide domains were found attached directly to the linkage region 
without any intermittent non- or mono-sulphated disaccharides (see chapter 3). 100% 
reduction in S-GAG was achieved in comeal KS with keratanase II as expected as it 
cleaves both mono- and di-sulphated disaccharides. However there was only a 60% 
reduction in S-GAG after keratanase II digestion in skeletal KS. This could possibly be 
due to incomplete pre-digestion of the BNC A1D1 aggrecan with chondroitinase ABC 
or contribution of the chondroitinase-generated sulphated CS disaccharide ‘stubs’ and 
linkage region to the DMMB assay.
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Table 2.4 - % reduction in sulphated GAG in corneal KS (KS type I) determined by DMMB
analysis
KS type 1 %Reduction in S-GAG
Time Total 
keratanase 
cone mU / 
mg GAG
Total 
keratanase 
II cone mU / 
mg GAG
Total 
endo-p-gal 
cone mil / 
mg GAG
Ker Ker
II
Endo
-p.
gal
Ker + 
ker II + 
endo- 
P-gal
24hrs 20 2 2 28% 90% 1% 94%
48hrs 40 4 4 50% 96% 14% 99%
72hrs 60 6 6 50% 98% 28% 100%
96hrs 80 8 8 55% 99% 40% 100%
120hr 100 10 10 57% 99% 40% 100%
Table 2.5 - % reduction in sulphated GAG in skeletal KS (KS type II) determined by DMMB
analysis
KS type II %Reduction in S-GAG
Time Total 
keratanase 
cone mil / 
mg GAG
Total 
keratanase II 
cone mU / 
mg GAG
Total 
endo-p-gal 
cone mil / 
mg GAG
Ker Ker
II
Endo
-P-
gal
Ker + 
Ker II + 
endo- 
p-gal
24hrs 20 2 2 40% 62% 29% 51%
48hrs 40 4 4 44% 55% 25% 65%
72hrs 60 6 6 45% 61% 41% 64%
96hrs 80 8 8 50% 58% 55% 70%
120hr 100 10 10 51% 60% 56% 73%
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Figure 2.2 - Corneal KS (type I) - percentage reduction in S-GAG with increasing concentrations of 
keratanase (A. 80 mU/mg GAG of keratanase was required for optimal digestion of KSI), keratanase II 
(B. 6 mU/mg GAG of keratanase II was required for optimal digestion) or endo-p-galactosidase (C. 8 
mU/mg GAG of endo-p-galactosidase was required for optimal digestion of KSI).
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Figure 2.3 - Skeletal KS (type II) showing the percentage reduction in S-GAG with increasing 
concentrations of keratanase (A. 80 mU of keratanase per mg GAG was required for optimal digestion 
of KSII), keratanase II (B. 6 mU of keratanase II per mg GAG was required for optimal digestion of 
KSII) or endo-P-galactosidase (C. 8 mU of endo-P-galactosidase per mg GAG was required for optimal 
digestion).
B. Kerr PhD thesis 2005 84
2.3.1.3 Silver stain analysis o f the molecular weight o f keratanase and keratanase II 
The molecular weight of proteins in the KS-degrading enzymes, keratanase and 
keratanase II, was determined using silver stain analysis (Morrisey, 1981) using 
molecular weight markers after loading 20 mU each of keratanase and keratanase II 
onto 4 - 12% Tris glycine gradient gels. Samples were separated by SDS-PAGE. 
Following gel electrophoresis, the gels were prefixed in 30% (v/v) ethanol and 10% 
(v/v) acetic acid for 2 x 1.5 hours or 1 x overnight, with gentle agitation throughout. 
They were then washed with 2 x 10 minute washes in 10% (v/v) ethanol solution 
followed by 3 x 10 minute washes with Milli Q™ water. Gels were soaked in 5 pg/ml 
dithiothreitol (DTT) for 30 minutes followed directly by 0.1% (w/v) silver nitrate
TMsolution for a further 30 minutes. Gels were rinsed with Milli Q water and rinsed 
again with a developing buffer containing 0.05% (v/v) formaldehyde (37%) in 3% 
(w/v) sodium carbonate before developing completely with fresh developing buffer 
until positive bands appeared. Development was stopped by adding 5 ml of 2.3 M 
citric acid to the developer for 10 minutes and washing repeatedly with Milli Q™ 
water.
Silver stain analysis of keratan sulphate degrading enzymes showed the keratanase 
enzyme to have a molecular weight of ~ 145 kDa and keratanase II to have a molecular 
weight of ~275 kDa (figure 2.4).
2.3.2 Isolation and characterisation of BNC A1D1 and trypsin digested BNC AID1 
KS *stub* peptide fragments
The methods for the isolation of a keratanase-generated ‘KS-stub’antigen are 
illustrated in figure 2.5. Expanded details are provided in the sections below.
Bovine nasal cartilage A1D1 aggrecan (A1D1 CsCl density gradient fraction) was 
provided by Professor Bruce Caterson, Cardiff University. Bovine cartilage aggrecan
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^-Keratanase II (~ 275 kDa) 
^-Keratanase (~ 145 kDa)
Figure 2.4 -  Silver stain analysis of the keratan sulphate degrading enzymes. Enzymes 
were run alone under reducing conditions at a concentration of 20 milli units per lane. Silver 
staining of the gel showed keratanase to have a Mw of -145 kDa (lane 1) and keratanase II to 
have a Mw of -275 kDa (lane 2) with a number of smaller bands.
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BNC A1D1 aggrecan
I Trypsin digestion 
Trypsinised BNC A1D1 aggrecan
IResource Q 
anion exchange chromatography
I
CS/KS-rich and KS-rich populations
I
Suprose 6 
size exclusion chromatography
1
KS enriched population
Keratanase digestion
\
‘KS stub’ antigen and enzyme
]
Superose 6
KS enriched KS ‘stub’ antigen
Figure 2.5- An overview of the procedures involved in production of the KS enriched ‘stub’ 
antigen used for immunization in mAb production.
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was selected as starting material for the purification of KS rich peptide fragments 
(Heinegard & Axelsson, 1977) for use in immunisation for the production of 
keratanase generated KS ‘stub’ antibodies. Cartilage aggrecan A1D1 (410 mg dry 
weight) was previously prepared by extraction in 4 M guanidine HC1 with a protease 
inhibitor cocktail (5 mM sodium acetate anhydrous, pH 5.8 -  6.8, 10 mM Na2EDTA), 
10 mM 6-aminohexanoic acid, 5 mM benzamidine-HCl, 0.5 mM PMSF, pH 5.8 - 6.8). 
The sample was then dialysed into 50 mM sodium acetate, pH 6.8 and partially 
purified under associative conditions by CsCl density gradient centrifugation. The 
aggrecan/link protein/HA complex (A1 fraction) was taken and solid Guanidine added 
to 4 M followed by subsequent CsCl density gradient separation under dissociative 
conditions. The dissociative density gradient was separated into three fractions (A1D1, 
A1D2 and A1D3) using methods described by Heinegard & Sommarin (1987). Bovine 
aggrecan monomers (A1D1) were obtained after dialysis against 0.15 M NaCl then 
water and freeze dried.
2.3.2.1 Characterisation o f the macromolecular status o f bovine A1D1 aggrecan by 
SDS-PAGE and Western blot analysis
DMMB analysis (see section 2.3.1.1) was carried out on appropriately diluted samples 
of the purified BNC A1D1 preparation. Subsequently 10 pg GAG was deglycosylated 
using 100 mU of chondroitinase ABC per mg GAG, 80 mU of keratanase per mg GAG 
and 6 mU of keratanase II per mg GAG (see section 2.3.1.2 above) and samples were 
lyophilised.
Equal amounts of the chondroitinase / keratanase digested BNC A1D1 samples were
diluted in an appropriate volume of Milli Q™ water and further diluted 1:1 with 2x
concentrated sample buffer (see table 2.3). The samples were reduced by adding 10%
(v/v) p-mercaptoethanol and boiled for 5 minutes prior to separation by SDS-PAGE.
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The samples were loaded onto 4 - 12% (or 4 - 20% Tris glycine gradient gels or slab 
gels of 12 or 15% depending on the molecule of interests predicted size) and separated 
under reducing conditions in SDS-running buffer (table 2.3) using a gel electrophoresis 
system at 150 volts for 90 minutes or until the bromophenol blue in the sample buffer 
reached the end of the gel cassette. Molecular weight of separated molecules were 
standardised utilizing a protein molecular weight standard from Bio-Rad. Samples 
were then electrophoretically transferred to nitrocellulose membranes using the SDS 
transfer buffer (table 2.3) in a transfer apparatus for 1 hour at 100 volts. For Western 
blot analysis, nitrocellulose membranes were blocked in 5% (w/v) BSA in TSA (see 
table 2.3) for a minimum of one hour at room temperature or overnight at 4 °C. 
Membranes were then probed with primary antibodies (see epitopes in table 2.2) 2B6 
(hybridoma culture media 1:100 dilution), 3B3 (hybridoma culture media 1:100 
dilution) and 1B5 (ascities 1:5000 dilution) in 1% BSA (w/v) in TSA overnight at 
room temperature. Blots were rinsed with 3 x 10 minute washes in TSA before 
incubation with an alkaline phosphatase conjugated goat anti-mouse secondary 
antibody at a dilution of 1:7500 in 1% (w/v) BSA in TSA for 1 hour at room 
temperature. After a further 3 x 10 minute washes in TSA, the immunoblots were 
incubated with an alkaline phosphatase substrate (see table 2.3 and section 2.2.5) for 
1 0 - 5 0  minutes at room temperature or until optimal colour development of 
immunopositive bands was achieved. This analysis was used to determine the 
biochemical and macromolecular status of the BNC A1D1 aggrecan core protein. 
Western blot analysis of the chondroitinase ABC and keratanase digested BNC A1D1 
aggrecan using antibodies 2B6/3B3/1B5 recognising CS ‘stub’ epitopes on 
proteoglycan core proteins displayed staining of high molecular weight products 
(figure 2.6), indicating that the PG core protein was intact and suitable for digestion 
with TCPK -  trypsin.
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BNC A1D1
Figure 2.6 -  Analysis of the macromolecular status of BNC A1D1. Chondroitinase ABC 
and keratanase digested bovine nasal cartilage aggrecan A1D1 was stained using CS isomer 
‘stub’ mAbs 1B5, 2B6 and 3B3. Results demonstrate that the aggrecan core protein 
macromolecule was essentially intact with core protein metabolites ranging in molecular 
weight from 150 -  400 kDa as determined using Biorad molecular weight standards.
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2.3.2.2 Trypsin digestion o f BNC A1D1
400 mg dry weight of the BNC A1D1 sample was subjected to trypsin digestion using 
2 pg TPCK treated trypsin per mg BNC A1D1 in a 0.1 M Tris, pH 7.3, 0.1 M Sodium 
acetate buffer (table 2.3), for 16 hours at 37 °C. The digest was then dialysed against 
Milli Q™ water and lyophilised (Heinegard & Axelsson, 1977).
2.3.2.3 Partial purification o f KS-peptide fragments from CS-peptide fragments o f  
trypsin digested BNC A1D1 using anion exchange chromatography
Trypsin digestion of the aggrecan core protein was predicted to result in the production
of KS rich fragments and CS rich fragments of aggrecan (Heinegard & Axelsson,
1977) which could then be separated using a series of ion exchange (Resource Q) and
size exclusion chromatographic (Superose 6) steps. Anion exchange chromatography
was used as the initial separation procedure for the more highly charged CS peptide
fragments which would elute at a higher molarity of NaCl (1M - 2M) from a
population of lesser negatively charged KS peptide fragments predicted to elute at a
lower molarity of NaCl (0.1 - 0.5 M). The freeze dried trypsin-digested aggrecan
peptide preparation was reconstituted in 6 ml equilibration buffer (5 mM Tris, pH 6.8;
see table 2.3) centrifuged at 1,500 rpm for 10 minutes and the supernatant passed
through a 0.22 pm filter to remove remaining debris or air bubbles. The sample was
then applied to a 6 ml Resource Q chromatography column equilibrated in 5 mM Tris,
pH 6.8, at a flow rate of 4 ml/min. Bound material was sequentially eluted with a
linear gradient of NaCl (0 M -  2 M) over 10 column volumes. 3 ml fractions were
collected, dialysed against Milli Q™ water and analysed for glycosaminoglycans using
the DMMB assay (section 2.3.1.1). SDS-PAGE and Western blot analysis (as section
2.3.2.1) was carried out on equal volumes of the GAG containing fractions after
digestion with chondroitinase ABC (100 mU per mg GAG). The samples were
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separated on 4 - 12% Tris-glycine gradient gels transferred onto nitrocellulose and 
analysed using Western blotting with mAbs 2B6/3B3 and 5D4 to determine the 
presence of any CS or KS GAG containing peptides, respectively.
In addition to Western blot analyses using antibodies, a set of membranes were also 
probed with the lectin peanut agglutinin -  PNA (see section 2.2.6) recognising the core 
substituted disaccharide Galp(l - 3)GalNAc in O-glycan linked oligosaccharides that 
occur on the linkage region of O-linked skeletal KS. This KS-linkage region can 
become exposed after different keratanase treatments. It should be noted however, that 
this lectin (PNA) is not KS specific as it also identifies O-linked oligosaccharides aside 
from KS which are also located on the protein core of aggrecan and other molecules. 
Briefly, 40 pi samples were digested overnight at 37 °C using 80 mU of keratanase per 
mg of sulphated GAG measured using the DMMB assay. Digested samples were run 
on 4 - 12% SDS-PAGE gels and transferred to nitrocellulose using methods described 
in section 2.3.2.1. Lectin affinity analysis was carried out using a DIG glycan 
differentiation kit according to the manufacturer’s protocol. Briefly, the nitrocellulose 
was blocked with 2 ml of blocking reagent (supplied with the kit) diluted 1:10 in TSA 
(see table 2.3) for a minimum of 1 hour at room temperature. Blots were rinsed 2 x 1 0  
minutes with TSA and 1 x 1 0  minutes with TSA containing lectin buffer (table 2.3). 
Blots were then incubated with 100 pi PNA lectin in 10 ml lectin buffer for 1 hour at 
room temperature and rinsed again for 3 x 10 minutes with TSA before the addition of 
10 pi polyclonal sheep anti-digoxigenin-AP (supplied with the kit) in 10 ml TSA for 1 
hour at room temperature. Immunopositive staining was achieved after the addition of 
10ml AP substrate buffer (table 2.3) containing NBT and BCIP (see section 2.2.5). 
Figure 2.7 shows the Resource Q anion exchange chromatographic profiles detected 
using 214 nm (blue), 232 nm (pink) and 280 nm (green) wavelengths. Detection of
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Figure 2.7 - Resource Q anion exchange chromatography profile (BNC-AlDl-trypsin),
showing profiles detection using wavelengths of 280 nm (green ), 232 nm (p ink  )
and 214 nm (b lue  ). DMMB analysis (red) of Resource Q fractions indicating quantities
of sulphated GAG in each fraction. Sulphated GAG (red dashed l in e  ) was present in
fractions 1 2 -2 9 .
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carbohydrates [214 nm (blue) detects N-acetyl groups on GAG disaccharides] was 
high through fractions 10 - 3 0  representing a 0.2 -  1 M salt gradient. DMMB analysis 
was carried out on all fractions as a detection method for S-GAG fragments. This 
analysis (figure 2.7, dashed red) showed the presence of S-GAG in a peak covering 
fractions 12-29.
2.3.2.4 Analysis o f Resource Qfractions by SDS-PAGE and Western blotting
The presence of CS and/or KS containing GAG in each of the Resource Q separated 
fractions was determined using SDS-PAGE and Western blotting with CS specific 
monoclonal antibodies (2B6/3B3 mix -  figure 2.8, A), KS specific monoclonal 
antibodies (5D4 -  figure 2.8, B) and PNA lectin (KS linkage region and O-linked 
oligosaccharides -  figure 2.8, C). All three analyses showed the presence of two 
populations of aggrecan fragments in these fractions, a high molecular weight CS/KS 
containing population was identified in fractions 14-18 as well as 1 9 - 3 2  (data not 
shown). A low molecular weight population containing KS was identified in fractions 
14-16.
2.3.2.5 Further purification o f anion exchange purified KS- and KS/CS- peptide 
fragments using a Superose 6 size exclusion chromatography column
Fractions 14-16 from the Resource Q purification step, rich in low molecular weight 
5D4 positive KS GAG-peptides and higher molecular weight 5D4 and 2B6/3B3 
positive CS/KS GAG-peptides were pooled then dialysed against Milli Q™ water, 
lyophilised and reconstituted in size exclusion chromatography equilibration buffer 
(see table 2.3) and applied to a Superose 6 HR 10/30 size exclusion chromatography 
column equilibrated in 0.1 M sodium sulphate, pH 6.5-7.5. The sample was loaded 
(1.5 ml) and separated at a flow rate of 0.3 ml/min and 0.5 ml fractions were
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Figure 2.8 - SDS-PAGE and Western blot analysis of fractions after Resource Q anion 
exchange chromatography. Results revealed two subpopulations, one a high molecular 
weight CS/KS peptide fragment population and the other was a lower molecular weight KS 
peptide population present in fractions 14 - 16 as determined by 2B6/3B3 (A), 5D4 (B) and 
PNA lectin (C) analysis.
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collected. Separation was monitored at wavelengths of 280 nm, 232 nm and 214 nm. 
UV absorbance at 214 nm (blue) showed two broad peaks in fractions 16-27 and 28-40 
(figure 2.9). Peak fractions were dialysed against Milli Q™ water and analysed for 
GAG content using the DMMB assay (see section 2.3.1.1). DMMB analysis of all of 
the fractions revealed S-GAG to be present in fractions 15-40 (figure 2.9, red dashed 
line) falling into two broad peaks (fractions 15- 27  and fractions 28 - 40), consistent 
with the absorbance profiles obtained at 214 nm (blue) and 232 nm (pink) [figure 2.9].
2.3.2.6 Western blot analysis o f fractions separated by Superose 6 size exclusion 
chromatography
Samples of appropriate fractions were digested with chondroitinase ABC (100 mU per 
mg GAG) diluted in 10% (v/v) of 10 x chondroitinase buffer (table 2.3) and further 
analysed by SDS-PAGE and Western blotting as described in section 2.3.2.1. 
Membranes were probed using anti-CS (2B6/3B3 mix) and anti-KS (5D4) monoclonal 
antibodies. Western blot analysis of deglycosylated S-GAG positive fractions with KS 
specific mAb 5D4 (figure 2.10; A) and CS specific mAbs 2B6/3B3 (figure 2.10; B) 
indicated the presence of higher molecular weight CS/KS fragments in fractions 17-24, 
and lower molecular weight KS fragments in later fractions 25-29, (figure 2.10; A & 
B). Fractions 25-29 were subsequently pooled as a KS-peptide enriched fragment.
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Superose 6 size exclusion chromatography
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Figure 2.9 - Superose 6 size exclusion chromatography profile, with detection using 280 
nm (green), 232 nm (pink) and 214 nm (blue). Two broad GAG (i.e. 214 nm absorbance) 
containing peaks (blue) separated in fractions 16-27 and 28-40. Sulphated GAG quantities are 
indicated by the red dashed profile and were determined by DMMB analysis. Fractions 15-40 
contain the majority of sulphated GAG.
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Figure 2.10 -  Western blot analysis of fractions after Superose 6 size exclusion 
chromatography. Pooled fractions 14-16 from DEAE anion exchange chromatography 
containing KS- and KS/CS- peptide fragments were applied to a Superose 6 size exclusion 
chromatography column. Western blot analysis of the column eluate with mAbs 5D4 (panel A) 
and 2B6/3B3 mix (panel B) revealed that the CS/KS and KS populations had separated 
efficiently. Subsequently fractions 25-29 were pooled as a purified KS enriched peptide 
fragment preparation.
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2.3.2.7 Digestion o f purified KS-peptide fragments with keratanase and separation o f  
contaminating keratanase from KS peptide fragment ‘stubs’ by size exclusion 
chromatography
KS positive fractions (25 -  29; see figure 2.10) from the Superose 6 chromatography 
separation procedure containing KS-peptide enriched fragments were pooled, dialysed 
against Milli Q™ water and analysed by the DMMB assay (section 2.3.1.1) and 
calculated to have a concentration of 2.2 mg S-GAG. The pooled sample was 
lyophilised and reconstituted in 0.1 M Tris-HCl, pH 7.4 (optimal keratanase buffer, 
table 2.3) and digested with 80 mU of keratanase per mg S-GAG using optimal 
keratanase digestion conditions (as determined in section 2.3.1.2). In order to remove 
the keratanase enzyme from the keratanase-generated KS ‘stub’ antigen, the digested 
sample was re-applied to a Superose 6 size exclusion column at a flow rate of 0.3 
ml/min. It was predicted that the keratanase (molecular weight ~145 kDa; see section
2.3.1.3 and figure 2.4, lane 1 and 2.11, B and C) would elute in the void volume of the 
column. 0.5 ml fractions were collected and equal volumes (4 pi) were loaded onto 4 - 
12% gradient gels in an appropriate sample buffer, electrophorised and transferred to 
nitrocellulose membrane (as described in section 2.3.2.1). Western blot analysis was 
carried out on all of the Superose 6 fractions using anti KS mAb 1B4 previously 
shown to recognise lower sulphated KS sulphation motifs still present after keratanase 
digestion (Mehmet et al., 1986). Blots showed positive 1B4 staining for KS in 
fractions 22 - 28 (figure 2.11; A).
SDS-PAGE and silver stain analysis (see section 2.3.1.3) was also carried out on 4 pi 
volumes of all fractions collected after size exclusion chromatography to analyse 
separation of the keratanase enzyme from the KS ‘stub’ peptide fragment. This was to 
ensure that no antibodies would be generated to any contaminating keratanase enzyme. 
Silver stain analysis of the fraction revealed a ~145 kDa band in fraction
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Pool fractions 22-28 
(KS ‘stub’ enriched antigen)
Figure 2.11 - Separation of lower molecular weight KS ‘stub’ peptides from higher 
molecular weight keratanase enzy me using size exclusion chromatography. Western blot 
analysis with mAb 1B4 revealed that KS ‘stubs’ eluted in fractions 22-28 (A). Silver stain 
analysis of fractions showed a band at ~145 kDa in fraction 14 (C). This was the same 
molecular weight as was previously observed for the keratanase enzyme control from the same 
keratanase batch (B).
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14 (figure 2.11; C) that was similar in size to a silver stain of the enzyme alone (figure 
2.4; lane 1 and figure 2.11, B). This data indicates that the keratanase enzyme had 
likely been separated in different fractions to the KS ‘stub’ peptide fragments (figure 
2.11). Fractions 22 - 28 were pooled and selected as the immunising antigen.
2.3.3 Immunisation andfusion using the keratanase-generatedKS ‘stub* antigen
Murine mAbs were generated by immunising a single 4-6 week old female Balb/c 
mouse with the keratanase generated KS ‘stub’ antigen prepared as described in 
section 2.3.2 and figure 2.5 (Kearney et al., 1981; Caterson et al., 1983; Caterson et 
al, 1987). The draining lymph nodes of the immunized animal were used as a source 
of antibody producing lymphocytes for fusion with immortal mouse myeloma cell line. 
On day 1, for the initial injection, the antigen was dissolved in PBS and 500 pi of the 
antigen solution was mixed with an equal volume of Freunds complete adjuvant. 10 - 
50 pi was injected subcutaneously at 6 sites (2 at the hind footpads [10 - 20 pi each], 2 
at lateral thoracic [50 pi each] and 2 at inguinal regions [50 pi each]). On day 3, the 
Ag was mixed with equal volumes Freunds incomplete adjuvant with similar volumes 
being injected at the same sites. The antigen was dissolved in saline for all subsequent 
immunisations with the same volumes at the same injection sites on days 6, 9 and 12. 
On day 10 of the immunisation period an X 63 Ag 8.563 myeloma cell line, that does 
not express immunoglobulin heavy or light chains, was cultured in RPMI-C media in 
preparation for hybridoma fusion (Kearney et al, 1979). Hybridoma fusion was 
carried out on day 14. The Ag 8 myeloma cells were harvested and washed twice with 
RPMI 1640 medium at 4 °C to remove FCS and other media components, resuspended 
in 20 ml RPMI-C and put on ice. The mouse was sacrificed by cervical dislocation 
and the draining lymph nodes nearest the sites of injection (axillary, brachial, inguinal 
and popliteal lymph nodes) were harvested under sterile conditions into ice cold (4 °C)
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PBS, kept on ice and used as a source of activated lymphocytes for hybridoma 
production. The lymph nodes were teased apart to release the lymphocytes and passed 
through a 16 gauge needle, prior to filtering through a sterile glass wool pipette to 
separate the cells from connective tissues. To this cell suspension 14 ml of cold RPMI 
was gently added and the lymph cells and Ag 8 cells were spun at 1,500 rpm for 10 
minutes at 4 °C. Media was aspirated off both cell pellets. The Ag 8s were resuspended 
in a known volume of cold RPMI and an appropriate volume representing a 2:1 Ag 8 
to lymphocyte cell ratio was overlaid onto the lymphocyte pellet. This was spun at 4 
°C for 10 minutes at 1,500 rpm. Media was aspirated from the tube and flicked to 
physically mix the two cell populations. 1 ml of poly ethylene glycol pre-warmed to 37 
°C was added drop wise very slowly whilst shaking over a period of 1 minute. 
Following this, 10 ml of RPMI 1640 (room temperature) was added drop wise slowly 
whilst shaking the tube to slowly dilute out the PEG and promote cell fusion 
(Pontecorvo, 1975). A further 40 ml of warm RPMI 1640 was added slightly faster. 
This was then spun at 1,500 rpm for 10 minutes at 23 °C. Media was aspirated off and 
the cells resuspended in 200 ml of HAT supplemented RPMI-C culture media (see 
section 2.2.4). The media was also supplemented with macrophage feeder cells from a 
3 ml peritoneal lavage of a Balb/c mouse. 1 ml per well of the fused cell media was 
applied to eight 24 well sterile Costar plates per fusion, and left at 37 °C for 2 weeks. 
Antibody producing hybridomas were generated from the fusion of mouse lymph node 
cells with the non Ig secreting Ag8 myeloma cell line (figure 2.12).
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Figure 2.12 -  General procedures for generating hybridomas which may permanently secrete 
monoclonal antibodies (adapted from: www.antibodyresources.com).
B. Kerr PhD thesis 2005 103
2.3.4 Screening and characterisation
2.3.4.1 Antigens used in screening for keratanase generated KS ‘stub’ neoepitope 
monoclonal antibodies
A series of antigens were required in order for appropriate screening of the hybridoma 
supernatants to determine antibody specificity for keratanase-generated KS ‘stub’ 
neoepitopes versus protein epitopes or other non KS epitopes and linear KS chain 
epitopes.
A series of screening antigens were prepared as follows:
1. Keratanase-generated immunizing antigens (BNC ABC-trypsin-KS peptides) 
(see section 2.3.2)
2. Bovine nasal cartilage aggrecan (BNC AID 1)
3. Keratanase II digested BNC (ABC)-trypsin-KS peptides (see section 2.3.2)
4. Bovine comeal KSPGs (see chapter 4 for preparation)
5. Keratanase digested bovine comeal KSPGs (see chapter 4 for preparation)
6. Keratanase II digested bovine comeal KSPGs (see chapter 4 for preparation)
2.3.4.2 Screening o f hybridoma culture supernatants using direct ELISAs 
Microtitre plates were coated with appropriate antigens at 5 pg/ml of 20 mM sodium 
carbonate, pH 9.6 over night at 37 °C. Primary screening analysed the immunising 
antigen specificity and secondary screening analysed the immunising antigen 
compared with non-keratanase digested BNC A1D1 and BNC ABC core. Plates were 
washed twice with TSA (300 pl/well) prior to blocking with 1% (w/v) BSA in TSA for 
a minimum of 1 hour at 37 °C. Plates were washed twice with TSA (300 pl/well) and 
100 jil of culture supernatant from hybridoma wells was removed under laminar flow 
and added to appropriate microtitre plate wells and incubated for 2 hours at 37 °C. The 
plates were then washed three times with TSA prior to addition of an alkaline-
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phosphatase (AP) conjugated secondary antibody (1:5000 dilution) incubated at 37 °C 
for 1 hour. The plates were washed again six times with TSA (300 pi/well). Finally an 
alkaline phosphatase substrate (1 mg/ml) was applied dissolved in DEA buffer (table
2.3) at 100 pl/well for 1 hour at 37 °C. The development of colour was observed and 
read using a Labsystems Multiscan MS plate reader at 405 nm. Positive development 
of colour indicated the presence of the sought monoclonal antibodies in the hybridoma 
media.
2.3.4.3 Screening for mAbs using SDS-PAGE and Western blot analysis
To further define the specificity of the new clones volumes equivalent to 5 pg of GAG, 
of the same antigens used in ELISA analysis (section 2.3.4.2), were separated on SDS- 
PAGE gradient gels and analysed by Western blotting (as described in section 2.3.2.1) 
using hybridoma supernatant from the new mAb clones, along with existing anti KS 
mAb (e.g. 5D4, 4D1, table 2.2) and lectin affinity blotting (PNA for skeletal KS and 
GNA for comeal KS, see section 2.3.2.3).
2.3.4.4 Cloning hybridoma cell lines to limiting dilution
New putative ‘KS stub’ antibody producing hybridoma cell lines of interest were 
expanded in 100 mm plates in 10 ml RPMI-C media (see section 2.2.4). A single 
confluent 100 mm plate of cells were re-suspended in 10 ml RPMI-C and further 
diluted 1:25000 by diluting 2pl of the cell suspension in 50 ml of RPMI-C 1 ml (tube 
1). Tube 1 was further diluted 1:10 in RPMI-C in tube 2. 200 pl/well of each tube was 
plated into two sterile 96 well plates and left for 2 weeks at 37 °C. After 2 weeks 
hybridoma media from the wells of the 2 plates were screened by ELISA (as described 
above in section 2.3.4.2) using keratanase versus non-keratanase digested BNC (ABC)
core (5 pg GAG / ml TSA) as coating antigens to re-screen for the keratanase ‘stub’
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mAbs. Positive subclones were culture expanded in several 100 mm plates and cells 
were preserved by re-suspending in a cryoprotective media [90% (v/v) fetal bovine 
serum, 10% (v/v) dimethyl sulphoxide (DMSO) see section 2.2.4] and frozen at -80 
°C and in liquid nitrogen.
2.3.4.5 Identification o f the Immunoglobulin class o f the subclones
The immunoglobulin subclass of the monoclonal antibodies was determined using a 
clonotyping ELISA kit (Clonotyping system-AP; Southern Biotechnology Ass Inc.). A 
goat anti-mouse immunoglobulin capture antibody was coated at a concentration of 5 
pg/ml in phosphate buffered saline (PBS) at 100 pl/well onto four 96 well microtitre 
plates and left overnight at 4 °C. After three washes with 300 pi TSA the plates were 
blocked with 200 pl/well 1% (w/v) BSA in TSA for a minimum of 1 hour at 37 °C. 
After a further three washes with TSA, 100 pl/well of the antibody hybridoma media 
was added and incubated for 1 hour at room temperature. Following four washes with 
TSA the plates were incubated with various alkaline phosphatase labelled secondary 
goat-anti mouse antibodies (IgM, IgA, IgG, IgG2a, IgG2b, IgG3) at a 1:500 dilution in 
1% (w/v) BSA in TSA for 1 hour at room temperature. After a final six washes with 
TSA, 100 pl/well of AP substrate (table 2.3) was added and plates were read at 405 nm 
after 30 minutes and 60 minutes incubation at room temperature.
All new antibodies (BKS-1 and BKS-2) were identified as IgM, kappa light chain 
monoclonal antibodies.
2.3.4.6 Analysis o f  BKS-1 reactivity after removal ofN-linked oligosaccharides from  
corneal and skeletal PG extracts
Eight volumes equivalent to 2 pg GAG of bovine comeal and cartilage PG extracts
were digested with 80 mU of keratanase per mg GAG (see section 2.3.1.2) in 0.1 M
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Tris acetate, pH 6.8 for 24 hours at 37 °C. After 24 hours, the samples were further 
digested with 6 mU of keratanase II per mg GAG and 8 mU endo-p-galactosidase per 
mg GAG of for 24 hours at 37 °C. Samples were further digested using enzymes from 
a protein deglycosylation kit obtained from Sigma-Aldrich according to the 
manufacturer’s protocol. Briefly, the corneal and skeletal KS samples that had been 
pre-digested with keratanase followed by keratanase II and endo-p-galactosidase were 
lyophilised and reconstituted in 7.5 pi of Milli Q™ water. 2.5 pi of 5 x reaction buffer 
and 0.61 pi of denaturation solution (both supplied with the kit) were added and mixed 
gently. Samples were heated at 100 °C for 5 minutes. When cooled, 0.61 pi of 
TRITON X-100 solution (supplied with kit) was added and mixed gently. Each 
enzyme was diluted 10 x in 1 x reaction buffer and 1 pi of each added individually or 
sequentially in the following order following deglycosylation using the keratanase 
enzymes:
Experiment A:
1. PNGase F (from cryseobacterium meningoseptium),
2. O-glycosidase (from streptococcous pneumonia).
Experiment B:
1. P (1-4) - galactosidase (from streptococcous pneumonia),
2. p-N-acetyl glucosaminidase (from streptococcus pneumonia)
3. Neuraminidase / galactosiminidase / N-acetylglucosaminidase.
Samples were incubated overnight at 37 °C and run on 12% slab gels. Gels were 
transferred as described in section 2.3.2.1 and analysed by Western blotting using mAb 
BKS-1.
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2.3.4.7 Analysis o f BKS-1 reactivity with KSPGs isolated from different animal species 
Tissues were obtained from bovine, porcine and human cornea and cartilage and from 
murine and avian cornea. These tissues were diced and extracted in 4 M guanidine HC1 
with protease inhibitors (table 2.3) as described in detail in chapter 4, section 4.3.1.1. 
Crude PG extracts were dialysed to Milli Q™ water and DMMB analysis carried out to 
ascertain GAG concentration of the samples. Volumes equivalent to 2 pg GAG were 
run undigested or digested with keratanase (80 mU/mg GAG, 24 hours at 37 °C) on 4 - 
12% Tris glycine gradient gels prior to transfer onto nitrocellulose for BKS-1 analysis 
using Western blotting.
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2.4 Results
2.4.1 Production and screening of novel keratanase-generated neoepitope mAbs, 
BKS-1 and BKS-2
2.4.1.1 ELISA analysis
Balb/c mice were immunised with the ‘KS stub’ peptide antigen and mAb hybridomas 
produced using procedures described in section 2.3.3. An initial screen of the 8 x 24 
well plates by direct ELISA coating with the immunising antigen, revealed 4 potential 
hybridomas (well numbers 6A5, 1D4, 4B4, 5D3) selected on the bases of their higher 
optical density readings of 0.5 -  1.5 at 405 nm (data not shown). Positive wells were 
re-screened by direct ELISA using the ‘KS stub’ immunising peptide antigen, BNC 
(ABC) core and BNC A1D1 as coating antigens. This screen showed 2 of the positive 
clones (6A5 and 1D4; figure 2.13) to have little or no reactivity with BNC (ABC) core 
or with BNC A1D1 with optical density (OD) readings of < 0.5. However, strong 
reactivity was achieved using the immunising antigen KS ‘stub’ with an OD reading of 
>3.0 (figure 2.13). In contrast, mAbs 5D3 and 4B4 showed positive reaction with the 
immunising antigen but also with BNC (ABC) core and BNC A1D1 suggesting that 
they may be antibodies to some other epitope common between all coating antigens, 
e.g. to a region of the protein core or an N- or O-linked oligosaccharide. Reactivity 
with 1B4 and 5D4 were used as positive and negative controls for binding of the 
coating antigens in these ELISAs (figure 2.13).
From these ELISA results 2 hybridoma cell lines, 6A5 and 1D4, were selected for 
further analysis and were designated BKS-1 and BKS-2, respectively. A third 
screening ELISA was carried out in which a keratanase generated ‘KS stub’ antigen 
was further digested with keratanase II. BKS-1 and BKS-2 immunoreactivity was 
shown to be greatly reduced with this coating antigen (results not shown). This 
indicated that the 2 antibodies were specifically recognising a keratanase-generated
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Figure 2.13 -  Direct ELISA analysis of the positive hybridoma lines, i.e. 6A5, 1D4, 4B4 
and 5D3 using the immunising antigen, BNC (ABC) core and bovine cartilage aggrecan 
(BNC A1D1) as coating antigens. Clones 6A5 and 1D4 were highly reactive with the 
keratanase digested immunising antigen and were not reactive with the undigested BNC 
(ABC) core or the BNC A1D1. Clones 4B4 and 5D3 were also positive with the immunising 
antigen; however, they also showed high reactivity with BNC ABC core and BNC A1D1. 
Anti-KS mAbs 1B4 and 5D4 were used as positive and negative controls for the coating 
antigens and showed reduced reactivity with the keratanase digested immunising antigen as 
expected.
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neoepitope on the KS ‘stub’ region, which could be further removed by keratanase II 
treatment.
2.4.1.2 Screening and further characterisation o f the specificity o f hybridoma cell lines 
BKS-1 and BKS-2 by Western blotting
Western blot analysis (as described in section 2.3.2.1) with mAbs BKS-1 (figure 2.14;
A) and BKS-2 (figure 2.14; B) against BNC (ABC) core (figure 2.14; lane 1),
keratanase digested BNC (ABC) core (lane 2) and keratanase II digested BNC (ABC)
core (lane 3), showed immuno-specific staining only with keratanase digested BNC
(ABC) core (figure 2.14; A and B, lane 2) which generated a non-reducing terminal 6-
sulphated N-acetylglucosamine (6-S-GlcNAc) residue. There was no staining for BNC
(ABC) core with native KS chains or keratanase II digested BNC(ABC) core (figure
2.14; A and B, lanes 1 and 3, respectively) which generated a KS ‘stub’ with either a
non-reducing terminal 6-sulphated galactose or an unsulphated galactose.
Controls for each of the antigens were run using anti-KS mAb 5D4 (figure 2.14; C)
recognising linear sulphated poly-N-acetyl-lactosamine motifs (depicted in figure 2.16)
and a PNA lectin (figure 2.14; D) recognising galactose-P-(l-3)-N-
acetylgalactosamine on O-linked oligosaccharides (also depicted in figure 2.16). As
expected 5D4 staining was strong before digestion of BNC (ABC) core with
keratanase (figure 2.14; C; lane 1), was considerably reduced after keratanase and even
more so after keratanase II digestion (figure 2.14; C; lanes 2 and 3).
Conversely, staining for PNA lectin was limited before digestion of BNC (ABC) core
(figure 2.14; D; lane 1) and was greatly increased after keratanase and keratanase II
digestion (figure 2.14; D; lanes 2 and 3, respectively) as expected.
Further characterisation was carried out by Western blotting against a preparation of
bovine comeal KSPGs with native KS chains (figure 2.15; A, B, C and D; lane 1),
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Figure 2.14 - Characterisation of mAbs against untreated BNC (ABC) core (lane 1), 
keratanase (lane 2) and keratanase II (lane 3) digested BNC (ABC) core. The new KS
‘stub’ mAbs ((A)]BKS-1 and [B] BKS-2) were specific only for keratanase digested BNC 
(ABC) core; [C] 5D4 control recognising the linear sulphated KS chain epitopes; [D] PNA 
lectin control recognising O-linked oligosaccharides similar to that remaining on KS after 
keratanase or keratanase II digestion.
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Figure 2.15 - Characterisation of mAbs against KS ‘stubs’ on corneal KSPGs. Comeal 
PGs (+/- keratanase or keratanase II) as screening antigens. The new KS ‘stub’ antibodies ([A] 
BKS-1 and [B] BKS-2) show specificity only for keratanase digested bovine comeal KSPGs 
(lane 2). [C] 4D1 control recognising linear sulphated KS chain epitopes showed reduced 
staining with digestion (lanes 2 & 3). [D] GNA lectin control to mannose of N-linked 
oligosaccharides similar to that remaining on KS after keratanase digestion. Lectin staining 
showed increased staining after both keratanase and keratanase II digestion of comeal KSPGs 
(D, lanes 2 & 3).
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Figure 2.16 Predicted neoepitopes for KS ‘stub’ mAbs BKS-1 and BKS-2 at the non-reducing 
terminal 6-sulphated-N-acetylglucosamine residue (orange squares) of a keratanase digested 
KS chain (blue squares represent Gal residues; F represents fucose attachments and S 
represents sulphate groups). The diagram also shows the epitopes for the antibodies (5D4 & 
4D1 in pink) and lectins (PNA & GNA in blue) used as controls for binding of coating 
antigens in direct ELISA screening analysis. 5D4 and 4D1 recognise linear sulphated poly-N- 
acetyl-lactosamine structures from within KS chains. PNA lectin recognises a Galpl-3 
GalNAc disaccharide from within the linkage region of KS type II or in O-linked 
oligosaccharides. GNA lectin recognises terminal mannose a(l-3), a (l-6 ) or a (l-2 ) linked to 
mannose, identifying high mannose N-linked oligosaccharides or KS type I linkage regions.
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keratanase digested bovine comeal KSPGs (figure 2.15; A, B, C and D; lane 2) and 
keratanase II digested bovine comeal KSPGs (figure 2.15; A, B, C and D; lane 3) 
[generating the neoepitopes described above]. There was strong reactivity with anti- 
KS mAb 4D1 [recognising linear sulphated poly-N-acetyl-lactosamine motifs within 
KS chains (depicted in figure 2.16) with bovine comeal KSPGs (figure 2.15; panel C; 
lane 1). A reduction in 4D1 staining was apparent with keratanase and keratanase II 
digestion as expected (figure 2.15; C; lanes 2 and 3).
GNA lectin (figure 2.15; D) [recognising high mannose oligosaccharide structures 
present in N-linked oligosaccharides or within the linkage region of N-linked KS, 
depicted in figure 2.16] showed an increase in staining after keratanase and keratanase 
II digestion of KS (figure 2.15; D; lanes 2 and 3). Specific reactivity of the new mAbs 
with keratanase treated comeal KSPGs (figure 2.15; A and B; lane 2), but not with 
undigested (lane 1) or keratanase II digested (lane 3) KSPGs, indicated that the BKS-1 
and BKS-2 mAbs generated were specifically recognising keratanase generated (i.e. 
not keratanase II generated) ‘stub’ structures in the KS chain. These analysis (figure 
2.14, BNC (ABC) core and figure 2.15, comeal PGs) also indicate that the reactivity of 
the two new mAbs (BKS-1 and BKS-2) was not directed against a linkage region 
epitope, or amino acid sequence present on the core protein, as these differ between 
aggrecan and comeal KSPGs.
The results presented above strongly suggest that the new KS ‘stub’ mAbs, BKS-1 and 
BKS-2, were recognising the non-reducing terminal 6-sulphated-N- acetylglucosamine 
(6-S-GlcNAc) neoepitope that was generated as a direct result of keratanase cleavage 
of either KS type I or KS type II chains (depicted in figure 2.16).
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2.4.1.3 Characterisation o f BKS-1 epitopes
A series of digests were carried out to further establish the epitope of mAb BKS-1. 
Digests were carried out on PGs with KS type I substitutions isolated from cornea and 
PGs with KS type II substitutions isolated from cartilage that were both digested with 
keratanase to expose BKS-1 epitopes. Additional and subsequent digests with endo-p- 
galactosidase and keratanase II were also carried out to remove as much of the KS 
chains as possible whilst maintaining the BKS-1 neoepitopes (see chapter 3; figure 3.4; 
A, B, C & D). A short KS ‘stub’ attached through either the N- or O- KS linkage 
regions of KS types I and II, respectively remained attached to the protein core.
Further deglycosylation of these N- or O- linked oligosaccharide structures and KS 
structures was performed using the enzymes tabulated below in Table 2.6.
Enzyme Structure cleaved
PNGase F Completely removes Asp-N-linked complex high 
mannose oligosaccharides including asp-N-linked KS
O-glycosidase Specifically cleaves serine or threonine linked 
unsubstituted Gal-P (l-3)-GalNAc from O-linked 
oligosaccharides, but not O-linked KS
a-2 (3,6,8,9) neuraminidase Cleaves all non-reducing terminal Sialic acids
p (1-4) galactosidase Specifically releases non-reducing terminal P(l-4) linked 
galactose residues
P-N-acetyl glucosaminidase Cleaves non-reducing terminal P-linked N- 
acetylglucosamine residues
Table 2.6 -  Deglycosylation enzymes and structures cleaved
This analysis was designed to demonstrate that BKS-1 specifically recognises the KS 
‘stub’ structure generated as a result of keratanase digestion of KS GAGs which show 
no specificity for N- or O-linked oligosaccarides or to non-reducing terminal 
neuraminic acid, unsulphated galactose or N-acetylglucosamine. BKS-1 staining was 
present on both KS types I and II after digestion with keratanase followed by endo-P- 
galactosidase and keratanase II (figures 2.17; A and B, lane 1). This observation is 
discussed in more detail in chapter 3.
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Figure 2.17 N- and O- glycosidase, digestion of KS types I (corneal KS - A) and II (skeletal 
KS - B) after keratanase followed by endo-[3-galactosidase and keratanase II digestion (lane 1). 
PNGase F removed the BKS-1 KS ‘stub’ neoepitope on corneal KS type I which is linked 
through N-glycosidic linkages while staining remained on skeletal KS after removal of N- 
linked oligosaccharides (lane 2), indicating that BKS-1 was recognising a keratanase generated 
stub neoepitope and not an N-linked oligosaccharide. O-glycosidase removed O-linked 
oligosaccharides and demonstrated that BKS-1 was not recognising these structures (lane 3).
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After PNGase F digestion of type I KS, BKS-1 positive immunostaining was abolished 
because there was cleavage of all asparagine N-linked complex mannose 
oligosaccharides (figure 2.17; A, lane 2). The KS chains on KS type I are known to be 
N-glycosidically linked to the core protein and PNGase F is an effective method for 
removal of complete N-linked oligosaccharides regardless of the extended chain 
structure, meaning that it is capable of completely removing KS type I chains from 
KSPGs. For this reason all BKS-1 neoepitopes were removed after such treatment and 
BKS-1 staining was negative. Conversely, after O-glycosidase treatment (figure 2.17; 
A, lane 3) which specifically removes only serine / threonine linked unsubstituted 
galactose p (l-3)-N-acetylgalactose-a, BKS-1 staining remained as KS type I chains 
are not linked through O-linked oligosaccharides. The molecular weight staining was 
slightly reduced in size, indicating that digestion did remove some O-linked 
oligosaccharides that were present on the comeal KSPG core proteins for which BKS- 
1 shows no specificity.
In bovine cartilage where skeletal KS type II KS is present the PG molecular weight 
was considerably reduced from 75 kDa to 60 kDa after PNGase F treatment (figure 
2.17; B, lane 1 compared to lane 2) indicating their removal of N-linked 
oligosaccharides was accomplished. However, BKS-1 staining was not markedly 
affected by PNGase F treatment because KS type II is the major O-glycosidically 
linked KS GAG found on the core protein in cartilage aggrecan. The O-glycosidase 
used in this analysis requires that the O-linked oligosaccharide to be removed, have the 
exact structure of Galpl—6GalNAc—O—S/T with no further substitutions (see table 
2.6). However O-linked KS type II has got a complex extended structure and therefore 
cannot be removed using this enzyme. BKS-1 reactivity to the KS ‘stub’ neoepitope is 
still present after digestion using O-glycosidase (figure 2.17; B, lane 3) and removal of 
O-linked oligosaccharides. Even after the removal of the majority of the extended KS
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portion of the chain using keratanase, endo-P-galactosidase and keratanase II treatment 
a range of structures still remain on the KS ‘stub’ (see chapter 3, section 3.3.2, figure
3.4) such as fucose and other attachments that would require removal before becoming 
a substrate for the O-glycosidase. The results reiterate the proposal that BKS-1 shows 
specificity for structures within the KS chain ‘stub’ (figure 2.16), and not to N- or O- 
linked oligosaccharides. BKS-1 staining was still present after a-2 (3, 6, 8, 9) 
neuraminidase [cleaving all non-reducing terminal branched or unbranched sialic 
acids], p (1-4) galactosidase [releasing only p (1-4) linked non-reducing terminal 
galactose] and p N-acetylglucosaminidase [cleaving all non-reducing terminal P-linked 
GlcNAc residues] on both KS types I and II (figure 2.18, lanes 1 - 4 )  demonstrating 
that BKS-1 showed no specificity for non-reducing terminal neuraminic acid, 
unsulphated galactose or unsulphated N-acetyl glucosamine which are all present on 
KS.
2.4.2 Western blot analysis examining species cross-reactivity of mAb BKS-1
BKS-1 immunoreactivity was analysed against cornea and cartilage proteoglycan 
extracts from a range of different animal species [bovine, human, chick, mouse and 
pig] (figure 2.19). BKS-1 showed a positive immunoreactivity with bovine, human and 
porcine cornea and cartilage, and weakly with avian and murine cornea after 
keratanase digestion.
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Figure 2.18 Neuraminidase, galactosidase and N-acetyl glucosaminidase digestion of KS 
types I (corneal) and II (skeletal) after keratanase followed by endo-p-galactosidase and 
keratanase II digestion. BKS-1 staining remained on both types I and II KS after treatment 
with each of these enzymes indicating that non-reducing terminal sailic acid, non-sulphated 
galactose or non-sulphated N-acetylglucosamine were not involved in the BKS-1 neoepitope.
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Figure 2.19 Animal species cross-reactivity o f the KS ‘stub5 mAb BKS-1 before and after 
keratanase treatment.
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2.5 Discussion
The aim of this chapter was to generate a novel monoclonal antibody probe which 
would recognise a keratanase-generated neoepitope at the non-reducing terminal of KS 
chains. The experiments described involved the partial purification of a keratanase 
digested bovine nasal cartilage aggrecan peptide antigen, isolated from within the 
keratan sulphate domain of trypsin cleaved bovine cartilage aggrecan. This was 
achieved using a series of anion exchange and size exclusion chromatographic 
techniques. The antigen was successfully used in immunisation to produce two 
antibodies that specifically recognise the non-reducing terminal 6-S-GlcNAc residue of 
the KS chain that was generated by keratanase digestion of type I or type II (and 
presumably type III) KS GAG chains. ELISA and Western blot screening analysis 
using a number of selected antigens (figures 2.13, 2.14 and 2.19) demonstrated that the 
new mAbs, designated BKS-1 and BKS-2, were immunoreactive with KS extracted 
from both skeletal and corneal tissues from a wide range of animal species. Screening 
indicated that the new mAbs were recognising the desired keratanase generated 
structure within the KS chain which was common to both KS types I and II and not a 
core protein or linkage region epitope as both of these latter structures differ between 
skeletal and corneal KS and KSPGs. These secondary screenings also demonstrated 
that the new Abs showed no specificity for the linear sulphated KS structure 
recognised by 5D4 and 4D1 as the tissue extracts required prior keratanase digestion to 
generate the antigen.
It was also shown that BKS-1 was not recognising N-linked oligosaccharides as 
digestion of corneal KSPGs (essentially all N-linked) with PNGase F abolished 
immunoreactivity with BKS-1. Similarly, PNGase F treatment of skeletal KSPGs did 
not remove BKS-1 reactivity as the majority of KS chains on cartilage aggrecan are 
attached to the core protein via an O-linked oligosaccharide. It was not possible to
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demonstrate this using an O-glycosidase because this enzyme cannot remove O-linked 
KS type II from skeletal PG core proteins (table 2.6). In addition, further evidence for 
BKS-1 neoepitope to be a non-reducing terminal 6-S-GlcNAc residue was generated 
from a lack of reactivity for keratanase II digested KS types I or II.
It is known that keratanase hydrolyses the p (1-4) galactosidic linkage between 
galactose and N-acetylglucosamine where the linking galactose is unsulphated but the 
N-acetylglucosamine residue is sulphated at position 6 (Nakazawa et al., 1975; 
Nakazawa & Suzuki, 1975) (see section 2.3.1) with a resulting 6-sulphated-N- 
acetylglucosamine remaining at the non-reducing terminal of the KS ‘stub’ on both 
skeletal and corneal KS after treatment. Based on the observations presented above it 
is proposed that BKS-1 specifically recognises the keratanase generated non-reducing 
terminal 6-S-GlcNAc residue that is generated after keratanase digestion of both KS 
types I and II (figure 2.16).
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2.6 Chapter summary
A keratanase digested bovine nasal cartilage aggrecan KS region peptide 
antigen was created and partially purified using anion exchange and size 
exclusion chromatography procedures.
Two novel monoclonal antibodies were generated to the keratanase-generated 
‘KS stub’ antigen and were called BKS-1 and BKS-2.
The new antibodies were screened using- ELISA and Western blotting 
techniques which demonstrated keratanase ‘KS stub’ specificity on both KS 
types I and II and presumably KS type III.
BKS-1 was shown in Western blot analysis to cross react with keratanase- 
generated ‘KS stub’ neoepitopes in KS GAG for human, bovine, porcine, 
murine and avian cornea and cartilage tissues.
The BKS-1 mAb specifically recognises a non-reducing terminal 6-sulphated 
N-acetyl glucosamine residue remaining on both KS types I and II after 
keratanase digestion. It shows no specificity for keratanase II digested KS.
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Chapter 3 - Sulphation motif analysis of KS types I and II 
glycosaminoglycans.
3.1 Introduction
KS type I and KS type II are currently defined by their N- and O-linkages to a core 
protein, respectively rather than from their tissue source (e.g. corneal versus skeletal) 
because N- and O-linked KS post-translational modifications can occur either 
individually or collectively on a large number of matrix, cell surface and intracellular 
proteins (Funderburgh, 2000, review). The generally accepted structure for KS type I 
has been proposed to be composed of a pattern of non-sulphated N-acetyl-lactosamine 
disaccharides located next to the linkage region oligosaccharide, with mono-sulphated 
N-acetyl-lactosamine in the mid-regions of the KS GAG chain and disulphated N- 
acetyl-lactosamine disaccharides concentrated towards the non-reducing end of the KS 
GAG chain (Oeben et al., 1987; Stuhlsatz et al, 1989; see chapter 1 for review). The 
generic structure for KS type II has been reported to occur with a predominance of 
disulphated and occasional interdispersed monosulphate N-acetyl-lactosamine residues 
present throughout the KS glycosaminoglycan chain with some mono-sulphated N- 
acetyl-lactosamine residues present towards the non-reducing terminal of the KS 
glycosaminoglycan chain (Funderburgh, 2000 - see figure 1.3 chapter 1).
This chapter describes the use of the newly developed mAb, BKS-1 (see chapter 2), 
recognising keratanase generated KS ‘stub’ neoepitopes, in conjunction with other pre­
existing anti-KS mAbs that recognise linear KS sulphation motifs (e.g. 5D4, Caterson 
et al., 1983; Mehmet et al., 1986), to examine KS disaccharide sulphation pattern 
motifs that occur on corneal (KS type I) and skeletal (KS type II) KSPGs after they 
have been subjected to sequential KS glycosaminoglycan degrading enzymes; i.e. 
keratanase, endo-p-galactosidase and keratanase II (see chapter 2, section 2.3.1 for 
further details).
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3.2 Materials and Methods
3.2.1 Materials
All enzymes and related buffers were as described in chapter 2, sections 2.2 and table
2.3 and were used as detailed in section 2.3.1. All SDS-PAGE and Western blotting 
material were as described in section 2.2.5 and table 2.3 and methods as described in 
section 2.2.3.1. Bovine nasal cartilage aggrecan (ABC) core was obtained from stocks 
available in the lab (see chapter 2, section 2.3.1.1).
3.2.2 Analysis of deglycosylated KS chains using anti-KS mAbs (5D4, 4D1 and 1B4) 
and anti-KS ‘stub’ mAb BKS-1 recognising keratanase-generated KS ‘stub’ 
neoepitopes.
Partially purified bovine comeal KSPGs were used as a source of type I KS chains 
whilst bovine nasal cartilage aggrecan was used as a source of type II KS chains. Both 
preparations were either used undigested or subjected to a series of digests as follows:
1. No digestion
2. + keratanase
3. + keratanase II
4. + endo-P-galactosidase
5. sequential digest of keratanase -> endo - P-galacto sidase -> keratanase II
Digests were carried out using optimal enzyme / substrate ratios as determined in 
chapter 2, section 2.3.1. Following digestion, samples were lyophilised and 
reconstituted in lx SDS-sample buffer (table 2.3) prior to separation on 4-20% Tris 
glycine gradient gels. Gels were transferred to nitrocellulose membrane and subjected 
to Western blot analysis (see chapter 2, section 2.2.3.1) with a series of different KS
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monoclonal antibodies recognising linear sulphation motif sequences within the KS 
chain, namely 5D4, 4D1, 1B4 [all at 1:100 dilution], (for epitopes see table 2.2) and 
with the new mAb BKS-1 recognising a keratanase-generated ‘stub’ neoepitope 
(hybridoma supernatant at a 1:100 dilution).
3,2.3 Sequential digestion of KS-rich PGs with specific KS degrading enzymes 
Optimal KS enzyme digests (see chapter 2, section 2.3.1) were carried out with various 
sequences of enzymes for 24 hours each at 37 °C as follows:
Experiment 1:
A. No digest
B. + keratanase
C. + keratanase -> endo-p-galactosidase
D. + keratanase -> endo-p-galactosidase -> keratanase II
E. + keratanase -> keratanase II
F. + keratanase -> keratanase II -> endo-P-galactosidase
Experiment 2:
A. No digest
B. + endo-p-galactosidase
C. + endo-p-galactosidase -> keratanase
D. + endo-p-galactosidase -> keratanase -> keratanase II
E. + endo-P-galactosidase -> keratanase II
F. + endo-P-galactosidase -> keratanase II -> keratanase
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Experiment 3:
A. No digest
B. + keratanase II
C. + keratanase II -> keratanase
D. + keratanase II -> keratanase -> endo-p-galactosidase
E. + keratanase II -> endo-P-galactosidase
F. + keratanase II -> endo-p-galactosidase -> keratanase
SDS-PAGE and Western blot analysis (as in chapter 2 section 2.3.2.1) was carried out 
on these digests with anti KS mAb 5D4 and anti KS ‘stub’ mAb BKS-1 to analyse the 
various KS chain structures remaining after such treatment.
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3.3 Results
3,3.1 New sulphation pattern structures fo r  KS - variations from  the accepted 
generic structure proposed fo r  KS
In order to determine the type of potential KS epitope structures that remain after 
different kinds of KS deglycosylation procedures, a series of digests were carried out 
as described in section 3.2.2 and were analysed on SDS-PAGE gels using Western 
blotting with KS specific mAbs. The results observed, showed positive 
immunoreactivity for all undigested KS type I chains (on corneal KSPGs) and KS type 
II chains (on nasal cartilage aggrecan) using existing mAbs 4D1, 1B4 (data not shown) 
and 5D4 (figure 3.1; A and B), which was consistent with previous observations 
(Caterson et al, 1983; Mehmet et al., 1986) that epitopes for these mAbs were all 
present on native KS GAG chains substituted on corneal KSPGs or nasal cartilage 
aggrecan.
Keratanase cleaves KS chains only between unsulphated Gal p i-4 GlcNAc-6S 
residues (Nakazawa et al., 1975; Nakazawa & Suzuki, 1975) [illustrated in figure 3.2]. 
Because the action of this enzyme (and endo-p-galactosidase) is hampered by the 
presence of a  (2 —► 3) - linked fucose residues attached to the 6-S-GlcNAc of the 
disaccharide (Tai et al, 1993), bovine nasal cartilage aggrecan was used as a source of 
KS type II B as it has been shown to be non-fucosylated whereas KS type II A from 
articular cartilage is fucosylated (Nieduszynski et al, 1990 B).
Results of Western blot analysis of KS chains (digested with keratanase) that were
substituted onto nasal cartilage aggrecan and corneal KSPGs showed for both samples
a slight reduction in staining with all linear epitope anti-KS mAbs (5D4, 1B4 and 4D1
recognising linear sulphated poly-N-acetyl-lactosamine motifs) that were still present
in the KS GAG chain. An example of this reduction in staining intensity is illustrated
for mAb 5D4 in figure 3.1; A and B, lane 2. In addition, keratanase digestion
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Figure 3.1 Antibody affinity blots resulting after no digest (lane 1), keratanase (lane 2), 
keratanase II (lane 3) or endo-p-galactosidase digests (lane 4), or a mixture of all 3 enzymes 
(lane 5) of bovine corneal KS type I (A) and bovine nasal cartilage KS type II (B) with 
detection using mAbs 5D4 and BKS-1.
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Keratanase II
so*
EndoKeratanase
/
Figure 3.2 The generic structure of KS type I formed from repeating galactose (blue) and N- 
acetyl glucosamine (orange) showing sites of cleavage by keratanase, keratanase II or endo-p- 
galactosidase at di-, mono- and non-sulphated domains. The diagram shows a yellow symbol 
at the non-reducing terminal of the KS type I chain that may possess a range of 
monosaccharides (e.g. N-acetyl neuraminic acid, glycosyl neuraminic acid, galactose, N-acetyl 
galactose, N-acetyl glucose). The green symbols at the reducing end represent the linkage 
region mannose monosaccharides with fucose attachments (F).
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of KSPGs isolated from cornea generated a shift in the migration of KS containing 
fragments form the 250 -  40 kDa range to a 100 -  20 kDa range. A similar shift in 
molecular weight products was not as markedly observed for KSPGs isolated from 
cartilage aggrecan, figure 3.1; B, lane 2, indicating that corneal KS contains a higher 
concentration of mono-sulphated disaccharides then skeletal KS.
Digestion with endo-p-galactosidase (Fukuda & Matsumura, 1976) cleaves at non- 
sulphated p i-4 galactosidic linkages, with weak reactivity at the keratanase cleavage 
sites (illustrated in figure 3.2). Results of Western blot analysis of KS chain 
substitutions on cartilage aggrecan and comeal KSPGs digested with endo-P- 
galactosidase again result in a slight reduction in staining with all linear epitope mAbs 
still present in the KS GAG chains. This is illustrated with 5D4 staining shown in 
figure 3.1; A and B, lane 4. In contrast to digestion with keratanase, exposure to endo- 
P-galactosidase did not significantly alter the molecular weight of products positive for 
5D4 epitopes in either the cartilage aggrecan or the KSPG preparations. Collectively, 
this data indicates that only a small proportion of structural epitope for 5D4, namely 
linear pentasulphated hexasaccharide motifs (Mehmet et al., 1986), are lost after 
digestion with either keratanase or endo-P-galactosidase resulting in decreased staining 
for each of the antibodies.
Keratanase II digestion, results in cleavage at p 1-3 glucosaminidic linkages in which 
the disaccharide structure may be either mono- or di- sulphated (Oguma et al., 2001; 
Yamagishi et al, 2003) [illustrated in figure 3.2]. Digestion of KS attached to cartilage 
or comeal KSPGs resulted in essentially a complete loss of staining for 5D4 in both 
comeal and skeletal KS (figure 3.1; A and B; lane 3), because keratanase II removes 
all linear mono- and di- sulphated poly-N-acetyl lactosamine epitopes required for 5D4 
recognition. All 5D4 staining was lost as expected in both cartilage and comeal KSPGs
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after sequential digestion of the extracts with keratanase followed by endo-P- 
galactosidase and keratanase II.
Conversely, after keratanase digestion of comeal and skeletal KS from comeal KSPGs 
and cartilage aggrecan, respectively, BKS-1 staining was positive as expected (figure 
3.1; BKS-1; A and B, lane 2). However, after endo-p-galactosidase treatment, there 
was weak immunoreactivity (figure 3.1; BKS-1; A and B; lane 4), this staining was 
more pronounced in the comeal KSPG preparation. This weak BKS-1 reactivity may 
be explained by the ability of endo-P-galactosidase to less preferentially cleave at P (1- 
4) galactosidic linkages where the disaccharide structure is mono-sulphated (the 
keratanase cleavage site) at a much lower reaction rate to keratanase. In contrast, 
immunoreactivity was absent after keratanase II treatment (figure 3.1; BKS-1; A and 
B; lane 3). Interestingly, after sequential digestion with all three enzymes, in the 
sequence of an initial keratanase digestion followed by endo-P-galactosidase and then 
followed by keratanase II, immunostaining for BKS-1 was present as three distinct 
KSPG populations in both comeal KSPGs and skeletal aggrecan (figure 3.1; BKS-1; A 
and B; lane 5).
This data suggests that the proposed generic structure for KS chains (Oeben et al,
1987; Stuhlsatz et al, 1989) depicted in figure 3.2, is perhaps not fully validated.
These researchers proposed a generic structure that constitutes a KS chain in which
disulphated disaccharides occur towards the non-reducing end of the chain, with
monosulphated disaccharides occurring towards the middle and non-sulphated
disaccharides predominant towards the linkage region of the chain. Such a structure
would suggest that keratanase digestion should result in a complete loss of 5D4
epitope and that the sequential digest (keratanase, endo-p-galactosidase then
keratanase II) should result in a complete loss of BKS-1 epitope. However, the results
presented above indicate that this was not the case and suggest that this structure
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cannot be totally correct for all KS substitutions on comeal KSPGs or cartilage 
aggrecan. In fact these results indicate that there must be a number of variations of KS 
chain sulphation patterns present on proteoglycan molecules isolated from cornea and 
cartilage.
Figure 3.3 illustrates a range of new proposed KS chain structures, which have been 
deduced from Western blot analysis of digests involving deglycosylation of KS chains 
on comeal KSPGs and nasal cartilage aggrecan and Western blot analysis with new 
(BKS-1) and existing (5D4) KS mAbs. The proposed structures for KS chains include 
GAG chain variations where non- mono- or di- sulphated domain structures can occur 
attached directly adjacent to the core protein linkage region or can be located at 
various positions throughout the KS chain. Figure 3.3 also depicts the predicted range 
of KS ‘stubs’ remaining on each of the KS chain variations after digestion using 
different KS degrading enzymes.
3.3.2 Use of mAbs BKS-1 and 5D4 to verify proposed KS type I  and KS type II 
structures
The analysis so far provided in this chapter indicates that both KS types I and II have 
complex patterns of sulphation motifs. We suggest that four basic types occur (figure 
3.3; A). Analysis using BKS-1 and 5D4 support this conclusion and the rational for 
this is provided below.
Figure 3.4 A schematically illustrates the four predicted intact KS chain structures 
where different patterns of di-sulphated, mono-sulphated and non-sulphated KS chain 
disaccharide motifs occur before digestion with different glycosidases (figure 3.4 A; 
where red symbols represent 5D4 linear sulphated epitopes) and after digestion using 
keratanase, keratanase II and endo-p-galactosidase (figure 3.4 B, C and D; where green 
symbols represent predicted keratanase-generated BKS-1 neoepitopes with 6
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Figure 3.3 A. Predicted KS sulphation pattern variations which are in contrast to the generic 
structure proposed for KS (orange = GlcNAc, blue = Gal, green = linkage region). B. Cleavage 
by keratanase, keratanase II and endo-p- gal showing ‘KS stubs’ and linear sulphated 5D4 
epitope remaining after digests of corneal or skeletal KS.
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Figure 3.4 A. Depicts a range of KS structures where sulphation pattern motifs occur at random 
positions throughout the KS chain. 5D4 (red symbols) is positive due to the presence of disulphated 
domain epitopes. No BKS-1 neoepitopes have yet been generated.
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Figure 3.4 B Digestion with keratanase exposes a number of BKS-1 epitopes reflected by an increase in 
staining with BKS-1 compared to undigested KS (panel A). 5D4 staining was only slightly reduced 
indicating that there are disulphated domains remaining that cannot be removed by keratanase alone.
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Figure 3.4 C. Additional digests of keratanase digested KS types I & II samples using endo-P- 
galactosidase showed a very mild reduction in staining using BKS-1 due to the further removal of non- 
sulphated domain structures which possessed a BKS-1 epitope at the non-reducing terminal. 5D4 
staining was only slightly reduced.
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Figure 3.4 D. Additional digestion of keratanase/endo-P-galactosidase digested KS I & II with 
keratanase II showed a significant reduction in staining. This was due to the removal of any disulphated 
domain structures which are also 5D4 epitopes. Any remaining immunostaining was due to BKS-1 
neoepitopes which could not be further cleaved by any of these three enzymes and indicated that 6-S- 
GlcNAc residues remained attached directly to the linkage region.
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sulphated N-acetylglucosamine). As expected Western blot analysis of both corneal 
KSPGs (KS type I) and cartilage aggrecan (KS type II) using mAb BKS-1 resulted in 
negative staining prior to digestion with keratanase (figure 3.4; A), but strong 
reactivity with 5D4 which recognises linear sulphated poly-N-acetyl-lactosamine 
motifs which are abundant in intact KS chains from bovine corneal and skeletal tissue. 
Post digestion with keratanase, there was intense immunoreactivity with BKS-1 (figure 
3.4; B). There was a mild reduction in 5D4 staining indicating that a number of 5D4 
disulphated disaccharide motifs were removed by keratanase at the non-reducing 
terminal. However, after keratanase-digestion the remaining staining intensity 
indicated that there were still disulphated disaccharides motifs (5D4 epitopes) present 
within the remaining KS chains. The remaining 5D4 positive linear sulphated poly-N- 
acetyl lactosamine epitopes must either be attached directly to the linkage region or be 
attached through keratanase resistant non-sulphated domains where keratanase could 
not remove them, as it specifically cleaves mono-sulphated disaccharide motifs (see 
figure 3.2). Thus the diffuse staining pattern observed for BKS-1 and 5D4 after 
keratanase digestion is predicted in our four KS chain structures to be due to the 
presence of partially digested or non-digested KS chains containing regions of non- 
sulphated and/or di-sulphated disaccharides which were keratanase resistant, so 
causing the proteins to smear as higher molecular weight products when separated by 
SDS-PAGE (figure 3.4; panel B).
Figure 3.4 C shows a schematic representation of previously keratanase digested KS
chain ‘stubs’ having now undergone further digestion with endo-p-galactosidase. The
green symbols show the predicted reduction in BKS-1 neoepitopes. Following endo-p-
galactosidase digestion, the BKS-1 staining was again partially reduced (figure 3.4; C)
in both KS types I (from cornea) and II (from nasal cartilage aggrecan) compared to
the keratanase digested KS chains (figure 3.4; B). This is predicted to be a result of the
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endo-p-galactosidase specifically removing of a number of keratanase resistant non- 
sulphated domain ‘stubs’ described above to leave a number of unsulphated GlcNAc 
residues at the non-reducing end of the KS chain which were not recognised by BKS- 
1. However, diffuse staining still remained with BKS-1 and 5D4 indicating that there 
were still a number of long di-sulphated domain ‘stubs’ remaining on the 
keratanase/endo-P-galactosidase digested KS chains. These partially digested KS 
chains possess a keratanase-generated BKS-1 neoepitope at the non-reducing terminal 
(figure 3.4; C; BKS-1 neoepitopes indicated by the green symbol) and a region of 
disulphated disaccharides large enough to be recognised by 5D4 (figure 3.4; C, 
indicated by red 5D4 symbol) that were not substrates for the previously applied 
keratanase or endo-p-galactosidase enzymes.
Figure 3.4 D shows a schematic representation of the keratanase/endo-P-galactosidase
digests of the four KS chain ‘stub’ structures followed by the predicted digestion
products generated after further digestion with keratanase II (figure 3.4; D) where the
reduced BKS-1 neoepitopes are indicated in green. Notably, after a final keratanase II
digestion, the BKS-1 staining appears to have been significantly reduced to the form of
two sharp bands of KSPGs at ~50 kDa and -30 kDa in comeal KSPGs (KS type I),
having similar molecular weights to a number of comeal KSPG core proteins
(lumican, keratocan and mimecan). There were also a number of distinct aggrecan
metabolite bands between ~ 150 and ~75 kDa in bovine cartilage PGs (KS type II).
5D4 staining was completely abolished, indicating that all remaining linear sulphated
poly-N-acetyl-lactosamine repeat motifs had been successfully removed using
keratanase II digestion. The sharp banding pattern observed using BKS-1 on the
Western blots after deglycosylation using all three enzymes indicates that extensive
deglycosylation of the KS chains on the core proteins of proteoglycan molecules had
taken place leaving short disaccharide KS ‘stub’ linkage regions (figure 3.4; D). The
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BKS-1 staining observed after such extensive deglycosylation, indicates that there 
were still a number of keratanase generated BKS-1 neoepitopes remaining which could 
not be further removed by either endo-P-galactosidase or keratanase II (figure 3.4; D). 
These neoepitope structures must therefore be on KS ‘stub’ structures that are attached 
directly to the KS linkage region, where there are no further di-, mono- or non- 
sulphated disaccharide substrates for further cleavage by any of these three enzymes. 
This suggests that the remaining low levels of BKS-1 staining results from non­
reducing terminal 6-S-GlcNAc which may be attached to either the linkage region 
mannose of corneal KS, to the linkage region GalNAc of skeletal KS or to an adjacent 
Gal or 6-S-Gal. This data strongly indicates BKS-1 mAh specificity for a non-reducing 
terminal neoepitope containing 6-S-GlcNAc, regardless of the nature of the 
penultimate attaching sugar.
Essentially similar results were obtained if digest sequences were carried out as 
follows:
• Keratanase -> keratanase II -> endo-p-galactosidase
• Endo-p-galactosidase -> keratanase -> keratanase II.
3.3.3 Analysis of keratanase II keratanase endo-p-galactosidase sequential 
digests with 5D4 and BKS-1
Figure 3.5 A schematically illustrates the four predicted undigested KS structures from 
either cartilage aggrecan or corneal KS. Figure 3.5 B shows the predicted KS 
structures remaining after digestion with keratanase II. As expected, Western blot 
analysis showed no reactivity with BKS-1 either before or after keratanase II digestion 
because 6-S-GlcNAc epitopes for BKS-1 were not generated by keratanase II cleavage 
(figure 3.5; B). Also, 5D4 staining was completely abolished with keratanase II
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Figure 3.5 A. Depicts a range of KS structures where sulphation pattern motifs occur at random 
positions throughout the KS chain. 5D4 is positive due to the presence of disulphated domains, no BKS- 
1 neoepitopes have yet been generated.
b. KS type I
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Figure 3.5 B Digestion with keratanase II removes all di- and mono- sulphated domain epitopes for 
5D4. There are a number of non-reducing terminal 6-Gal or Gal residues which do not act as BKS-1 
neoepitopes, therefore there is no BKS-1 staining.
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c. KS type I
5D4BKS1
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Figure 3.5 C Sequential digestion of KS I or II with keratanase II followed by keratanase was weakly 
positive for BKS-1. This was unexpected as all keratanase susceptible mono-sulphated domains were 
previously removed by keratanase II. 5D4 staining was again negative as in panel B above.
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Figure 3.5 D No immunoreactivity was observed for either mAb after the addition of endo-(3- 
galactosidase to the digested KS samples for similar reason to those given in panels B and C above.
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digestion as all mono- and di-sulphated disaccharide domain 5D4 epitopes were 
removed.
Figure 3.5 C shows a schematic representation of KS chain structure after keratanase II 
digestion followed by a sequential digest with keratanase. After this treatment weak 
staining for BKS-1 was observed in the corneal KSPG preparation at ~50kDa and in 
skeletal KS at ~75kDa (figure 3.5, C). This is unexpected as keratanase II should have 
initially cleaved away all mono- and di-sulphated disaccharide domains leaving none 
which can be further digested by keratanase. This may be due to incomplete digestion 
during the initial keratanase II digestion step. The staining is also only observed for 
one (~ 50 kDa) of the two possible corned KSPG bands that were previously 
identified in the same corneal preparation after keratanase -> endo-p-galactosidase -> 
keratanase II digestion illustrated in figure 3.4 D.
Finally, figure 3.5 D, depicts predicted KS chain structural domains following a 
sequential digest of products generated in figure 3.5 C by endo-P-galactosidase 
treatment after prior keratanase II and keratanase digestion. Because all monosulphated 
domains should have been cleaved by keratanase II, there are only non-sulphated 
domains available for endo-P-galactosidase cleavage. Therefore no BKS-1 epitopes are 
generated after this panel of sequential digestions. It is noted that BKS-1 epitopes 
generated in figure 3.5 C digests are no longer present after endo-P-galactosidase 
digests (figure 3.5, D). In any other digestion combination where keratanase II was 
added before keratanase (i.e. keratanase II -> endo-p-gal -> keratanase or endo-p-gal 
-> keratanase II -> keratanase) it was not possible to generate a BKS-1 epitope (results 
not shown).
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3.4 Discussion
The currently accepted dogma from several studies (Oeben et a l, 1987; Stuhlsatz et al, 
1989; Tai etal., 1996, 1997; Funderburgh, 2000 review) have established generic structures 
for KS types I and II chains (see figure 1.2 and 1.3) derived from comeal and skeletal 
tissues, respectively. The distribution of unsulphated N-acetyl-lactosamine motifs, 
mono-sulphated disaccharides and di-sulphated disaccharides from the linkage region 
to the non-reducing termini between KS types I and II have been reported. They 
suggested that in comeal KS type I chains, non-sulphated N-acetyl-lactosamine 
disaccharides are found predominantly contiguous with the linkage region 
oligosaccharide, mono-sulphated N-acetyl-lactosamine occur in the mid-regions of the 
KS chain and disulphated N-acetyl-lactosamine disaccharides are clustered towards the 
non-reducing end of the KS glycosaminoglycan chain (Oeben et al, 1987; Funderburgh, 
2000 review). In contrast, KS type II chain structures occur with a predominance of 
disulphated N-acetyl-lactosamine residues present throughout the KS 
glycosaminoglycan chain but with some intermittent mono-sulphated N-acetyl- 
lactosamine residues (see figure 1.3). Previous reports have indicated limited levels 
(Plaas et al, 2001) or a complete absence of unsulphated N-acetyl-lactosamine within 
KS type II extended chain (Brown et al, 1994; Huckerby et al, 1994; Plaas et al, 
2001).
This study has used mAbs BKS-1 and 5D4 in Western blot analysis to investigate
similarities and differences in the KS disaccharide sulphation motif patterns within KS
chains from different tissue sources (i.e. KS types I and II from bovine cornea and
bovine nasal cartilage, respectively). The results of these analyses have demonstrated
that KS type I and KS type II chains both contain a combination of differentially
sulphated (mono- versus di- versus unsulphated) N-acetyl-lactosamine domains on the
different KSPG GAG chains. The resultant data suggests that in the bovine model
B. Kerr PhD thesis 2005 144
different tissue sources of KS most likely produce similar varieties of KS disaccharide 
structures, but that sulphation patterns are more randomly located along the KS chain 
than previously reported (Oeben et al, 1987; Stuhlsatz et al, 1989). The frequency of 
the regions containing di-sulphated disaccharide motifs appears to be greater in KS 
type II compared to KS type I. Also, there was no reactivity with BKS-1, recognising 
6-sulphated N-acetylglucosamine residues, with native KS (i.e. before digestion with 
keratanase). This suggests that there are no 6-sulphated N-acetylglucosamine residues 
present as capping structures at the non-reducing terminal of KS as postulated 
previously by Huckerby et al., 1995.
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3.5 Chapter summary
Monoclonal antibody BKS-1 was used in conjunction with mAb 5D4 in the 
analysis of KS sulphation motif patterns in KS types I and II from cornea and 
cartilage, respectively.
Results demonstrated that, in contrast to the generic structure for KS proposed 
by Oeben et al, 1987 and Stuhlsatz et al, 1989 KS is more randomly 
substituted with sulphate groups than previously reported. It was found that 
non-, mono- and di-sulphated domain motifs were located at various linkage 
regions, mid regions and non-reducing terminal positions through both KS 
types I and II chains.
KS type II appears to contain a larger portion of disulphated disaccharide 
motifs than KS type I.
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Chapter 4 - Production and characterisation of two new mAbs to 
bovine corneal keratan sulphate proteoglycans.
4.1 Introduction
The cornea is a source particularly rich in KS containing proteoglycans where the KS 
is found primarily attached to one of 3 SLRPG core proteins; i.e. lumican 
(Blochberger et al, 1992; Funderburgh et al., 1993), keratocan (Corpuz et al, 1996) 
or mimecan (Funderburgh et al, 1997 A) [reviewed in chapter 1]. The enzymatic 
addition of sulphate groups to KS on KSPGs present in corneal tissues is thought to be 
essential for the proper interaction of comeal proteoglycans with collagen fibrils and 
in the regulation of collagen fibrillogenesis and the ultrastructural arrangement of the 
comeal extracellular matrix. The development of comeal transparency depends upon 
the proper interaction of these molecules (Scott & Haigh, 1988; Funderburgh et al, 
1991 A; Scott, 1992; Rada et al, 1993; Comuet et al, 1994; Chakravarti et al, 1998). 
Lumican has also recently been shown to have an important role in comeal wound 
healing by regulating polymorphonuclear (PMN) leukocyte infiltration in wounded 
corneas (Chakravarti et al, 2005; Kao et al, 2005; Yeh et al, 2005).
These proteoglycans were selected as potential KS containing antigens for the 
production of mAbs to KS ‘stub’ epitopes generated after keratanase II digestion. 
Such immunisations could result in the production of antibodies recognising either a 
keratanase II generated KS ‘stub’ neoepitope containing a non-reducing terminal Gal 
or Gal-6-sulphate, or to SLRP protein core epitopes on lumican, keratocan or 
mimecan, all of which are currently not available in our lab but would be useful 
research tools.
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4.2 Materials
4.2,1 Materials
All chemicals were of analytical grade and were purchased from Sigma-Aldrich 
unless otherwise stated. A comprehensive catalogue of materials and suppliers used 
throughout this project is listed in Appendix A.
All DMMB material (section 2.2.2), GAG degrading enzymes (section 2.2.3), 
immunisation and tissue culture material (section 2.2.4), SDS-PAGE and Western 
blotting material (section 2.2.5) and Lectin affinity material (section 2.2.6), were as 
described in chapter 2, section 2.2 and table 2.3. Bovine and porcine tissues were 
obtained from a local abattoir. Normal and pathological human cartilage was obtained 
as described in chapter 6, section 6.2.1.
4.2.2 Stock solutions
Solutions and their components required for practical work are listed in tables 2.3 and 
4.1. Ethanol, acetic acid, hydrochloric acid, sodium hydroxide, methanol and urea 
were all obtained from Fisher Scientific.
Buffer solution Components
Anion exchange chromatography 
equilibration buffer
6 M Urea, 0.05 M Tris, pH 6.8, containing 0.1% (w/v) 
chaps
Anion exchange chromatography 
elution buffer
6 M Urea, 2 M NaCl, 0.05 M Tris, pH 6.8, containing 
0.1% (w/v) chaps
Proteoglycan extraction buffer 4 M Guanidine-HCl, 0.05 M Sodium acetate 
(anhydrous), 0.01 M Disodium EDTA, 0.1 M 6-amino 
hexanoic (caproic) acid, 5 mM Benzamidine-HCl, 0.5 
mM phenyl methyl sulfonyl fluoride (PMSF), pH 5.8-6.8
Size exclusion chromatography 
equilibration buffer
0.1 M Sodium sulphate, pH 6.8
Table 4.1 Buffer solutions and their components
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4.3 Methods
4.3.1 Preparation and purification o f  a keratanase II-generated bovine corneal 
KSPG antigen.
An overview of the keratanase II ‘stub’ KSPG antigen purification methods are 
illustrated in figure 4.1. Expanded details are provided in the sections below.
4.3.1.1 Proteoglycan extraction from bovine cornea
ECM molecules are firmly associated within their native tissues in a naturally 
occurring state. In order to isolate various proteoglycans they must be dissociated 
from their surrounding tissue. In cartilage, 4 M Guanidine HC1 (a chaotrophic agent) 
acts to dissociate PG aggregates by breaking any non covalent bonds and removing 
them from their native environment into solution (Sajdera & Hascall, 1969; Heinegard 
& Sommarin, 1987). 4 M guanidine also facilitates extraction of SLRPs from comeal 
extracellular matrices (Comeut et al., 1994).
20 bovine corneas were dissected, weighed and finely diced prior to extraction. The 
tissue was extracted in 10 ml 4 M Guanidine-HCl containing proteolytic inhibitors 
(table 4.1) per gram wet weight of tissue at 4 °C for 24 hours. Supernatants were 
collected and fresh extraction buffer was added to the tissue residue for a further 24 
hours. Both supernatants were pooled.
4.3.1.2 Anion exchange chromatography o f  guanidine extracted corneal matrix 
molecules
The comeal PG extracts were pooled and dialysed against 6 M Urea; 50 mM Tris; pH 
6.8, containing 0.1% (w/v) CHAPS (table 4.1). This crude PG extract was applied to a 
Resource Q anion exchange chromatography column (see chapter 2, section 2.3.2.3) 
which had been equilibrated in 6 M Urea; 50 mM Tris; pH 6.8, containing 0.1% (w/v)
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Bovine cornea PG extract
\
Resource Q 
anion exchange chromatography
I
CS/DS PG^ KSP^ hondroitinase ABC
KSPGs and chondroitinase ABC digested CS/DS PGs
\
Sephacryl S-200 
size exclusion chromatography
I
KS enriched population
I —  Keratanase II
KS II ‘stub’ KSPG antigen and enzymei
Sephacryl S-200 
size exclusion chromatography
I
KS enriched KS II ‘stub’ antigen
Figure 4.1 - An overview of the procedures involved in purification of a keratanase II- 
generated ‘stub’ KSPG antigen.
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CHAPS (table 4.1), using a 50 ml superloop at a flow rate of 1 ml/min. Bound 
material was sequentially eluted into 1 ml fractions using a linear salt gradient of 0 -  2 
M NaCl. The separation was monitored at wavelengths of 214 nm (protein and GAG), 
232 nm (unsaturated CS disaccharides) and 280 nm (protein) [figure 4.2]. Eluted 
fractions were analysed for sulphated GAG by DMMB (see chapter 2, section 
2.3.1.1).
A number of peaks were detected at 280 nm (------), 232 nm (------), and 214 nm (—
—) presumably containing sulphated PGs that had eluted between a 1.3 M and 1.6 M 
NaCl gradient (figure 4.2). Fractions from these peaks were analysed for S-GAG
content using the DMMB assay (figure 4.2 [-----]). One major peak (fractions 12-18)
was positive for S-GAG.
4.3.1.3 Analysis o f Resource Q separatedfractions by Western blotting 
Further analysis using Western blotting was carried out on aliquots of fractions 8 - 2 6  
following separation of native proteins by SDS-PAGE for immunodetection with anti 
KS mAb 5D4, or separation by SDS-PAGE following chondroitinase ABC (100 mU 
per mg GAG) and keratanase (80 mU per mg GAG) digestion of samples allowing 
immunodetection with the anti KS ‘stub’ mAb BKS-1, anti CS mAbs 2B6 and 3B3, 
anti decorin mAb 70.6 and anti-biglycan mAb PR 8A4.
Results showed fractions 13 -  17 to have strong positive staining against anti KS mAb 
5D4 and anti ‘KS stub’ mAb BKS-I (figure 4.3; A and B, respectively) indicating the 
presence of a large amount of KS in these fractions. There was also positive 
immunoreactivity in these fractions for anti CS mAbs 2B6/3B3 at -40, 30 and 17-20 
kDa (figure 4.3, C), indicating that these fractions most likely contained a number of 
SLRPs such as decorin and biglycan that had CS / DS GAG attachments. There was 
also positive immunoreactivity for anti decorin protein epitope mAb 70.6 (figure 4.3;
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Figure 4.2 Resource Q anion exchange chromatography of bovine corneal proteoglycan extracts 
and DMMB analysis of separated fractions: pink -  214 nm (carbohydrate); blue -  232 nm 
(carbohydrate); green — 280 nm (protein) and dashed red -  DMMB results (fig/ml S-GAG). All 
sulphated PGs eluted within a 1.3 -  1.6 M NaCl gradient (fractions 12-18).
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Figure 4.3 - Western blot results after Resource Q anion exchange chromatography.
KSPGs and CS/DSPGs eluted in fractions 13 -  17 as shown by mAbs 5D4 & BKS-1 (A & B). 
Comparison of anti CS mAbs 2B6/3B3 (C), anti decorin mAb 70.6 (D) and 5D4 (B) blots 
depicted a difference in molecular weights of undigested KSPGs (~50 -  250 kDa) compared 
to chondroitinase ABC digested CS/DSPG (-40 kDa) indicating suitability of size exclusion 
chromatography as a further separation procedure.
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D) in a larger range of fractions (10 -  18), where CS / DS substituted decorin had 
eluted in the same fractions as the KSPGs (13 -  17). Decorin that was not substituted 
with CS / DS GAG side chains appeared to elute in earlier fraction numbers 10 -  12. 
Western blot analysis using the anti biglycan mAb PR 8A4 (results not shown), 
showed that low levels of biglycan was also present in fraction numbers 13-17.
It was observed from this series of Western blots that the molecular weight of the core 
protein of decorin and biglycan in the preparation had a molecular weight of -40 kDa 
after chondroitinase ABC digestion, however KS containing PGs which were non­
deglycosylated were in the range of -50 - 250 kDa (figure 4.3; panel A compared to 
panels C and D). Thus, in order to further purify the KSPG population, size exclusion 
chromatography was selected as a further separation step after chondroitinase ABC 
digestion of the pooled fractions 13-17.
4.3.1.4 Separation o f Resource Q KS-enriched corneal PGs from CSPGs by Sephacryl 
S-200 size exclusion chromatography
Sephacryl S-200 is a chromatography method that utilises a pre-packed cross-linked 
copolymer of allyl dextran and N, N-methylenebisacrylamide which allows for 
separation of protein or peptide molecules ranging in size from 5 to 250 kDa. 
Appropriate fractions (13 -  17) containing KS positive proteoglycan from the 
Resource Q anion exchange chromatography step described above in section 4.3.1.2, 
were pooled and subjected to chondroitinase ABC digestion (100 mU per mg GAG) in 
a 0.1M Tris acetate buffer, pH 6.8 (see table 2.3) over night at 37 °C in order to 
remove the CS chains and allow for the separation of the core proteins of decorin and 
biglycan from native KS containing small PGs using size exclusion chromatography 
procedures. DMMB analysis was carried out before and after chondroitinase ABC 
digestion to determine GAG concentration. Total sulphated GAG (S-GAG) levels fell
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from 4.7 mg to 2.7 mg after chondroitinase ABC digestion, indicating that 
approximately 2.7 mg of sulphated KS remained in the preparation. The sample was 
then dialysed against Milli Q™ water.
The chondroitinase ABC digested sample was lyophilised and reconstituted in 600 pi 
0.1 M Na2 SC>4 , pH 6.8 (table 4.1). 500 pi was applied to a HiPrepR Sephacryl S-200 
size exclusion chromatography column at a flow rate of 0.5 ml/min and 2 ml fractions 
collected. Separation was monitored at wavelengths of 214 nm (protein and GAG), 
232 nm (unsaturated CS disaccharides) and 280 nm (protein). Eluted fractions were 
analysed by DMMB analysis (as described in section 2.3.1.1) and appropriate 
fractions selected for further analysis. A number of peaks resulted across fractions 20
-  65 (figure 4.4) with a large 214 nm (------) peak between fractions 2 0 - 3 5  predicted
to contain the majority of the larger molecular weight KSPGs. DMMB analysis 
(figure 4.4; — ) revealed a higher content of S-GAG between fractions 20 -  33, 
concurring with the 214 nm chromatographic trace, and indicating that this was a peak 
of interest, predicted to contain the KSPGs.
4.3.1.5 Analysis o f size exclusion chromatography separated fractions by SDS-PAGE 
and Western blotting
Following Sephacryl S-200 size exclusion chromatography and DMMB analysis
(figure 4.4), fraction samples were further deglycosylated using keratanase where
necessary and separated on 4 - 20% Tris glycine SDS-PAGE gradient gels and
transferred for Western blotting using mAh probes 5D4 (anti-KS), 70.6 (anti-decorin),
2B6/3B3 and BKS-1 (requiring pre-digestion with keratanase at 80 mU per mg GAG).
Western blot analysis of fractions 1 8 -3 4  revealed that the majority of the KSPGs did
separate in earlier fractions 20 - 26 (figure 4.5; A & C) and the deglycosylated CS/DS
PGs in later fractions 28 - 34 (figure 4.5; B). From these results, fractions 20 - 26
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Figure 4.4 Sephacryl S-200 size exclusion chromatography separation of chondroitinase ABC  
digested CSPGs from undigested KSPGs: pink - 214 nm (protein and GAG); blue - 232 nm 
(carbohydrate); green - 280 nm (protein). The sulphated KSPGs detected using DMMB analysis (red 
dashed line) were present in fractions 20-33 where there was high absorbance at 214nm.
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A. B. C.
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Keratanase II digest
I
Size exclusion chrom atography 
Sephacryl S-200
Figure 4.5 - Western blot results of fractions 18 -  34 after sephacryl S-200 size exclusion 
chromatography. Larger KSPGs separated in earlier fractions 20 -  26 (A and C) while smaller 
molecular weight decorin separated in later fractions 28 -  34 (B).
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were pooled and dialysed against Milli Q™ water prior to further processing to 
generate keratanase II ‘stub’ and corneal KSPG antigens.
43.1.6 Keratanase II digestion o f KS-enriched corneal PGs to generate a range o f  
keratanase II ‘stub ’ and KSPG core protein antigens
From the information generated from Western blot analysis above, fractions 20-26 
were pooled and dialysed against Milli Q™ water. DMMB analysis was carried out to 
determine the concentration of sulphated GAG in the pooled sample. It was found to 
contain a total of 922 pg of sulphated GAG. The sample was then lyophilised and 
reconstituted in 600 pi of 10 mM sodium acetate, pH 6.8 (table 2.3). Keratanase II 
was added at a concentration of 6 mU per mg of sulphated GAG and the sample 
incubated for 24 hours at 37 °C for optimal digestion. The resultant keratanase II 
digested comeal KSPG preparation (with an approximate molecular weight of 25-40 
kDa) was re-applied to a Sephacryl S-200 size exclusion column (as in section 4.3.1.4 
above) to separate it from the higher molecular weight keratanase II enzyme 
(molecular weight -275 kDa, see figure 2.4, chapter 2).
Fractions were pooled based on UV profile peaks (figure 4.6) pool 1: fractions 18-23, 
pool 2: fractions 24-30, pool 3: fractions 31-40. They were dialysed against Milli Q™ 
water, lyophilised and reconstituted in 2 ml Milli Q™ water.
4.3.1.7 Analysis o f separation o f keratanase II enzyme from keratanase II ‘stub ’
KSPG antigen using Silver staining and Western blotting analysis
Silver stain analysis was used on 30 pi samples from each pool to determine where the
keratanase II enzyme had been separated from the KSPGs with keratanase II
generated ‘KS stubs’. 30 pi samples were also used in SDS-PAGE and Western blot
analysis using mAbs 2B6/3B3/1B5 (all at a 1:100 dilution) to analyse for the presence
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Figure 4.6 - Sephacryl S-200 size exclusion chromatography profile, separation of the 
keratanase II enzyme from the keratanase II digested KSPG ‘stub’ antigen. Showing detection 
at 280 nm (green), 232 nm (blue) and 214 nm (pink). Fractions were pooled based on peaks, 
pool 1: fractions 1 8 -2 3 , pool 2: fractions 24 -  30 and pool 3: fractions 3 1 -4 0 .
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of any contaminating CS/DS and galanthus nivalis agglutinin (GNA) lectin (10 jul per 
10 ml lectin buffer, see table 2.3 and similar to method described in section 2.3.2.3) to 
determine the peaks containing the keratanase II ‘stub’ KSPGs. GNA lectin recognises 
high mannose N-linked oligosaccharides similar to those on the KS type I linkage 
region which become exposed after enzymatic deglycosylation of KS type I chains. It 
was therefore used to assess where the keratanase II KS ‘stub’ KSPGs had separated. 
This lectin is not KS specific. It also recognises N-linked oligosaccharides on a range 
of matrix glycoproteins.
Silver stain analysis of fractions showed the higher molecular weight protein present 
in keratanase II enzyme preparations (-275 kDa, see chapter 2, figure 2.4) eluted in 
pool 1 (figure 4.7; A). GNA lectin indicated the presence of keratanase II generated 
KS ‘stubs’ in both pool 1 and pool 2 (figure 4.7; B) and 2B6/3B3 (figure 4.7; C) was 
negative for all pooled fractions indicating the absence of any contaminating CS ‘stub’ 
containing core proteins. Pool 1 was enriched with KS stub antigens but silver stain 
analysis had indicated contamination with other substances, therefore pool 2 was 
selected for immunisation because it was an enriched keratanase II digested KS ‘stub’ 
and KSPG core protein antigen containing no keratanase II enzyme and negligible 
levels of CSPGs.
4.3.2 Immunisation with a keratanase II-generatedKSPG KS ‘stub’ antigen, fusion, 
cloning and screening of resulting hybridomas
Murine mAbs were generated again by immunising a single 4 - 6  week old female 
Balb/c mouse with the keratanase II KSPG ‘stub’ antigen, fusing resulting antibody 
producing lymphocytes with the mouse myeloma Ag 8 cell line and cloning resulting 
hybridomas of interest as described previously in chapter 2, section 2.3.3. Hybridoma 
culture media was screened using ELISA and Western blotting techniques using the
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—
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Figure 4.7 - Fractions from separation were pooled (PI, P2, P3) based on profile peaks
(see figure 4.6). (A) Silver stain analysis showing which pool the keratanase II enzyme was 
present in (PI ~ 275 kDa); (B) Western blotting using GNA lectin showing KS ‘stub’ positive 
samples; (C) Western blotting using mAbs 2B6/3B3 showing the absence of any 
contaminating CS.
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keratanase II digested KS ‘stub’ immunising antigen prepared as described above in 
section 4.3.1 and the panel of antigens listed in chapter 2, section 2.3.4.1.
Further screening was carried out using purified bovine arterial lumican, bovine 
comeal extracts containing a lumican and mimecan mix, keratocan and lumican mix 
and bovine cartilage fibromodulin screening antigens were a gift from Professor 
James Funderburgh, University of Pittsburgh, USA. 5 pg samples of each were 
subjected to digestion with keratanase (10 mU), keratanase II (10 mU) and endo-P- 
galactosidase (10 mU) for 24 hours at 37 °C. The deglycosylated antigens were then 
separated on 15 % slab gels in SDS PAGE running buffer (see chapter 2, table 2.3) for 
1.5 hours at 150 volts and transferred onto nitrocellulose in an SDS transfer buffer 
(see chapter 2, table 2.3) at 100 volts for 1 hour (as described in detail in chapter 2, 
section 2.3.2.1). Western blot screening analysis was carried out with newly generated 
KSPG mAbs to define the antibody specificity. Selected hybridoma cell lines were 
cloned to limiting dilution (see chapter 2, section 2.3.4.4), and the Ig subclass 
determined (see section 2.3.4.5).
The two new KSPG antibodies (LUM-1 and KER-1) were identified as IgM, kappa 
light chain monoclonal antibodies.
4.3.3 Analysis of mAb reactivity after removal of N- and O-linked oligosaccharides 
from corneal KSPG extracts
Eight volumes equivalent to 2 pg GAG of bovine comeal KSPG extracts were
digested with 80 mU of keratanase per mg GAG, 6 mU of keratanase II per mg GAG
and 8 mU of endo-P-galactosidase per mg GAG (see section 2.3.1.2) in 0.1 M Tris
acetate, pH 6.8 for 24 hours at 37 °C. Samples were either left as such, or further
digested using enzymes from a protein deglycosylation kit obtained from Sigma-
Aldrich as described in chapter 2, section 2.3.4.6 where PNGase F or O-glycosidase
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enzymes were either added individually or sequentially in the following order 
following deglycosylation using the keratanase enzymes:
1. KSPG + keratanase/keratanase II/endo-P-gal;
2. KSPG + keratanase/keratanase II/endo-P-gal + PNGase F;
3. KSPG + keratanase/keratanase II/endo-p-gal + O-glycosidase;
4. KSPG + keratanase/keratanase II/endo-P-gal + PNGase F + O-glycosidase.
Samples were incubated overnight at 37 °C and run on 12% slab gels. Gels were 
transferred as described in section 2.3.2.1 and analysed by Western blotting using the 
new KSPG mAbs.
4.3.4 Analysis of LUM-1 and KER-1 reactivity with KSPGs isolated from different 
animal species
Tissues were obtained from 18 moth old bovine cornea, cartilage and tendon, porcine 
cornea and cartilage, normal and OA human cartilage. These tissues were diced and 
extracted in 4 M guanidine HC1 with protease inhibitors (table 2.3 and section 
4.3.1.1). Crude PG extracts were dialysed to Milli Q™ water and DMMB analysis 
carried out to determine GAG concentration of the samples. Volumes equivalent to 6 
pg GAG were digested with keratanase (80 mU per mg GAG) and keratanase II (6 
mU per mg GAG, ) and 3 pg GAG samples run on 4 - 20% Tris glycine gradient gels 
prior to transfer onto nitrocellulose for Western blot analysis with mAbs LUM-1 and 
KER-1.
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4.4 Results
4.4.1 Screening of resulting hybridomas
4.4.1.1 Screening ELISAs
The primary screening of 8 x 24 well plates by direct ELISA against the keratanase II 
‘stub’ immunising antigen revealed 4 possible wells containing antibody secreting 
hybridomas (2C6, 7C4, 11C4 and 1C3) with higher optical density readings (0.6 -  
2.5) at 405 nm (figure 4.8). In addition, 2C6 and 7C4 were immunoreactive with 
keratanase II digested BNC (ABC) core, indicating that they were potential new 
keratanase II ‘stub’ mAbs. In contrast, mAbs 1C3 and 11C4 appeared to be reactive 
only with the keratanase II digested comeal KSPG immunising antigens, indicating 
potential new KSPG core protein mAbs.
A secondary screen by ELISA, coating with keratanase II digested BNC (ABC) core, 
keratanase digested bovine comeal KSPG and the keratanase II generated immunising 
antigen showed that two of the previously identified clones (2C6 and 7C4) were 
positive for the keratanase II generated ‘stub’ neoepitope as they had positive 
immunoreactivity with both of the keratanase II digested antigens (figure 4.9) but 
were negative for the keratanase digested KSPG antigen (figure 4.9), demonstrating 
that these two antibodies were specifically recognising keratanase II generated ‘KS 
stub’ neoepitopes containing either a non reducing terminal Gal-6-S or a Gal residue. 
The other 2 clones (11C4 and 1C3) showed positive immunoreactivity with both 
keratanase II and keratanase digested bovine comeal KSPG antigens but not with the 
keratanase II digested BNC (ABC) core (figure 4.9). This indicated that the new 
mAbs 11C4 and 1C3 were in fact specific for comeal SLRP core protein epitopes. 
Controls were carried out using 5D4, 4D1 and 1B4 monoclonal antibodies 
(recognising sulphated linear KS chain epitopes, see table 2.2) and results were as 
expected, with no immunoreactivity against keratanase II digested antigens and
B. Kerr PhD thesis 2005 164
P r i m a r y  s c r e e n  f o r  Kll & S L R P  m A b s
2.5 -
2C6 7C4 1C3
H y b rid o m a
11C4
□  I m m u n i s i n g  a n t i g e n  (Kll c o r n e a l  K S P G )  □  B N C  ( A BC )  c o r e  + Kll
Figure 4.8 - Primary screen using ELISA against the keratanase II (KII) digested bovine 
corneal KSPG immunising antigen and a keratanase II digested bovine nasal cartilage ABC 
core antigen. 2C6 and 7C4 show strong immunoreactivity with both keratanase II digested 
bovine corneal KSPGs and keratanase II digested BNC ABC core suggesting that these are 
keratanase II generated ‘KS stub’ mAbs. However, 1C3 and 11C4 only show reactivity with 
keratanase II digested bovine corneal KSPGs, indicating that these may be KSPG core protein 
mAbs as opposed to GAG mAbs.
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S e c o n d a r y  s c r e e n  of  Kll ' s t u b '  & K S P G  m A b s
2C6 7C4 11C4 1C3 5D4 control 4D1 control 1B4 control
Hybridoma cell lines
□  I m m u n i s i n g  A n t i g e n  (K II ' s t u b ' )  □  B N C  ( a b c )  c o r e  +  Kll  □  K S P G  + K e r a t a n a s e
Figure 4.9 -  Secondary screening using ELISA against keratanase II digested KSPGs, 
keratanase digested KSPGs and keratanase II digested BNC (ABC) core. 5D4, 4D1 and 1B4 
were used as controls. 2C6 and 7C4 were specific for keratanase II generated ‘KS stub’ 
neoepitopes in both corneal and skeletal KS. 11C4 and 1C3 showed specific immunoreactivity 
with both keratanase and keratanase II digested bovine corneal PGs with no reactivity with 
BNC, indicating they were corneal KSPG core protein specific antibodies.
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positive immunoreactivity remaining against keratanase digested antigens (figure 4.9). 
From these ELISA results 4 positive hybridomas (2C6, 7C4, 11C4 and 1C3) were 
selected and expanded for further analysis by Western blotting.
4.4.1.2 Screening and characterisation o f  keratanase II ‘stub ’ mAbs and corneal 
KSPG mAbs by Western blotting and ELISA
Western blot screening analysis was carried out using a series of undigested (figure 
4.10, lane 1), keratanase digested (figure 4.10, lane 2) and keratanase II digested 
(figure 4.10, lane 3) bovine comeal KSPGs along with the keratanase II enzyme by 
itself (figure 4.10, lane 4). Control blots using 4D1 (figure 4.10, A) recognising linear 
sulphated KS epitopes showed a decrease in immunostaining with keratanase and 
keratanase II, BKS-1 (figure 4.10, B) showed specificity only for keratanase treated 
KSPGs and GNA lectin (figure 4.10, C) showed an increase in immunostaining with 
keratanase and keratanase II, as expected, indicating that digests were successful and 
antigens were displaying the desired epitopes.
Western blot analysis using mAbs 11C4 and 1C3 (figure 4.10; D and E) on the 
partially purified comeal KSPGs, revealed staining of molecules with a molecular 
weight of ~60 -  100 kDa (lane 1; D and E). After keratanase digestion (figure 4.10, D 
and E, lane 2) these mAbs (11C4 and 1C3) were recognising molecules having 
molecular weights of 37 -  40 kDa and 50 -  60 kDa, respectively. After keratanase II 
digestion (figure 4.10, D and E, lane 3) the antibodies also recognised similarly sized 
products (11C4 recognising a 30 -  37 kDa molecule and 1C3 recognising a 45 -  55 
kDa molecule). This data in conjunction with the ELISA data strongly suggests that 
these antibodies are recognising core protein epitopes within the KSPG populations 
present in comeal tissue and further more the two antibodies are recognising two 
different proteins. There was no immunoreactivity with the keratanase II enzyme ran
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Figure 4.10 -  Controls in panel 1 [4D1 (A), BKS1 (B) and GNA lectin (C)] show that the 
screening antigens have been digested appropriately (lane 1 = undigested comeal KSPGs, lane 
2 = keratanase digested comeal KSPGs, lane 3 = keratanase II digested comeal KSPGs and 
lane 4 = keratanase II enzyme by itself). Panel 2, 11C4 and 1C3 (D and E) show positive 
immunoreactivity with both keratanase (lane 2) and keratanase II (lane 3) digested KSPGs at 2 
different molecular weights (-37 kDa and -50 kDa) indicating that they are recognising 2 
distinct KSPG core proteins. 2C6 and 7C4 (F and G), the potential keratanase II ‘KS stub’ 
antibodies have lost reactivity for the epitope they were initially recognising in ELISA 
analysis.
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on its own (figure 4.10, panel 2, D and E, lane 4).
Negative results obtained by Western blotting (figure 4.10; F and G) using hybridoma 
culture supernatant from 2C6 and 7C4 (predicted in section 4.4.1.1 to be recognising 
keratanase II cleavage sites) against native corneal KSPGs, keratanase II digested 
KSPG antigens and a keratanase digested KSPG antigen suggested that these 
hybridomas had lost their antibody producing capabilities (figure 4.10; panels F and 
G). They were subsequently re-screened by ELISA (figure 4.11) against untreated, 
keratanase II treated and keratanase treated KSPGs. Results concurred with Western 
blot analysis that hybridomas 2C6 and 7C4 had lost their Ab specificity to the 
keratanase II ‘stub’ neoepitope or that they had stopped secreting the ‘KS II stub’ 
specific mAbs. No further analyses were performed on these hybridomas.
Figure 4.12 shows results of further Western blot screening analysis of mAbs 1C3 and 
11C4 for reactivity against keratanase II treated BNC (ABC) core and corneal KSPGs. 
Immunostaining was observed for keratanase II treated KSPG but not for keratanase II 
treated BNC (ABC) core. Negative reactivity to keratanase II digested BNC (ABC) 
core further indicates that both mAbs are specific only for KSPG core proteins 
isolated from comeal tissues and not to a keratanase II generated ‘stub’ epitope 
expected to also be present on aggrecan.
Preparations of purified bovine arterial lumican, bovine comeal lumican/mimecan,
bovine comeal keratocan/lumican and bovine cartilage fibromodulin antigens, were
obtained as a gift from Professor James Funderburgh, and used to definitively
characterise 1C3 and 11C4 immunoreactivity to these specific KSPGs (figure 4.13).
Samples were deglycosylated using a keratanase/keratanase Il/endo-p-galactosidase
mixture and 2pg loaded onto 15% slab gels for Western blot analysis with 1C3 and
11C4. 1C3 was shown to react with deglycosylated bovine arterial (figure 4.13, A,
lane 1) and comeal lumican (figure 4.13, A, lanes 3 and 4) at -50 kDa. 1C3 was
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ELISA s c r e e n  of  k e r a t a n a s e  II 'KS  s t u b '  m A b s
2C6 7C 4  1C3 11C4
Hybridoma cell lines
■  Untreated corneal KSPGs □  Corneal KSPGs + Kll ■  Corneal KSPGs + K'ase
Figure 4.11 - Screen for keratanase II ‘KS stub’ mAbs against bovine corneal KSPGs, 
keratanase II digested bovine corneal KSPGs and keratanase digested bovine corneal KSPGs. 
Hybridomas from wells 2B6 and 7C4 appear to have lost their antibody producing capacity.
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IC3 11C4
kDa
100 -
7 5 -
5 0 -
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+ +
Figure 4.12 -  Western blot screening analysis of new mAbs 1C3 and 11C4 against keratanase 
II treated bovine corneal KSPGs (lane 1) and keratanase II treated bovine aggrecan (lane 2). 
The results indicate that these mAbs are recognising corneal KSPG core protein epitopes and 
not a linear KS epitope or KS ‘stub’ neoepitope.
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1C3 (LUM-1) 11C4 (KER-1) 
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Cartilage fibromodulin - + - - - + - -
Corneal lumican / mimecan - - + - - - + -
Corneal keratocan / lumican - - - + - - - +
Figure 4.13 -  Screening of LUM-1 and KER-1 using a range of KSPG antigens. LUM-1 
was positive with bovine arterial lumican (A, lane 1), bovine corneal lumican / mimecan mix 
(A, lane 3) and with the bovine corneal keratocan / lumican mix (A, lane 4) at approximately 
50 kDa. KER-1 was positive only with the bovine corneal keratocan / lumican mix (B, lane 4) 
at approximately 30 -37  kDa. There was no immunoreactivity with either of the antibodies to 
bovine cartilage fibromodulin (A and B, lane 2).
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subsequently named LUM-1 on account of its now defined specificity for lumican 
core protein. In contrast, 11C4 was shown to be specific for the deglycosylated bovine 
corneal keratocan at -37 kDa (figure 4.13, B, lane 4). It was named KER-1 on account 
of its specific immunoreactivity with keratocan. There was no immunoreactivity with 
either antibody with bovine cartilage fibromodulin (figure 4.13, A and B, lane 2) or 
bovine corneal mimecan (figure 4.13, lane 3).
4.4.1.3 Reactivity o f  mAbs LUM-1 and KER-1 with KSPGs after removal ofN- and O- 
linked oligosaccharides.
Further Western blot analysis was carried out on partially purified bovine comeal 
KSPGs that had been pre-digested with keratanase, keratanase II and endo-p- 
galactosidase (figure 4.14, A and B, lane 1) and with further PNGase F to remove N- 
linked oligosaccharides (figure 4.14, A and B, lane 2), O-glycosidase to remove O- 
linked oligosaccharides (figure 4.14, A and B, lane 3) or mixture of PNGase F and O- 
glycosidase (figure 4.14, A and B, lane 4) treatment. Results demonstrated that after 
removal of N- and O-linked oligosaccharides (A and B, lane 4) the LUM-1 and KER- 
1 mAbs were specifically recognising core protein epitopes, at molecular weights of 
-37 kDa and -30 kDa, respectively (Funderburgh & Conrad, 1990; Funderburgh et 
al, 1993), and not keratanase II generated ‘KS stub’ linkage region neoepitopes or N- 
or O- linked oligosaccharides (figure 4.14).
4.4.1.4 Species cross-reactivity o f mAbs KER-1 and LUM-1
LUM-1 and KER-1 were analysed for reactivity against cornea, cartilage and tendon 
proteoglycan extracts from a range of different species (bovine, human and pig) after 
keratanase and keratanase II digestion (figure 4.15). KER-1 showed strong reactivity 
with keratocan from bovine comeal tissue extracts and 18 month old bovine tensional
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Figure 4.14 -  Western blot analysis of LUM-1 and KER-1 reactivity and molecular weight 
shifts in lumican and keratocan after treatment with the three KS degrading enzymes alone (A 
and B, lane 1), with PNGase F to remove N-linked oligosaccharides (A and B, lane 2) with O- 
glycosidase (A and B, lane 3) and with a mixture of PNGase F and O-glycosidase (A and B, 
lane 4). The results conclusively demonstrate that mAbs LUM-1 and KER-1 are specific for 
lumican and keratocan core proteins and that they are not recognising any KS linkage region 
neoepitopes or N- or O- linked oligosaccharides. Core protein molecular weights of 37 kDa 
for lumican and 30 kDa for keratocan are in agreement with previously reported core protein 
sizes (Funderburgh & Conrad, 1990).
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Species & tissue activity with KER-1 & LUM-1
BC BAC BT PC PAC HAC HOAC
Keratanase I I II
KER-1
LUM-1
BC = bovine cornea BAC = bovine articular cartilage
BT = bovine tendon PC = pig cornea
PAC = pig articular cartilage HAC = human articular cartilage
HOAC = human OA cartilage
Figure 4.15 - Species reactivity of KER-1 and LUM-1 in Western blot analysis of KSPGs 
from bovine, porcine and human tissues. KER-1 reacted with keratocan present in bovine 
cornea and tendon, but not with bovine cartilage PG extracts. It also reacted with porcine 
cornea but not with porcine cartilage extracts. There was no reactivity with KER-1 in normal 
human articular cartilage, but it reacted strongly with osteoarthritic cartilage. LUM-1 only 
reacted with bovine cornea and was negative with tendon and cartilage PG extracts. It was 
positive with porcine cornea and negative with porcine cartilage extracts. There was weak 
LUM-1 reactivity with normal human articular cartilage and immunoreactivity was increased 
in OA cartilage.
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tendon proteoglycan extracts, but was negative in extracts of 18 month old bovine 
cartilage. It reacted strongly with extracts of porcine cornea, but was negative in 
porcine cartilage. Interestingly it also reacted with keratocan extracted from 
pathological human articular cartilage but not with normal cartilage extracts 
(discussed further in chapter 6).
Like KER-1, LUM-1 was also shown to be a useful marker for identifying increasing 
expression of lumican in OA human articular cartilage compared to normal cartilage 
(also discussed further in chapter 6). It also reacted strongly with 18 month old bovine 
cornea and was negative with bovine tendon and cartilage PG extracts. It was positive 
with porcine cornea and negative with porcine cartilage extracts. The results 
demonstrate that the mAbs KER-1 and LUM-1 cross react with a range of different 
species and may prove to be useful bio-markers for the onset of degenerate joint 
disease.
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4.5 Discussion
The aim of the work described in this chapter was to produce monoclonal antibodies 
to either the keratanase II generated ‘KS stub’ neoepitope on keratan sulphate chains 
or to KSPG core protein epitopes. Bovine corneas were used as a source of KS 
containing proteoglycans because they contained high levels of KSPGs and were 
therefore a rich source of KS chains. An antigen was therefore used that had potential 
to make a number of very useful monoclonal antibodies to both KSPG core protein 
epitopes and to keratanase II generated KS ‘stub’ neoepitopes. Keratanase II is a 
commercially available keratan sulphate degrading enzyme that cleaves the chain at 
p i-3 linkages between N-acetylglucosamine and galactose, where the disaccharide 
structure is either monosulphated on the N-acetylglucosamine or disulphated on both 
residues (see chapter 2, section 2.3.1; Oguma et al, 2001; Yamagishi et al, 2003). It 
would therefore remove all sulphated disaccharides from the KS chain, leaving only 
non-sulphated disaccharide domains on the remaining KS ‘stubs’, making a 
keratanase II generated KS ‘stub’ mAb a potentially important antibody for analysing 
KS sulphation patterns. The experiments described in this chapter detail the 
production of a number of antibodies by partially purifying a selected keratanase II 
digested bovine corneal KSPG antigen through a series of Resource Q anion exchange 
and Sephacryl S-200 size exclusion chromatographic steps and using the partially 
purified antigen for immunisation. This antigen preparation was also predicted to 
contain keratocan, lumican and mimecan core proteins. Resource Q anion exchange 
chromatography was used initially to separate the negatively charged comeal 
proteoglycans from other matrix proteins. Pooled sulphated PGs were then 
chondroitinase ABC digested to reduce the molecular weight of CS/DSPGs compared 
to native KSPGs. Size exclusion chromatography separated the CS/DSPGs core 
proteins from the high molecular weight KSPGs which were then keratanase II
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digested. Size exclusion chromatography removed the keratanase II enzyme leaving a 
partially purified KSPG ‘stub’ antigen mixture. The antibodies produced to this 
antigen were characterised by ELISA and Western blot analysis (figures 4.8 -  4.15), 
which demonstrated that the experiments were successful in producing two antibodies 
to two different comeal KSPG core protein epitopes, lumican and keratocan. These 
antibodies were designated LUM-1 and KER-1, respectively. Removal of N- and O- 
linked oligosaccharides (figure 4.14) did not affect LUM-1 or KER-1 recognition 
capabilities, indicating that the antibodies were recognising KSPG core protein 
epitopes and not oligosaccharide side chain epitopes or a combination of both core 
protein and carbohydrate attachments. Keratan sulphate side chains would also have 
been removed by PNGase F in comeal KSPGs (see chapter 2, section 2.4.1.3, figure 
2.17), therefore these monoclonal antibodies were not recognising a KS chain or KS 
linkage region epitope.
The procedure was also successful in producing two different mAbs (2C6 and 7C4) to 
a keratanase II generated non-reducing terminal Gal or Gal-6-S neoepitope. However, 
these cell lines were found to be unstable and failed to maintain antibody production. 
None-the-less, these antibodies did demonstrate that it was possible to generate such 
mAbs which could be useful tools in future analysis of KS structure.
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4.6 Chapter summary
An antigen was prepared using a keratanase II digested bovine corneal KSPG 
extract that was partially-purified using anion exchange and size exclusion 
chromatography.
The antigen was used in immunisation to produce monoclonal antibodies to 
both the keratanase II generated ‘stub’ neoepitope, and to protein epitopes on 
comeal KSPG core proteins.
Antibody specificity was determined by screening using a range of 
differentially deglycosylated KSPGs from cartilage and cornea.
Keratanase II ‘stub’ mAb cell lines (2C6 and 7C4) were unstable and failed to 
maintain production of antibodies recognising the keratanase II generated ‘KS 
stub’ neoepitope.
KSPG protein core mAbs were shown to be specific for lumican and 
keratocan, and were designated LUM-1 and KER-1, respectively.
LUM-1 and KER-1 were shown to cross react with a number of different 
species.
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Chapter 5 -  Applications of BKS-1, LUM-1 and KER-1 monoclonal
antibodies
5.1 Introduction
Chapters 2 and 3 detailed the production of three new mAbs, one that recognises a 
keratanase generated ‘stub’ neoepitope on KS (BKS-1) and two that recognise protein 
core epitopes on two of the KS-substituted small leucine rich proteoglycans (SLRPs) 
commonly found in cornea, lumican and keratocan (mAbs LUM-1 and KER-1, 
respectively). The aim of this chapter was to provide some examples of useful 
applications for mAbs BKS-1, LUM-1 and KER-1 in the analysis of KSPG metabolism 
in biological tissue samples.
5.2 Materials
All chemicals were of analytical grade and were purchased from Sigma-Aldrich unless 
otherwise stated. A comprehensive catalogue of materials and suppliers used 
throughout this project is listed in Appendix A. All enzymes and related buffers were as 
described in chapter 2, section 2.2.2 and table 2.3. SDS-PAGE and Western blotting 
material was the same as described in chapter 2, section 2.2.1 and table 2.3. Bovine 
corneas were obtained from a local abattoir. Normal and pathological human corneas 
were obtained from Dr Saeed Akthar, School of Ophthalmology and Vision Science, 
Cardiff University.
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5.3 Methods
5.3.1 Analysis of KS substitution on lumican and keratocan from bovine cornea 
using BKS-1, LUM-1 and KER-1
50 pg GAG samples of partially purified bovine comeal PG extracts, prepared as 
described in chapter 4 section 4.2.2, were digested with 80 mU of keratanase per mg 
GAG (see section 2.3.1) in 0.1 M Tris acetate pH 6.8 for 24 hours at 37 0 C, followed 
by digestion using endo-P-galactosidase (8 mU per mg GAG) and keratanase II (6 mU 
per mg GAG). Equal GAG concentrations (3 pg -  pre-digestion equivalent 
concentrations) of undigested and keratanase followed by endo-p-galactosidase and 
keratanase II digested bovine KSPGs were reduced using 10% (v/v) P-mercaptoethanol 
and loaded onto 12% slab gels as described previously in section 2.2.3.1. Gels were 
transferred and Western blot analysis carried out using mAbs LUM-1, KER-1 (see 
chapter 4), BKS-1 [recognising a keratanase generated KS ‘stub’ neoepitope] (see 
chapter 2) and 5D4 [recognising linear sulphated poly-N-acetyl-lactosamine motifs 
within KS chain structures] to analyse the level of KS substitution on keratocan and 
lumican in the bovine comeal PG extract.
5.3.2 Analysis of KS quantities in human cornea, limbus and sclera using mAb BKS- 
1 compared to mAb 5D4
Normal human cornea, limbus and sclera were obtained from Dr Saeed Akthar, 
Department of Opthamology and Vision Science, Cardiff University. The tissue sample 
was diced, extracted and partially purified as described for bovine cornea in chapter 4, 
section 4.2.2. Extracts were dialysed to Milli Q™ water and DMMB analysis carried 
out to determine GAG content. 3 pg GAG samples each of comeal, limbal and scleral 
extracts were left undigested for Western blot analysis with mAb 5D4 or digested with
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80 mU of keratanase per mg GAG for Western blot analysis with mAb BKS-1. 
Samples were run on 4 -  20% Tris glycine gradient gels at 100 volts for 1.5 hours as 
described in section 2.2.3.1. Blots were transferred and probed with mAbs 5D4 and 
BKS-1 to analyse differential staining patterns of BKS-1 compared to 5D4.
5.3.3 Western blot analysis of normal versus pathological human cornea using mAbs 
BKS-1, 5D4, LUM-1 and KER-1
Pathological human cornea was obtained from Dr Saeed Akthar, Dept, of 
Ophthalmology and Vision Science, Cardiff University. Partially-purified comeal PGs 
were prepared for analysis as described in chapter 4, section 4.2.2 and DMMB analysis 
carried out to measure GAG content. 2 pg equivalent GAG samples of pathological 
human comeal PG extracts were analysed by SDS PAGE and Western blotting on 4 - 
20% Tris glycine gradient gels, using mAbs LUM-1, KER-1, BKS-1 and 5D4 after 
deglycosylation using keratanase. 2 pg GAG samples of normal human comeal PG 
extracts were also analysed by Western blotting using these mAbs for comparison to 
the pathological human comeal extracts.
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5.4 Results
5.4.1 BKS-1 -  a useful monoclonal antibody for analysing variations in quantities of 
KS substitution on different proteoglycans from within a tissue extract
Western blot analysis of bovine comeal PG extracts demonstrated the presence of 
lumican at -50 kDa and keratocan at -30 kDa as expected after keratanase digestion 
followed by keratanase II and endo-p-galactosidase digestion and prior to the removal 
of N- or O-linked oligosaccharide side chains (figure 5.1). Interestingly, BKS-1 also 
showed a sharp band at -50 kDa, corresponding to the same molecular weight as 
lumican (-50 kDa, see figure 5.1), indicating that lumican in this preparation was 
highly substituted with keratanase susceptible KS, i.e. a large proportion of mono- 
sulphated disaccharides. There was also very weak BKS-1 reactivity at corresponding 
molecular weight to keratocan, indicated at -30 kDa in figure 5.1. This suggests that 
the keratocan in this particular preparation was either very mildly substituted with KS, 
or that any KS on that keratocan was largely di-sulphated or non-sulphated and 
therefore not initially keratanase susceptible.
5.4.2 BKS-1 -  a useful monoclonal antibody for analysing variations in quantities of 
KS from different tissue extracts - a comparison to 5D4
Western blot analysis of PG extracts from normal human cornea, limbus and sclera 
from the eye demonstrated that BKS-1 was a more sensitive monoclonal antibody 
compared to 5D4 for analysis of KS quantities from different tissues. BKS-1 staining 
showed a much more subtle distribution of staining than 5D4 (figure 5.2). BKS-1 
allows the observation that the cornea contains more KS than the sclera per 3pg GAG 
loaded, with lowest levels of KS present in the limbus. 5D4 showed a much more 
diffuse staining pattern, with little indication of differences in KS quantities within the 
cornea, limbus or sclera.
B. Kerr PhD thesis 2005 183
kDa
LUM-1
150—► 
100->
75—►
50—► m
37—►
j
25—►
KER-1 BKS-1 5D4
Bov corneal KSPGs
+KII + E-P-G
KS levels on 
lumican at 50kDa
.KS levels on 
Keratocan at 30kDa
+ + + +
Figure 5.1 Western blot demonstration of the effectiveness of novel mAb BKS-1 in analysis of 
KS substitution and sulphation patterns on different KSPGs in bovine comeal PG extracts 
compared to 5D4 immunostaining.
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5D4 BKS-1
Cornea + 
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Figure 5.2 BKS-1 shows a more subtle distribution of staining in comparison to 5D4. It 
demonstrates differences in KS quantities within the cornea, limbus and sclera, whereas 5D4 
does not.
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5.4.3 LUM-1, KER-1 and BKS-1 analysis o f  normal versus pathological human 
cornea
The newly generated mAbs were also used in analysis of normal human comeal PG 
extracts compared to pathological human comeal PG extracts. Lumican levels were 
increased from normal to pathological human corneas at -50 kDa when volumes 
equivalent to 2 (ag GAG were loaded onto gels (see figure 5.3). There was also a weak 
band at -25 kDa with LUM-1 in pathological human cornea that was not apparent in 
normal extracts.
Interestingly, there was no staining with the keratocan mAb in normal human comeal 
extracts, this may be due to inefficient extraction of the molecule from normal human 
comeal tissues. There were a number of bands at -25, -27 and -30 kDa in pathological 
cornea (figure 5.3) showing that PG extractability may be increased with pathology. 
BKS-1 staining was present at -50 kDa, equivalent to lumican, with weaker bands at 
lower molecular weights in normal human comeal extracts. In pathological human 
comeal extracts BKS-1 staining was in the form of a diffuse band. One possible reason 
for such a diffuse smear here is that pathological human comeal KS may be much more 
highly sulphated towards the linkage region of the KS chain than normal human 
comeal KS, making it less keratanase susceptible at these di-sulphated domain regions 
therefore leaving larger ‘stubs’ on the KS chain from pathological tissue compared to 
normal tissue. This would the electrophoretic mobility of the pathological KSPG 
samples causing them to drag more into the gel causing the diffuse staining pattern 
observed in figure 5.3.
5D4 staining appeared as large molecular weight smear (37 — 300 kDa) in normal 
comeal extracts with a shift downwards in molecular weight (20 - 250 kDa) in 
pathological comeal tissue extracts, possibly due to the presence of KS on the 
proteoglycan breakdown products observed with LUM-1 and KER-1 immunostaining.
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Figure 5.3 Lumican, keratocan and KS concentrations in normal versus pathological human 
corneal PG extracts.
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5.5 Discussion
The aim of chapter 5 was to provide some examples of applications of all three newly 
generated mAbs (LUM-1, KER-1 and BKS-1), and to compare BKS-1 
immunoreactivity to 5D4 reactivity in the analysis of variations in KSPG and KS 
quantities and sulphation patterns in normal versus pathological tissue extracts. Several 
tissue PG extracts were prepared from normal bovine cornea and normal and 
pathological human cornea.
BKS-1 proved to be a more sensitive mAb than 5D4 as it showed a more subtle 
staining distribution when analysing KS quantities on either lumican or keratocan from 
the same PG extract from bovine cornea in Western blot analysis (figure 5.1). It 
allowed identification of exactly which KSPG molecules in the extract had KS 
attachments substituted onto them because the keratanase followed by keratanase II and 
endo-P-galactosidase digested extracts ran to the same position as the core proteins of 
deglycosylated lumican and keratocan. Alternatively, mAb 5D4 positive KSPGs ran 
into the gel as a smear (before digestion) due to the presence of the large sulphated KS 
side chains recognised as strong 5D4 immunoreactivity. Also, 5D4 staining was 
abolished after deglycosylation using keratanase, endo-p-galactosidase and keratanase 
II, enzymes which facilitated mAb BKS-1 recognition and reduced the molecular 
heterogeneity of the KSPGs. MAb 5D4 did not allow for specific identification of 
which molecules contained KS GAGs. However, BKS-1 proved to be a more specific 
mAb for analysis of KS substitution on different KSPGs from the same tissue extract. 
The results show the importance of using BKS-1 as an antibody in analysis of 
differential KS substitution on different KSPGs and how this GAG substitution pattern 
may change with development, age and disease. These applications could also be 
utilised in analysis of tissues other than comeal KSPGs. For example, mAb BKS-1 can 
be used, in conjunction with the related CS ‘stub’ antibodies 2B6, 3B3 and 1B5, and N-
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terminal sequence analysis of trypsin digested aggrecan core protein to determine the 
differential substitution of KS in different aged cartilage tissues. This analysis would 
help definitively identify the sites of KS substitution compared to the sites of CS 
substitution, and precisely how these substitutions change with age (reviewed in 
chapter 1, section 1.5.1) when there is an observed increase in KS compared to CS. 
BKS-1 was also used to compare 5D4 staining in PG extracts from normal human 
cornea, sclera and limbus (figure 5.2). Again, this antibody proved BKS-1 to be a more 
specific mAb for identification of KS quantities in these extracts of different ocular 
tissues where mAb 5D4 staining did not show differences; i.e. these studies indicated 
that BKS-1 was shown to be a more sensitive antibody for gauging KS quantities in a 
tissue compared to 5D4 because it recognises just one neoepitope per KS chain whereas 
5D4 recognises multiple epitopes on a single KS chain.
BKS-1 was also useful in the analysis of KS sulphation patterns in normal compared to 
pathological human comeal PG extracts compared to 5D4. BKS-1 staining in the 
normal human cornea showed that KS was substituted onto a molecule of about -50 
kDa, equivalent to the molecular weight of deglycosylated lumican. There was much 
weaker staining at -20, -30 and ~37 kDa. In pathological comeal extracts, BKS-1 
staining formed a diffuse smear of between 20 -  200 kDa. This diffuse pattern may 
result from an increase in sulphation of KS chains towards the linkage region in 
pathological tissue making them less keratanase susceptible in these areas. This may 
help to explain the large smear observed after keratanase digestion due to the longer 
disulphated ‘stub’ regions remaining after such treatment. The positive 5D4 staining in 
pathological comeal extracts supports the hypothesis that these ‘stub’ structures are the 
result of sulphated domains opposed to non-sulphated domains as the 5D4 recognises 
linear sulphated poly-N-acetyl-lactosamine regions. The results show how BKS-1 can
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be used in combination with 5D4 to give information on sulphation patterns within the 
KS chain in different tissues.
MAb LUM-1 showed that there was an increased level of lumican and a number of 
breakdown products in pathological compared to normal human corneas. KER-1 
staining was negative in normal human comeal extracts. This may be due to problems 
with extracting this particular molecule from normal human cornea. KER-1 staining 
was positive at -25, ~27 and ~30 kDa in pathological comeal extracts, indicating that 
keratocan extraction is allowed from this tissue.
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5.6 Chapter summary
• Monoclonal antibodies BKS-1 and 5D4 were used in Western blot analysis of 
bovine comeal and human comeal, limbal and scleral PG extracts, to observe 
KS sulphation patterns and variations in levels of KS substituted onto the KSPG 
molecules in health and disease.
• BKS-1 immunostaining of bovine comeal PGs was able to distinguish that 
lumican, identified using mAb LUM-1, was more highly substituted with 
keratanase susceptible KS than keratocan, i.e. the KS present on the extracted 
lumican was largely mono-sulphated, whereas any KS present on the extracted 
keratocan may have been either largely di-sulphated or non-sulphated and 
therefore not susceptible to the initial keratanase digestion.
• BKS-1 staining showed a more subtle staining distribution in normal human 
comeal, limbal and scleral PG extracts compared to 5D4 where staining was 
more diffuse. BKS-1 allowed identification of variations in levels of KS 
substitution in different tissues.
• Lumican staining was increased in pathological compared to normal human 
corneas showing a number of lower molecular weight breakdown products.
• Extraction of keratocan from normal human cornea appeared to be inefficient 
and staining was negative with KER-1 in Western blotting.
• In contrast keratocan was extractable from pathological human corneas using 
the same extraction procedures where a number of bands were observed at ~25, 
~27 and ~30 kDa.
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Chapter 6 — Lumican and keratocan expression in normal and 
pathological human articular cartilage and intervertebral disc
6.1 Introduction
The functional stability of articular cartilage and intervertebral disc (IvD) tissues is
sustained by the interactions of a large range of matrix molecules that are produced by
the chondrocytes and disc tissue cells that are present there. These include collagens,
proteoglycans and matrix proteins (reviewed in chapter 1). Whilst aggrecan provides a
negatively charged environment through its CS and KS side chain attachments, that
maintains a highly hydrated tissue, SLRPs such as decorin, biglycan, fibromodulin and
lumican interact with each other and other matrix molecules to provide a stable
structural environment where they are involved in collagen fibril assembly, cell
adhesion and growth factor regulation (reviewed by Iozzo, 1999). Osteoarthritis is a
disease that affects the functional capacity of cartilage primarily in hip and knee joints.
It occurs as a result of biochemical abnormalities, inflammation and mechanical
changes. During osteoarthritis and disc degeneration, changes in abundance and
integrity of the matrix molecules cause the extracellular matrix to become disorganised
and disrupted with increased water content (Buckwalter & Mankin, 1998). A range of
proteases, which have not yet been fully identified, target the various matrix molecules
present in the cartilage. Several enzymes have been identified that are responsible for
degradation of aggrecan in these diseases; e.g. aggrecanases (ADAMTS-4 & -5) and
MMPs; however, little is known about the roles of the KS SLRPs present there and any
proteases responsible for their degradation in pathological conditions.
Lumican and keratocan are two small leucine rich keratan sulphate proteoglycans that
are usually found in high levels in the cornea where they are thought to influence the
regulation of collagen fibril diameter and interfibrillar spacing to endow an ordered
and transparent corneal stromal structure that allows the passage of light through the
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eye (reviewed in chapter 1). The presence of lumican has been previously reported in 
many tissues other than cornea such as cartilage, bone, aorta, sclera, IvD, skin, muscle, 
lung, amniotic membrane, kidney and teeth (Funderburgh et al, 1987; Funderburgh & 
Conrad, 1989; Funderburgh et al, 1991 B; Grover et al, 1995; Cheng et al, 1996; Cs- 
Szabo et al, 1997; Chakravarti et al, 1998; Knudson & Knudson, 2001, review; Raouf 
et al, 2002; Chakravarti, 2003; Young et al, 2005 A). An increased expression of 
lumican at the mRNA and protein level has been observed in pathological human 
articular cartilage compared to normal cartilage (Grover et al, 1995; Cs-Szabo et al, 
1997) and in experimental animal models of OA (Young et al, 2005 A). An increase 
in lumican protein levels has been demonstrated in the annulus fibrosis of human IvD 
with increasing age (Sztrolovics et al, 1999 A). However, little is known about the 
molecular or proteomic changes in lumican expression that occur in human IvD 
degeneration (Urban & Roberts, 2003). In adult tissues keratocan expression has so far 
been reported as being largely “cornea specific” (Conrad & Conrad, 2003; Carlson et 
al, 2005; Kawakita et al, 2005) although expression has been demonstrated in the 
developing avian ocular tissues and nephrogenic mesenchymes where it has been 
proposed to have a role in embryonic cell migrations (Conrad & Conrad, 2003).
The aims of this chapter were to comprehensively examine the changes in expression 
of both lumican and keratocan, at the proteomic and molecular level, in human 
articular cartilage and intervertebral disc tissues in health and disease.
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6.2 Materials
All chemicals were of analytical grade and were purchased from Sigma-Aldrich unless 
otherwise stated. A comprehensive catalogue of materials and suppliers used 
throughout this project is listed in Appendix A. All enzymes and related buffers were 
as described in chapter 2, section 2.2.3 and table 2.3. SDS-PAGE and Western blotting 
material was the same as that described in chapter 2, section 2.2.5 and table 2.3. All 
DMMB material was the same as that described in chapter 2, section 2.2.2 and table 
2.3. A Bicinchoninic Acid (BCA) protein assay reagent kit was obtained from Pierce. 
Tri reagent and Chloroform (CHCI3) were obtained from Sigma-Aldrich. RNeasy mini 
kit for isolation of RNA was obtained from Qiagen, UK. Oligonucleotide primers were 
from Invitrogen. RNA PCR kits containing GeneAmp, 10 x PCR buffer II (100 mM 
Tris-HCl pH 8.3; 500 mM KC1), MgCh (25 mM solution), dNTPs (dATP, dCTP, 
dGTP, dTTP, all at a concentration of 10 mM), Rnase inhibitor, MuLV reverse 
transcriptase and oligo d(T) for RT-PCR reactions were all obtained from Applied 
Biosystems, UK. Taq DNA polymerase was from Promega. DNA molecular markers, 
6 x tracking dye and ethidium bromide were from Cambio, Cambridge, UK. Agarose 
(genetic technology grade) was from MP Biomedicals. QIA quick PCR purification kit 
for purification of PCR reaction products for sequencing was obtained from Qiagen, 
UK. Big dye terminator v l.l  cycle sequencing kit was from Applied Biosystems. 
Technegene thermal cycler for RT-PCR reactions was obtained from Techne, UK. An 
UltroSpec 2000 spectrophotometer was obtained from Amersham Pharmacia Biotech, 
UK.
6.2.1 Tissues for extraction of RNA and matrix proteoglycans
Normal human hip cartilage (n = 5) was obtained post operatively from the University 
Hospital of Wales, Cardiff within 5 hours of surgical procedures from patients
B. Kerr PhD thesis 194
undergoing hip replacements due to hip fracture caused by osteoporosis. Osteoarthritic 
human hip cartilage (n = 7) and knee cartilage (n = 10) from similarly aged patients 
were obtained from Llandough Hospital, Cardiff within 5 hours of surgery from 
patients undergoing hip and knee replacement surgery. The degree of degeneration of 
the articular cartilage samples was graded at the hospitals based on methods previously 
described by Kellgren & Lawrence in 1957. OA grading was carried out by Dr Kedar 
Deogaonkar, Clinical Research Fellow, Dept of Orthopaedics, University Hospital of 
Wales, Cardiff, and was based as follows:
Grade 0: No features
Grade 1: Doubtful: minute osteophytes, doubtful significance and narrowing of
the joint space, possible osteophytes lipping.
Grade 2: Minimal: definite osteophytes formation, unimpaired joint space and
possible narrowing of joint space.
Grade 3: Moderate: moderate diminution of joint space, moderate multiple
osteophytes formation, definite narrowing of joint space, some sclerosis 
and possible deformity of bone contour.
Grade 4: Severe: joint space greatly impaired, sclerosis of subchondral bone,
large osteophytes formation, marked narrowing of joint space, severe 
sclerosis and definite deformity of bone contour.
(Kellgren & Lawrence, 1957).
Normal intervertebral discs from patients with Scoliosis (n = 2) and degenerate IvD (n 
= 5) from patients with different grades (I - V) of disc degeneration determined using a 
method described by Pfirrmann et al., (2001) were obtained from the University 
Hospital of Wales and Llandough Hospitals following surgical procedures. Samples
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were graded from MRI scans again by Dr Kedar Deogaonkar, Clinical Research 
Fellow, Dept of Orthopaedics, University Hospital of Wales, as follows:
Grade I: Homogeneous in structure, bright white, distinction of nucleus and
annulus is clear, signal intensity was hyperintense and isointense to 
cerebrospinal fluid, height of IvD is normal.
Grade II: Inhomogeneous in structure with or without horizontal bands,
distinction of nucleus and annulus is clear, signal intensity was 
hyperintense and isointense to cerebrospinal fluid, height of IvD is 
normal.
Grade III: Inhomogeneous in structure, gray in colour, distinction of nucleus and
annulus is not clear, signal intensity was intermediate, height of IvD is 
normal or slightly decreased.
Grade IV: Inhomogeneous in structure, gray to black in colour, distinction of
nucleus and annulus is lost, signal intensity was intermediate to 
hypointense, height of IvD is normal or moderately decreased.
Grade V: Inhomogeneous in structure, black in colour, distinction of nucleus and
annulus is completely lost, signal intensity was hypointense and IvD 
space is collapsed.
(Pfirrmann et al, 2001).
All samples were collected with patient consent and ethical approval. Patient numbers, 
age, sex and grade of degeneration are listed in table 6 .1 .
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Articular cartilage Patient
number
X-ray grading 
of OA
Age Sex
N orm al hip 1 0 83 F
33 0 92 F
34 0 81 F
35 0 69 F
36 0 89 F
O A hip 8 4 76 M
9 3 73 M
11 3 33 F
12 4 75 F
20 4 69 F
23 4 83 M
24 4 67 F
OA knee 3 4 80 F
5 3 60 M
6 3 79 M
7 4 51 F
10 4 82 M
13 3 82 M
14 3 76 M
19 3 70 F
21 4 84 M
22 4 54 M
IvD Patient
num ber
M R I grade o f  
degeneration
Age Sex
Norm al IvD 25 I 14 F
26 I 13 F
Degenerate IvD 4 III 27 M
15 IV 34 F
16 IV 41 F
17 V 54 F
18 IV 43 M
Table 6.1 Normal and Osteoarthritic articular cartilage and normal and degenerate IvD 
samples collected for analysis by Western blotting and RT-PCR.
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6.3 Methods
6.3.1 Lumican and keratocan mRNA expression in normal and OA human cartilage
6.3.1.1 RNA isolation
For the amplification of human complementary DNA (cDNA), total RNA was isolated 
from weight bearing areas of normal human hip (patient numbers: 1 , 3 3 , 3 4 , 3 5  and 36, 
see table 6.1) and pathological (patient numbers: 3, 5, 6 , 7, 8 , 14, 19, 20,21, 22, 23 and 
24, see table 6.1) human hip and knee cartilage samples. Approximately 100 mg 
cartilage cuttings were initially weighed, snap frozen in liquid nitrogen and 
homogenised for 1 minute at 2,000 rpm in liquid nitrogen chilled Braun Mikro- 
Dismembrator Vessel (B.Braun Biotech International GmbH). 1 ml of Tri reagent per 
100 mg tissue was added to the powdered cartilage. 200 pi of CHCI3 was added and 
the mixture left to sit at room temperature for 15 minutes. Samples were then 
centrifuged at 13,200 rpm for 15 minutes in a U-32R centrifuge (Boeco, Germany). 
The upper aqueous phase was removed and mixed with an equal volume of 70% (v/v) 
ethanol. Qiagen RNeasy miniprep kit and reagents were used according to standard 
manufacturer’s procedures to isolate total RNA from the sample. The minicolumns in 
the miniprep kit work by binding RNA to the silica-gel-based membrane allowing 
contaminants to be washed away by microspin technology. To remove DNA 
contaminants, the membranes were incubated with DNAse I (80 pi, Qiagen) during the 
wash steps. Purified RNA was subsequently eluted in 60 pi of sterile Milli Q™ water 
and the sample was then stored at —80 °C until used in RT-PCR analysis experiments. 
RNA concentrations and purity in each sample were measured using an Ultraspec 2000 
(Pharmacia Biotech, UK) at 260 nm and 280 nm. RNA was also extracted from bovine 
cornea as a positive control for the human/bovine lumican and keratocan specific 
primers.
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6.3.1.2 Reverse transcription o f RNA (RT-PCR)
cDNA required for primer specific polymerase chain reaction amplification of a 
required target sequence was produced during the initial reverse transcription 
polymerase chain reaction (RT-PCR) procedure. RT-PCR required a concentration of 
either 50 or 500 ng of RNA for lumican or keratocan cDNA amplification respectively, 
in hip and knee articular cartilage, and also from the bovine comeal total RNA sample, 
with a final reaction volume of 20 pi (see table 6.2). The RT reaction mixture was 
gently mixed and incubated at room temperature for 10 minutes. It was then subjected 
to the following cycle: 42 °C for 30 minutes, 99 °C for 5 minutes and soaked at 4 °C.
RT mix Volume
Mg free lOx PCR buffer II 2pl
25 mM MgCl2 1.6 pi
2.5 mM dNTPs 1.6 nl
RNAse inhibitor i n i
Reverse transcriptase 1 Pi
Oligo dT 1 Pi
Milli Q™ water 11.8 pl -  RNA volume
RNA sample Volume = 50 -  500 ng
Table 6.2 RT-PCR reaction mixture
6.3.1.3 Primer design
For amplification of portions of lumican and keratocan cDNA, primers were designed 
using sequences of interest obtained from Genbank. They were designed using the 
Oligo 4.0s program for Macintosh. Primers were designed where sequences matched 
both bovine and human lumican and keratocan, so that bovine comeal RNA extracts 
could be used as positive controls for the lumican and keratocan primers. Primer 
sequences to lumican and keratocan are listed in table 6.3. A number of criteria had to 
be considered when designing the primers, these included:
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1. primers should be between 20-25 nucleotides in length;
2. they should have an annealing temperatures of between 50 -  65°C;
3. they should have a GC content of between 40-60%;
4. self complementary sequences should be avoided to minimise primer dimer 
formation.
Human glyceraldehydes-3-phosphate dehydrogenase (GAPDH 1 and 2 [see table 6.3]) 
specific primers were also designed to be used as positive tissue controls in RT-PCR 
analysis of human cartilage tissues.
Primers Specificity Sequence Size of 
product
Annealing 
temp (°C)
BCK 19 
BCK 20
Human/
bovine
keratocan
5’CCTGATAGAAACCATTCCTGA
5’CTGCATTGTATTGGCTGGTAA
409 bp 52.1
BCK 21 
BCK 22
Human/
bovine
lumican
5 ’ ATGGTGCCTCCTGGAATCAAG 
5’AGCTCAAGTCAAGGTATTCGA
391 bp 52.5
Hum GAPDH 1 
Hum GAPDH 2
Human
GAPDH
5’TGGTATCGTGGAAGGACTCAT
5’GTGGGTGTCGCTGTTGAAGTC
370 bp 58.1
Table 6.3 -  Oligonucleotide primers used in RT-PCR amplification of human and bovine 
keratocan and lumican and human GAPDH positive control.
6.3.1.4 Polymerase chain reaction
Polymerase chain reactions (PCRs) were prepared as described in table 6.4, using 1 pi 
of the RT reaction mixture (see section 6.3.1.3 above) from each sample for lumican 
reactions and 2 pi of the RT reaction mixture for keratocan reactions. PCR reactions 
were processed in a Technegene thermal cycler. After an initial denaturation step at 95
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°C for 60 seconds, the PCR reaction mixtures were amplified at 95 °C for 30 seconds, 
45 seconds at the specified annealing temperature of the primers (52.1 °C for keratocan 
and 52.5 °C for lumican), 72 °C for 45 seconds and a final extension step of 5 minutes 
at 72 °C. Amplification was repeated 30 times for lumican and 40 times for keratocan. 
GAPDH housekeeping primers were run with an annealing temperature of 58.1 °C 
with each sample as a positive control.
PCR mix Volume
Mg free lOx PCR buffer II 5 pi
25 mM MgCl2 3 pl
2.5 mM dNTPs 4 pi
Primers (10 pM stock) 1 pl
Taq polymerase 0.3 pl
RT sample 1 -  5 pl
Milli Q™ water 34.7 - 30.7 pl
Table 6.4 - PCR reaction mixture
6.3.1.5 Agarose gel electrophoresis o f  PCR products
PCR reaction products were run for visualisation on 2 % (w/v) agarose gels made up in 
30 ml Tris Borate EDTA buffer (Sigma T-3913). The solution was micro-waved to 
dissolve the agarose and allowed to cool from boiling to warm. 2  pi of a 1 0  mg/ml 
ethidium bromide solution was added to the gel. The gel was poured into a PCR 
cassette and allowed to set at room temperature for 10 minutes and at 4 °C for 10 
minutes. A DNA ladder of standards was prepared by mixing 1 pi of dye solution (6 x 
tracking dye Cambio BV-BT-10) with 2 pi of lx PCR buffer and 3 pi of DNA ladder 
(LMV 50-1000 bp Cambio BV-1159-01). 5 pi of all PCR reaction products were 
mixed with 1 pi of tracking dye. 5 pi of the DNA ladder and 5 pi of all samples were 
loaded into wells in the gel and run at 120 volts in 0.5x TBE until the dye front
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reached the bottom of the gel running cassette. Bands were visualised on a UV light 
box and pictures taken.
6.3.1.6 Sequence analysis o f  RT-PCR reactions
Samples from each set of RT-PCR reactions carried out were purified using a QIA 
quick PCR purification kit in order to purify single or double stranded DNA fragments 
from PCR reaction components such as primers, nucleotides, polymerases and salts. 
Briefly, 5 volumes of PB buffer from the kit were added to 1 volume of the PCR 
reaction. The sample was placed in a QLAquick spin column in a 2 ml collection tube 
and DNA was bound by spinning for 60 seconds at 13,200 rpm. The flow through was 
discarded and the spin column washed with 750 pl of PE buffer and spun again at 
13,200 rpm for 1 minute. The flow through was discarded again and the column spun 
for a further 1 minute. The column was placed in a clean 1.5 ml microcentrifuge tube 
and 50 pl of EB buffer added to the centre of the membrane to elute the DNA by 
centrifuging at 13,200 rpm for 1 minute. Sequencing reactions using BigDye 
Terminator cycle sequencing kit (Applied Biosystems) were prepared as follows:
PCR sequencing mix Volume
Big Dye 4 pl
5 pM forward primer 1 pl
Purified DNA 5 pl
h 2o To 15 pl
Table 6.5 PCR sequencing reaction
The sequence reaction was gently mixed, spun and cycled as follows: 96 °C for 20
seconds; 50 °C for 10 seconds; 60 °C for 4 minutes °C and soaked at 4 °C.
Amplification was repeated 26 times. 8  pl of Milli Q™ water; 2 pl of 3 M Sodium
acetate, pH 5; and 50 pl of 100% ethanol were added to the PCR sequence reaction
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product. This solution was mixed, spun and incubated at room temperature for 20 
minutes and then centrifuged at maximum speed (13,200 rpm) for 20 minutes. The 
supernatant was removed and discarded and the DNA pellet washed with 250 pl of 
70% (v/v) ethanol. The reaction mixture was centrifuged again at maximum speed for 
5 minutes and the supernatant removed and discarded. The pellets were dried at 90 °C 
and brought to the sequencing department at Cardiff University for sequence analysis 
and verification of PCR products.
6,3.2 Preliminary SDS PAGE and Western blot analysis of lumican, keratocan and 
KS substitutions in normal and pathological human cartilage and IvD tissues 
Preliminary studies were preformed on normal and OA human articular cartilage 
extract samples and pathological IvD tissue samples that were provided to our lab 
through ongoing collaboration with Dr Sally Roberts and Professor Stephen 
Eisenstein, Centre for Spinal Studies, RJAH, Orthopaedic Hospital, Oswestry. These 
samples were analysed by SDS PAGE and Western blot analysis using mAbs LUM-1 
and KER-1 (see chapter 4 for characterisation). Volumes equivalent to 5 pg GAG were 
either left undigested or digested with keratanase (80 mU per mg GAG), keratanase II 
( 6  mU per mg GAG) or endo-p-galactosidase ( 8  mU per mg GAG). Samples were 
loaded onto 4 -  20% Tris glycine gradient gels for SDS-PAGE and Western blot 
analysis as described previously in section 2.3.2.1. Blots were probed with mAbs 
LUM-1 and KER-1 to analyse the presence of comeal related KSPGs (lumican and 
keratocan) and the types of KS substitutions present on those KSPGs in normal versus 
pathological human articular cartilage and IvD.
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6.3.3 KSPG protein levels in normal and OA human articular cartilage from hip and 
knee, analysis by Western blotting
Articular cartilage samples were harvested from weight bearing areas of all graded 
normal hip, OA hip and OA knee patient samples described above in table 6.1. These 
tissues were then finely diced and extracted in 4 M Guanidine HC1 with a protease 
inhibitor cocktail as described previously (section 4.3.1.1). Crude 4M Guanidine HC1 
extracts were dialysed to 50 mM sodium acetate, pH 6 . 8  and DMMB analysis carried 
out to determine the sulphated GAG concentration of each sample. Protein 
concentrations were also determined for each sample using a Pierce Bicinchoninic 
Acid (BCA) protein assay kit. Briefly, a standard curve of 0, 20, 40, 60, 80, 100 and 
200 pg/ml bovine serum albumin (BSA) was prepared in 50 mM sodium acetate, pH 
6 . 8  and applied in triplicate to a 96 well microtitre plate. Samples were diluted 1:5, 
1:10, 1:25 and 1:50 in 50 mM sodium acetate, pH 6 . 8  and applied in triplicate to the 
same 96 well micro titre plate. Working reagent was prepared according to the 
manufacturers protocol and 200 pl applied to each well and gently mixed. The plates 
were covered and incubated at 37 °C for 30 minutes. Plates were measured at and 
optical density of 575 nm on a labsystems multiscan MS plate reader and protein 
concentrations determined for all cartilage and IvD extract samples.
Further analysis was carried out on a range of normal hip and OA hip and knee PG 
extracts (table 6.1). 8  pg GAG per well and 25 pg protein per well of each of the 
samples were digested with keratanase, keratanase II and endo-p-galactosidase (as 
described in chapter 2, section 2.3.1.2) and were loaded onto 2 different 4 -  20% Tris 
glycine SDS-PAGE gradient gels and run as described previously in section 2.3.2.1. 
Blots were probed with mAbs LUM-1 and KER-1 to analyse the presence of comeal 
related KSPGs, lumican and keratocan, in normal versus OA human cartilage.
B. Kerr PhD thesis 204
6.3.4 Lumican and keratocan mRNA expression in normal and degenerate human 
IvD
100 mg IvD tissue was removed from normal scoliosis patient samples (n = 2, patient 
sample numbers 25 and 26, see table 6.1), from grade III degenerate IvD samples (n = 
1, patient sample 4), from grade IV degenerate IvD patient samples (n = 3, patient 
sample numbers 15, 16 and 18) and from grade V degenerate IvD patient samples (n = 
1, patient sample number 17) and RNA extracted as described in section 6.3.1 above. 
RNA concentrations and purity in each sample were measured using an Ultraspec 2000 
at 260 nm and 280 nm.
RT-PCR reactions were set up as described above in sections 6.3.1.2 -  6.3.1.4 (table 
6.2). Volumes equivalent to 50 ng RNA were used for each sample to analyse lumican 
mRNA expression in normal compared to pathological human IvD using human 
lumican specific primers (BCK 21 and BCK 22) detailed in table 6.3. 1 pi of IvD RT 
cDNA was used in PCR reactions (table 6.4) with lumican specific primers.
Volumes equivalent to 215 ng RNA were used for each sample to analyse keratocan 
mRNA expression in normal compared to degenerate IvD. Human/bovine keratocan 
specific primers (BCK 19 and BCK 20) were designed (table 6.3) for amplification of 
keratocan message. 5 pi of IvD RT cDNA was used in PCR reactions (table 6.4) with 
the keratocan primers.
6.3.5 Analysis of lumican and keratocan protein levels in different grades of IvD 
degeneration
IvD samples were extracted in 1 ml 4 M Guanidine HC1 with protease inhibitors per 
mg tissue as described previously in section 4.3.1.1. Samples were dialysed to 50 mM 
sodium acetate, pH 6 . 8  and DMMB (see section 2.3.1.1) and protein concentration 
analysis (see section 6.3.3) was carried out to determine sulphated GAG and protein
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concentration, respectively. Volumes equivalent to 8  pg GAG and 25 pg protein were 
digested with a keratanase/keratanase II/endo-|3-galactosidase mixture (section 2.3.1.2) 
and run on two different 4-20% Tris glycine gradient gels for electrophoresis as 
described in section 2.3.2.1. Western blot analysis was carried out using mAbs LUM-1 
and KER-1, to analyse changes in protein expression of small leucine rich KSPG in 
degenerating human IvD PG extracts.
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6.4 Results
6.4.1 Preliminary analysis of lumican, keratocan and KS substitutions in normal 
and pathological human cartilage and IvD tissues
Preliminary Western blot analysis of 5 pg GAG samples of undigested, keratanase 
digested (80 mU per mg GAG), keratanase II digested (6 mU per mg GAG) or endo-p- 
galactosidase digested (8 mU per mg GAG) PG extracts from normal and OA tissue 
samples and graded pathological IvD tissue extracts (grade I -  IV) showed that 
lumican and keratocan levels were increased in pathological compared to normal 
tissues (figures 6.1 knee cartilage; A versus B; and figure 6.2 IvD samples, grade I, II, 
III and IV). This analysis also showed that digestion using keratanase or endo-p- 
galactosidase digestion of human articular cartilage and IvD lumican and keratocan 
resulted in a very slight decrease in molecular weight of the core protein by 
approximately 1 - 4  kDa (figures 6.1 and 6.2). Keratanase II digestion did not result in 
a shift in molecular weight of the core proteins of lumican or keratocan metabolites 
compared to undigested samples in cartilage or IvD tissues (figures 6.1 and 6.2). The 
results indicated that the KSPG molecules found in human articular cartilage and IvD 
tissues were substituted with very low molecular weight unsulphated or low- sulphated 
KS chains, and that there were no di-sulphated forms of KS attachments (figures 6.1 
and 6.2). The results agreed with previously reported observations that the lumican 
found in human articular cartilage may possess either low or non-sulphated forms of 
KS (Melching & Roughley, 1999).
This preliminary analysis indicated that unlike the keratocan or lumican found in 
comeal tissues, both the keratocan and lumican present in normal or pathological 
cartilage and IvD did not necessarily require pre-digestion with any form of KS 
degrading enzyme to expose the core protein epitope recognised by LUM-1 or KER-1 
because very little KS appeared to be present on these molecules.
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Figure 6.1 Preliminary Western blot analysis o f normal human cartilage (A) compared to 
osteoarthritic human cartilage (B) using monoclonal antibodies to the small leucine rich PGs 
lumican (LUM-1, -45 -50  kDa) and keratocan (KER-1, -30  kDa) show that expression of 
these molecules are increased in pathological human articular cartilage tissues compared to 
normal. There were also a number o f smaller molecular weight breakdown products (10-20 
kDa) of keratocan in pathological tissue. Keratanase and endo-p-galactosidase digestion 
decreased the molecular weights of both lumican and keratocan metabolites only slightly 
compared to that observed with corneal lumican and keratocan standards (see chapter 4, 
section 4.4.1.2; figure 4.10). Keratanase II did not affect the molecular weight of any of the 
KSPG molecules.
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Figure 6.2 Western blot analysis o f degenerate IvD tissues using mAbs LUM-1 to lumican 
(-45-50 kDa) and KER-1 to keratocan (-30 kDa) show that expression of these molecules are 
present in normal (grade I) and pathological (grades D, III, IV) IvD tissues at the protein level 
to different extents. Again keratanase and endo-p-galactosidase digestion caused a decrease in 
the molecular weights o f both lumican and keratocan metabolites only slightly compared to 
that observed with bovine comeal lumican and keratocan standards (see chapter 4, section 
4.4.1.2; figure 4.10). Keratanase II did not affect the molecular weight of the KSPG molecules.
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6.4.2 Molecular and proteomic expression of lumican in normal versus OA human 
articular cartilage
Lumican mRNA expression appeared to be constitutively expressed for all OA 
samples except patient number 7 (OA knee) where there was a small reduction in 
expression of lumican mRNA compared to other OA samples (figure 6.3; A). Three 
patients (numbers 33, 35 and 36) of the five normal cartilage samples analysed also 
appeared to have similar levels of lumican mRNA expression as the OA patient 
samples (14, 20, 3, 5, 19, 22, 23 and 24). Normal patient samples 1 and 34 showed a 
reduction in lumican mRNA expression compared to OA patient samples, these results 
concurring with results reported recently in animal models of OA (Young et al., 2005 
A) where there was reported to be an increase in the expression of lumican in OA 
compared to normal articular cartilage tissues. GAPDH PCR analysis was positive 
with consistent intensity for all samples analysed (figure 6.3; B). Milli Q™ water was 
run as a negative control. Sequence analysis carried out on samples from the GAPDH 
and lumican RT-PCR reactions confirmed that the bands observed were human 
GAPDH and human lumican.
In contrast to the RT PCR analysis of normal patient samples 33, 35 and 36, and all 
OA patient samples, protein levels of lumican identified in Western blot analysis of 
extracts from the same patient samples using mAb LUM-1, showed an overall increase 
in protein expression of the lumican core protein (figure 6.3; C). This suggests that the 
increased lumican observed at the proteomic level in OA compared to normal cartilage 
may be due to an increase in lumican translation or a decrease in lumican breakdown 
and rather than an increase in lumican RNA synthesis.
Samples were loaded both on equal GAG (8 pg per well) and equal protein (25 pg per 
well) basis for SDS PAGE and Western blot analysis (figure 6.3, panels C and D, 
respectively). The same pattern was obtained where there was an increase in lumican
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Figure 6.3 Lumican expression at the molecular (A) and proteomic (C and D) level observed 
in extracts from normal and pathological human articular cartilage obtained from hips and 
knees of patients undergoing joint replacement surgery. Panel A shows PCR analysis of RNA 
extracts from normal and OA patient tissues using lumican specific primers, Milli Q™ water 
was run as a negative control. Panel B shows GAPDH as a positive control for qualitative 
comparison of message levels. Panel C shows levels of lumican proteoglycan from the same 
normal and OA patient samples in SDS PAGE and Western blot analyses that had been loaded 
based on equal GAG concentrations. Panel D also shows lumican proteoglycan levels in 
Western blot analysis where patient samples had been loaded based on equal protein levels.
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at the proteomic level in OA compared to normal cartilage regardless of loading 
method applied.
Samples were also run with no primary antibody applied to analyse for any non­
specific binding of tissue extracts with the secondary antibody. Results showed that, 
particularly in pathological tissue samples, there was non-specific binding at -25 kDa 
(results not shown). This molecular weight corresponds to the same molecular weight 
as the light chain of reduced endogenous human immunoglobulin present in the tissue. 
Immunoglobulin light chains identical to those that showed up in the no primary 
controls also showed up in Western blot analysis using LUM-1 and are indicated in 
figure 6.3; C and D.
6.4.3 Keratocan mRNA and protein expression is increased in osteoarthritic human 
cartilage
Keratocan RNA and protein expression were analysed in normal human articular 
cartilage compared to OA human articular cartilage by RT-PCR and Western blot 
analysis. Normal cartilage RNA extracts (n=5, patient numbers 1, 33, 34, 35 and 36 
aged 83, 92, 81, 69, & 89 years, respectively) showed no expression of keratocan when 
500 ng of RNA was used in RT PCR analysis (figure 6.4; A). In contrast, OA patient 
samples from a similar age range (n = 8, patient numbers 8, 20, 23, 3, 5, 7, 19 and 22 
who were 76, 69, 83, 80, 60, 51, 70 and 54 year old patients, respectively) showed a 
large increase in expression of keratocan at the molecular level (figure 6.4; A). Milli 
Q™ water was run as a negative control and bovine cornea RNA RT-PCR was run as a 
positive control for keratocan expression. GAPDH was positive with consistent 
staining intensity for all cartilage samples. Sequence analysis of PCR products was 
carried out on samples from the GAPDH and keratocan RT-PCR reactions to confirm 
that the bands observed were human GAPDH and human keratocan.
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Figure 6.4 Keratocan expression at the molecular (A) and proteomic (C and D) level observed 
in normal and pathological human articular cartilage obtained from patients undergoing hip 
and knee joint replacement surgery. Panel A shows PCR analysis of RNA extracts from 
normal and OA patient tissues using keratocan specific primers. Panel B shows GAPDH as a 
positive control. BC = bovine corneal tissue run as a positive control. Milli Q™ water was run 
as a negative control. Panel C shows proteoglycan levels o f keratocan from the same normal 
and OA patient samples in SDS PAGE and Western blot analyses using KER-1 that had been 
loaded based on equal GAG concentrations. Panel D also shows keratocan proteoglycan levels 
in Western blot analysis using KER-1 where samples had been loaded based on equal protein 
levels.
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In agreement with RT-PCR analysis of normal and pathological cartilage samples, 
Western blot analysis using KER-1 showed no staining or very low levels of staining 
when the same normal (grade 0) articular cartilage samples that were analysed for RT- 
PCR were loaded for SDS PAGE and Western blot analysis based on equal GAG 
(figure 6.4; C) or protein (figure 6.4; D) concentrations. Western blot analysis of the 
same OA cartilage samples previously analysed in RT-PCR analysis and also some 
extra OA hip and knee samples collected (n = 7, patient numbers 11, 12, 14, 24, 6, 10 
and 13 from patients aged 33, 75, 76, 67, 79, 82 and 82 years, respectively) showed 
that they contained keratocan core proteins that were highly immunoreactive with 
KER-1 at -30 kDa in all samples (figure 6.4; C and D). Samples also showed a 
number of lower molecular weight breakdown products between 2 3 - 1 4  kDa 
indicating that there had been a degree of proteolysis of the elevated levels of 
keratocan as a result of pathology in the tissues.
Samples were also run with no primary antibody applied to analyse for any non­
specific binding of tissue extracts with the secondary antibody. Results showed that in 
pathological tissue samples there was a high degree of non-specific binding at ~25 kDa 
(results not shown). These light chains also showed up in Western blot analysis using 
KER-1 and are indicated in figure 6.4; C and D.
6.4.4 Lumican expression is increased at the molecular and proteomic levels in 
grade/ -  Vintervertebraldisc degeneration
For this study, levels of expression of lumican in scoliosis patients were considered as 
non-degenerate; i.e. ‘normal’. RT PCR analysis of tissue samples from scoliosis 
patients (n = 2, patient numbers 25 and 26, aged 13 and 14 years, respectively), grade 
III IvD degeneration (n = 1, patient number 4, aged 27 years), grade IV IvD 
degeneration (n = 3, patient numbers 15, 16 and 18, aged 34, 41 and 54, respectively)
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and grade V IvD degeneration (n = 1, patient number 17, aged 43) showed very low 
levels of lumican expression in ‘normal’ scoliosis patients and in one of the grade IV 
patients (figure 6.5; A). In all other patients with different grades of degenerate disc 
lumican expression was greatly increased (figure 6.5; A). Milli Q™ water was run as a 
negative control and bovine cornea RNA RT-PCR run as a positive control. GAPDH 
was positive with consistent staining intensity for all IvD patient samples. Sequence 
analysis was carried out on samples from the GAPDH and lumican RT-PCR reactions 
and confirmed that the bands observed were human GAPDH and human lumican. 
SDS-PAGE and Western blot analysis of extracts from patients with grade I -  V IvD 
degeneration (grading methods determined by Pfirrmann et al., 2001) demonstrated an 
apparent up-regulation of lumican in pathological disc tissues (figure 6.5; C and D). 
Lumican was present in low levels in one of the non-degenerate scoliosis patients 
(patient number 25) and appeared to be absent when 8 pg GAG or 25 pg protein were 
loaded for Western blot analysis of the second normal patient (patient number 26). 
Lumican levels were increased in all other pathological disc tissues, with the 
occurrence of breakdown product visible at ~30 kDa in extracts from patient number 
15 where there was no apparent expression of lumican at the molecular level when 50 
ng RNA were used in analysis (figure 6.5; A, C and D). Again the same increasing 
pattern of lumican expression was observed when samples were loaded for analysis 
based on GAG or protein concentrations. No primary antibody controls were run for 
the same tissue extracts and again showed the presence of non-specific binding at ~25 
kDa in grade III and IV degenerate discs (results not shown). Identical non-specific 
binding was also present in Western blot analysis of samples with LUM-1 mAb and 
are indicated in figure 6.5, C and D.
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Figure 6.5 Lumican expression at the molecular and proteomic level observed in non­
degenerate and pathological human intervertebral disc. Panel A shows PCR analysis of RNA 
extracts from non-degenerate and degenerate tissues using lumican specific primers (BCK 21 / 
22). Panel B shows GAPDH as a positive control using human GAPDH specific primers (1 / 
2). BC = bovine corneal tissue run as a positive control. Milli Q™ water was run as a negative 
control. Panel C shows levels of lumican protein from the same non-degenerate and degenerate 
IvD tissue samples in SDS PAGE and Western blot analysis using LUM-1 that had been 
loaded based on equal GAG concentrations. Panel D also shows lumican levels in Western blot 
analysis using LUM-1 where samples had been loaded based on equal protein levels.
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6.4.5 Keratocan mRNA and protein expression in normal and degenerate IvD
For the amplification of human IvD cDNA, total RNA was isolated from non­
degenerate discs from patients with scoliosis (n = 2, patient numbers: 25 and 26, see 
table 6.1) and pathological patient discs (n = 5, patient numbers: 4, 15, 16, 17 and 18, 
see table 6.1) samples as described in section 6.3.1 above. Low levels of keratocan 
expression were detected for all patients except patient number 18 with grade IV 
degeneration (figure 6.6; A) when 215 ng of RNA were used in RT-PCR analysis. 
Total RNA was collected from IvD tissues and limited concentrations were available 
for analysis. 215 ng was the highest concentration of RNA available for RT-PCR 
analysis using the keratocan primers, where 500 ng of RNA was available for 
keratocan detection by RT-PCR analysis in human articular cartilage analysis 
described above in section 6.4.3. Milli Q™ water was run as a negative control and 
bovine cornea RT-PCR was used as a positive control (figure 6.6; A). GAPDH RT- 
PCR analysis of all IvD samples was positive and consistent for all samples analysed 
(figure 6.6; B). Sequence analysis was carried out on samples from the GAPDH and 
keratocan RT-PCR reactions and results confirmed that the bands observed were 
human GAPDH and human keratocan.
Western blot analysis using mAb KER-1 demonstrated that keratocan core protein was 
present in non-degenerate and degenerate IvD tissues when samples were loaded based 
on equal GAG or equal protein concentrations (figure 6.6; C and D). Extracts from 
patient numbers 4 (grade III), 15 (grade IV) and 16 (grade IV) showed lower levels of 
keratocan at -30 kDa and higher levels of keratocan breakdown products at -13 kDa 
compared to other samples (figure 6.6; C and D). These patients (4, 15 and 16) also 
showed higher levels of non-specific binding of endogenous immunoglobulin at —25 
kDa (figure 6.6; C and D).
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Figure 6.6 Keratocan expression at the molecular (A) and proteomic (C and D) levels 
observed in non-degenerate and pathological human intervertebral disc. Panel A shows PCR 
analysis of RNA extracts from non-degenerate and degenerate tissues using keratocan specific 
primers (BCK 19 / 20). Panel B shows GAPDH as a positive control using human GAPDH 
specific primers (1 /2 ) .  Panel C shows levels of keratocan from the same non-degenerate and 
degenerate IvD tissue samples in SDS PAGE and Western blot analysis using KER-1 that had 
been loaded based on equal GAG concentrations. Panel D also shows keratocan levels in 
Western blot analysis using KER-1 where samples had been loaded based on equal protein 
levels.
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6.5 Discussion
The aim of the work described in this chapter was to analyse levels of the small leucine 
rich proteoglycans, lumican and keratocan, at the molecular and proteomic level in 
normal (hip fracture) and osteoarthritic human articular cartilage and non-degenerate 
(scoliosis patients) and differentially graded pathological human IvD tissues.
The expression of a range of SLRPs such as lumican, biglycan and fibromodulin have 
been demonstrated in cartilage at both the protein and molecular level in normal versus 
OA human articular cartilage (Cs-Szabo et a l, 1997). Strolovics et al, (1999 A) 
observed an increase in lumican in the annulus fibrosis and a decrease in fibromodulin 
in the nucleus pulposus at the protein level in ageing human IvD. Lumican, biglycan 
and fibromodulin have also been identified in normal ovine articular cartilage, with an 
increase in expression at the protein and mRNA levels observed in experimental OA 
models (Young et al, 2005 A). Keratocan has not previously been identified as a 
constituent of either normal or pathological human cartilage or intervertebral disc 
tissues.
In this chapter monoclonal antibodies, LUM-1 and KER-1, which were generated and 
characterised as described in chapter 4, were used in the analysis of lumican and 
keratocan protein levels in normal compared to OA human cartilage and in normal 
compared to pathological human IvD by SDS PAGE and Western blot analyses. RT- 
PCR analysis was also carried out on RNA extracts from the same samples where 
possible, using human/bovine keratocan and human/bovine lumican specific primers. 
Western blot and PCR analysis of tissue and total RNA extracts from normal and OA 
human articular cartilage have demonstrated an increased expression of keratocan at 
both proteomic and molecular levels in pathological cartilage. A number of smaller 
molecular weight breakdown products were observed for keratocan PGs in OA tissue 
compared to normal tissue. Similar analysis of differentially graded pathological IvD
B. Kerr PhD thesis 219
extracts showed that keratocan was expressed at the molecular level in low amounts in 
all grades of disc degeneration when 215 ng of RNA were used in RT-PCR analysis. 
Keratocan was also expressed at the proteomic level in all grades of disc degeneration 
but with a larger degree of proteolysis in grades III and IV degraded tissues compared 
to grades I and V. These grades (III and IV) also showed an increased presence of non­
specific binding of endogenous immunoglobulin. This molecule (keratocan) was 
previously thought to be largely ‘corneal specific’ (Carlson et al, 2005; Kawakita et 
al, 2005).
Lumican mRNA was also present in three of the normal articular cartilage samples 
with the same intensity as nine of the OA cartilage samples, but at a reduced intensity 
in two normal samples compared to the OA samples. Lumican was shown to increase 
dramatically at the protein level in osteoarthritic cartilage compared to all normal 
cartilage samples. This suggests that the increased lumican protein expression in OA 
compared to normal cartilage may be due to an increase in lumican translation or a 
decrease in lumican breakdown and not due to an increase in lumican RNA synthesis. 
Lumican mRNA was not expressed in normal human IvD tissues when 50 ng of RNA 
were used in analysis. Expression was greatly increased when the same concentration 
of RNA was analysed in pathological IvD tissues. Lumican protein levels were absent 
or extremely low in non-degenerate IvD extracts and protein expression was also 
dramatically increased in pathological tissue.
Analysis of undigested, keratanase, keratanase II and endo-p-galactosidase digested 
extracts of keratocan and lumican from both articular cartilage and IvD tissues 
demonstrated that in contrast to the keratocan and lumican found in corneal tissue the 
keratocan and lumican present here was substituted with small molecular weight 
(approximately 1 —4 kDa) low- or non-sulphated KS chains.
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The new mAbs (LUM-1 and KER-1) have proved to be useful tools in identification of 
low and increased levels of comeal associated KSPGs in irregular tissue locations with 
pathology. It is still not clear whether the increase in expression observed for these 
SLRPs is an attempt to repair damage caused by losses due to aggrecan degradation or 
whether it actually causes more damage to the tissue extracellular matrix structure. The 
observed up-regulation of lumican and keratocan synthesis in cartilage and IvD by 
chondrocytes and disc cells, along with other generally non-cartilage associated 
molecules, such as collagen I (Young et al., 2005 A), may reflect an attempt to 
compensate for the damage caused by aggrecan degradation or an attempt to produce 
the fibrocartilage scar tissue associated with OA and degenerative disc tissue.
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6.6 Chapter summary
RNA message for lumican is constitutively expressed in normal human and OA 
cartilage. However, lumican protein is increased in its expression with the 
onset of OA, a finding similar to that described by Cs-Szabo et al, 1997.
A novel finding was that RNA message for lumican is also expressed in human 
IvD tissues and this expression increases with the progression of disc 
pathology; i.e. expression patterns for lumican appear to be different with the 
onset of cartilage and disc degeneration. An additional novel finding was that 
lumican protein is also increased with the progression of IvD degeneration.
A novel finding was the induction of RNA expression for keratocan in normal 
versus OA cartilage. Thus, lumican and keratocan expression patterns differ in 
normal and OA cartilage.
In addition, keratocan expression at the protein level also occurs with the onset 
of degenerate joint disease.
A novel finding was that keratocan is also expressed at the RNA and protein 
levels in IvD tissues. RNA expression appears to increase with pathology but 
this may not be reflected at the protein level.
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Chapter 7 - General Discussion
In the early 1980s the challenge of connective tissue research was assisted with the 
emergence of a range of novel monoclonal antibodies recognising various matrix 
proteoglycans (Funderburgh et al, 1983; Hughes et al, 1995) and carbohydrate side 
chains present on proteoglycans (Christner et al, 1980; Conrad et al, 1982; Caterson 
et al, 1983; Couchman et a l, 1984; Caterson et al, 1985). Matrix molecules were 
emerging as being important structural and functional entities of connective tissues. 
The availability of antibodies allowed for the elucidation of the distribution and 
structures of these molecules and for a better understanding of pathological conditions 
associated with them as they could be used to analyse the structural and metabolic 
changes that occur during development, in ageing and with the onset of disease.
The Caterson laboratory was the first lab to generate monoclonal antibodies such as 
5D4 (Caterson et al, 1983) and 1B4 (Caterson et al, 1985), recognising linear 
sulphated poly-N-acetyl-lactosamine epitopes on KS. These mAbs have been shown to 
recognise subtle differences in sulphation patterns of the linear poly-N-acetyl- 
lactosamine epitopes that they recognise (Mehmet et al, 1986; Caterson et al, 1987). 
Mehmet et al, (1986) demonstrated that the epitopes recognised by 5D4 contain a 
minimum penta-sulphated hexasaccharide structure, whereas 1B4 recognised a 
minimum tetra-sulphated hexasaccharide. Caterson et al, (1987) demonstrated through 
the use of competitive radioimmunoassays that 5D4 epitope is equally represented on 
both skeletal and comeal KS, whilst there appeared to be seven times more IB4 epitope 
on comeal KS than on skeletal KS indicating that there were differences in sulphation 
patterns within these KS chains and that they could be investigated using antibodies 
such as these. Antibodies have also been generated to native CS (e.g. 6C3 and 7D4)
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and also to chondroitinase generated ‘CS stub’ neoepitopes (e.g. 2B6, 3B3, 1B5) that 
have been well characterised (Caterson et al, 1985; Caterson et al., 1990). Together 
these and other similar antibodies have helped to identify matrix molecules that have 
CS or KS side chain attachments in a wide range of tissues besides cartilage or cornea 
(Caterson et al, 1987; Sorrell et al, 1990; Shiozawa et al, 1991; Meyer-Puttlitz et al, 
1995; Fischer et al., 1996; Takagi et al, 1996; Hamanaka et al., 1997; Inkinen et al., 
1998; Akama et al., 2001; Papageorgakopoulou et al., 2002). They have also been 
important for the identification of subtle changes in sulphation patterns in different 
tissues (Sorrell et al., 1988; Sharif et al., 1996; Takagi et al., 1996; Inkinen et al., 
1998; Plaas et al., 1998; Bayliss et al., 1999; Young et al., 2005 B). In recent times, a 
large proportion of the analysis of KS structural composition has also been carried out 
using nuclear magnetic resonance (NMR) spectroscopy (Thornton et al., 1989; 
Nieduszynski et al., 1990; Brown et al., 1994 & 1998; Lauder et al., 1997; Huckerby 
etal., 1998 & 1999).
The aims of this study were to (i) develop and characterise a range of novel keratanase 
or keratanase II generated ‘KS stub’ monoclonal antibodies, (ii) to use any newly 
generated ‘KS stub’ mAbs in conjunction with existing anti KS mAbs such as 5D4 to 
analyse variations in KS types I and II sulphation patterns from the generally accepted 
opinion, (iii) to generate monoclonal antibodies to KS SLRPs such as lumican and 
keratocan, and then (iv) to investigate the expression of lumican and keratocan at the 
RNA and protein expression levels in musculoskeletal connective tissues.
Initially the investigation resulted in the production and characterisation of two novel 
keratanase generated ‘KS stub’ monoclonal antibodies (BKS-1 and BKS-2; see chapter
2). Characterisation of the new antibodies demonstrated that they showed specificity 
for the non-reducing terminal 6-sulphated-N-acetyl-glucosamine neoepitope, on both
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KS type I and KS type II (and presumably type KS III), generated as a direct result of 
keratanase digestion.
The novel anti 4KS stub’ mAh BKS-1, was used in conjunction with existing anti KS 
mAb 5D4 to facilitate a new approach to the analysis of subtle differences in 
sulphation patterns on KS derived from bovine cornea and nasal cartilage aggrecan 
after the application of different sequences of three KS degrading enzymes (see 
chapter 3). To date structural analysis of KS from a number of studies have found two 
essentially different sulphation patterns for KS type I and KS type II (see chapter 1, 
figures 1.2 - 1.4). Both comeal and skeletal KS are composed of repeating units of 
galactose and N-acetyl glucosamine disaccharide structures linked through an N- or O- 
linked oligosaccharide to the core protein, respectively. Oeben et al., (1987) have 
proposed that in comeal KS type I, di-sulphated N-acetyl-lactosamine disaccharides 
are concentrated towards the non-reducing terminal of the chain, with mono-sulphated 
N-acetyl-lactosamine disaccharides found in the mid regions and non-sulphated N- 
acetyl-lactosamine disaccharides at the linkage region of the chain. This reasoning was 
based on a combination of their analysis of the disaccharide composition of four 
peptidokeratan sulphate preparations from porcine cornea, and on their assumption that 
during KS biosynthesis, as chain elongation proceeded, an associated increase in 
sulphotransferase activity also occurred resulting in the addition of two sulphate 
groups per disaccharide [pi - 4(SC>3‘-6)GlcNAcpi - 3(SC>3'-6)Galpl] towards the non­
reducing end of the chain. For the same reason when the KS chain was shorter at the 
beginning of elongation, sulphotransferase activity was low and this resulted in either 
low-sulphated [pi - 4(S03'-6)G1cNAcP 1 - 3Gaipi] or non-sulphated [pi - 4GlcNAcpi 
- 3Galpl] regions being positioned closer to the linkage region. It is now somewhat 
clearer that KS chain elongation and sulphation takes place in two independent steps
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(see chapter 1, section 1.4.3.1; Seko & Yamashita, 2004). First the KS chain is 
extended through the action of a number of glycosyltransferases that add GlcNAc and 
Gal to the non-reducing end of the growing chain (Brew et al, 1968; Schanbacher & 
Ebner., 1970; Sasaki et a l , 1997; Ujita et a l, 1999; Zhou et al, 1999; Shiraishi et a l, 
2001). At the same time an N-acetylglucosamine sulphotransferase enzyme catalyses 
the addition of a sulphate group to C-6 of GlcNAc creating mono-sulphated 
disaccharides as the chain elongates (Uchimura et a l, 1998; Akama et a l, 2001). Once 
the mono-sulphated version of the KS chain is formed a Gal sulphotransferase enzyme 
catalyses the addition of sulphate groups to internal Gal residues within the KS chain 
(Fukuta et al, 1997). This suggests that the degree of sulphation does not rely on the 
chain length as suggested and may be regulated by something else.
Other studies (Stuhlsatz et al, 1989) have reported skeletal KS type II to have varying 
degrees of sulphation where KS from the KS domain of aggrecan was more highly 
sulphated ( 5 - 7  di-sulphated disaccharide repeats with 1 - 3  mono-sulphated 
disaccharide repeats) compared to KS from the CS I and II domains of aggrecan ( 1 - 4  
di-sulphated disaccharide repeats with larger [2 -  6] mono-sulphated disaccharide 
regions). Stuhlsatz et al, (1989) also postulated a KS type II structural pattern similar 
to that proposed for KS type I with non-sulphated disaccharide motifs concentrated at 
the linkage region, mono-sulphated disaccharide motifs at the mid regions and di- 
sulphated disaccharide motifs concentrated towards the non-reducing terminal of the 
chain. Skeletal KS has also been reported to be composed of predominantly 
disulphated disaccharide motifs with occasional monosulphated disaccharides in which 
the participating galactose is sulphated with very low or no non-sulphated disaccharide 
structures (Brown et al, 1994; Funderburgh, 2000 review).
A number of other studies (Dickenson et al, 1990; Block et al, 1992; Huckerby et al, 
1998) have identified anomalies to the generic structure described for KS. In 1998
B. Kerr PhD thesis 2005 226
Huckerby et a l , analysed endo-P-galactosidase derived bovine comeal KS type I 
oligosaccharides using LH-NMR spectroscopy. They reported evidence for unsulphated 
N-acetylglucosamine residues within the “sulphated” region of the KS type I chain 
indicating that non-sulphated disaccharides were located at regions other than being 
concentrated towards the linkage region of the chain as previously postulated for 
porcine comeal KS type I by Oeben et al, (1987). Also, bovine IvD KS type II has 
been shown to contain a 6-S-GlcNAc residue attached directly to the linkage region 
GalNAc (Dickenson et al, 1990) where Oeben et al, (1987) and Stuhlsatz et al, 
(1989) had predicted only non-sulphated disaccharide domains to be. The results 
obtained in chapter 3 using mAbs 5D4 and BKS-1 to analyse KS sulphation patterns in 
bovine comeal and bovine nasal cartilage aggrecan KS support these observations. 
Both KS types I and II showed a partial insensitivity to keratanase digestion which was 
supported by the appearance of a large 5D4 positive smear (only mildly reduced in 
comparison to undigested samples) in Western blot analysis of keratanase digested 
samples. The results indicated that there were variations in sulphation patterns within 
KS chains as keratanase is known to cleave at monosulphated disaccharides where 
GlcNAc is sulphated and Gal is unsulphated. The results demonstrated that, after 
keratanase digestion, there were regions that remained attached towards the reducing 
terminal that were keratanase resistant with over sulphated (recognised by 5D4) and 
non-sulphated domains (figure 7.1). By using bovine nasal cartilage aggrecan as a 
source of KS type II, that has been shown to be devoid of fucose attachments 
compared to articular cartilage aggrecan KS type IIA (Nieduszynski et al, 1990 B), 
the presence of regions of mono-sulphated fucosylated disaccharides that would be 
resistant to keratanase digestion (Tai et al, 1993) could be mled out. The results were 
supported by analysis of further digestion using endo-p-galactosidase, which
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Figure 7.1 Heterogeneity in the sulphation patterns of KS with non-, mono- or di-sulphated 
domains occurring attached directly to the linkage region.
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successfully removed any remaining undersulphated motifs present towards the 
linkage region, and failed to remove the 5D4 staining, and finally using keratanase II 
digestion, which successfully removed any remaining di-sulphated motifs (present 
attached directly to the linkage region) and all 5D4 reactivity. The fact that there was 
BKS-1 immunoreactivity remaining after all three enzyme digests indicated that there 
had also initially been a KS population that had a region of mono-sulphated 
disaccharides concentrated at the linkage region of the chain that allowed the complete 
removal of those particular KS chains. This is in agreement with results reported by 
Dickenson et al, (1990) and Brown et al., (1994), who demonstrated the presence of 
6-S-GlcNAc (the BKS-1 neoepitope) attached directly to the linkage region of KS type 
II. Further digestion using keratanase II or endo-p-galactosidase was not able to 
remove the BKS-1 neoepitopes present here as there were no further non- or di- 
sulphated disaccharides between this mono-sulphated region and the linkage region.
It has previously been reported that KS from within different regions of a single 
aggrecan molecule can show a large degree of heterogeneity in hydrodynamic size, 
charge density (Block et al, 1992) and in sulphation levels (Stuhlsatz et al, 1989). 
The KS heterogeneity observed in chapter 3 may be due to the fact that intact aggrecan 
was used to analyse KS type II and a range of KSPG molecules (a lumican / keratocan 
/ mimecan mixture) were used to analyse KS I sulphation patterns. Analysis of KS 
from within different peptide fragments of purified aggrecan (i.e. the KS, CS I and CS 
II domains) or from purified lumican, keratocan or mimecan, would help to determine 
if particular populations of KS (e.g. figure 7.1) exist on specific regions of aggrecan or 
on particular KSPGs that specifically have non-, mono- or di-sulphated disaccharide 
domain patterns attached directly to the linkage region of the KS chains.
An increase of KS GAG substitutions compared to CS substitutions on the KS, CS I 
and CS II domains of cartilage aggrecan with age has been well documented (Mourao
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etal., 1976; Heinegard & Axelsson, 1977; Thonar & Sweet, 1981; Inerot & Heinegard, 
1983; Thonar et al, 1986; Bayliss, 1990; Barry et al., 1995; Pratta et al, 2000). 
However the exact sites of KS substitution along these regions are less well defined by 
consensus sequence assignment. The new ‘KS stub’ mAbs (BKS-1 or BKS-2) 
generated and characterised as described in chapter 2, could be used in the future for 
analysis of purified aggrecan A1D1 from bovine articular cartilage of different aged 
animals (foetal, newborn, lyr, 2yr and 7yr old), to determine sites of KS substitution 
which remain common or change during development and ageing. To allow for 
identification of the sites of KS substitution, trypsin digested aggrecan could be 
separated into KS, CS/KS and CS rich fragments using anion exchange and size 
exclusion chromatography. After deglycosylation using keratanase and chondroitinase 
ABC, mAb affinity purification of fragments containing KS and CS ‘stubs’ identified 
by SDS PAGE and Western blotting, samples could be subjected to N-terminal amino 
acid sequencing to identify the site for attachment of KS chains on PG core proteins. 
Competitive ELIS As can be set up using mAb BKS-1 in conjunction with anti CS 
‘stub’ mAbs to quantify changes in KS and CS substitutions on aggrecan identified 
with ageing.
Attempts to also produce an antibody to a non-reducing terminal 6-sulphated-galactose 
or an unsulphated galactose neoepitope, generated as a result of keratanase II digestion 
of KS chains, resulted in the production of two such novel monoclonal antibodies. The 
hybridoma cell lines failed to maintain production of keratanase II-generated ‘KS stub’ 
epitope mAbs. However, the work demonstrated that it was possible to generate such 
mAbs; i.e. proof of principle.
As a by-product of the attempts to generate the keratanase II ‘KS stub’ mAbs, two 
monoclonal antibodies to SLRPs lumican and keratocan were generated. The new 
mAbs (LUM-1 and KER-1) have proved to be useful tools in identification of low and
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increased levels of corneal associated KSPGs in musculoskeletal tissue locations with 
pathology (chapter 6). It is still not clear whether the increase in expression observed 
for these SLRPs is an attempt to repair damage caused by losses due to aggrecan 
degradation or whether it actually causes more damage to the matrix structure. The 
observed up-regulation of lumican and keratocan synthesis in cartilage and IvD by 
chondrocytes and IvD cells, along with other generally non-cartilage associated 
molecules, such as collagen I (Young et al, 2005 A), may reflect an attempt to repair 
the cartilage damage caused by the proteolytic degradation of aggrecan due to the 
action of MMPs and aggrecanases or an attempt to produce the fibrocartilage scar 
tissue associated with OA.
In the cornea, lumican containing the non-sulphated polylactosamine form of KS, 
similar to the form that has been identified in chapter 6 as being present in pathological 
cartilage and IvD, has been shown to be involved in the infiltration of macrophages in 
comeal wounds through interaction with lumican receptors (Funderburgh et al, 1997 
B). Molecules such as lumican have also been implicated in regulating comeal wound 
healing and inflammatory responses (Yeh et al, 2005; Vij et al, 2005 A; Chakravarti 
et al, 2005; Kao et al, 2005). Lumican knockout models have demonstrated its 
importance as an up-regulator of Fas-Fas Ligand (FasL) signalling and induction of 
pro-inflammatory cytokines in comeal inflammatory responses during wound healing 
(Vij et al, 2005 A & 2005 B; Chakravarti et al, 2005). Lumican is thought to have a 
role in binding FasL and in presenting it to Fas or to stabilise the Fas-FasL complex 
and help mediate signalling (Vij et al, 2005 B). The Fas-FasL signalling pathway has 
been implicated in many inflammatory diseases including osteoarthritis and 
rheumatoid arthritis. Fas-FasL has been shown to have two major functions. Firstly it 
activates apoptotic pathways to regulate cell turnover and maintain a balance between 
synthesis and degradation. OA tenocytes have been shown to undergo spontaneous
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apoptosis and to be much more susceptible to the higher levels of FasL than tenocytes 
from normal tissues (Machner et al, 2003). It has also been shown to have pro- 
inflammatory functions through its chemotactic properties towards neutrophilic 
polymorphonuclear (PMNs) leukocytes. Very low levels of Fas-FasL have been shown 
to attract large numbers of inflammatory cells into the tissue (Ottonello et al., 1999; 
O’Connell, 2001). They induce the infiltrated neutrophils and other cells to produce 
cytokines such as IL-1 p, which is a neutrophil chemotactant itself, thus amplifying the 
infiltration process and maintaining inflammatory responses. Infiltration of PMNs in 
comeal healing after epithelium debridement has been shown to be slowed from 24 
hours in wild type mouse models to 48 hours in lumican knock out models and 
induction of inflammatory cytokines was reduced in lumican -/- models indicating 
lumican as an important modulator of the inflammatory response in comeal wound 
healing (Chakravarti et al, 2005; Kao et al., 2005).
In cartilage, pro-inflammatory cytokines such as IL-1, which are produced by 
inflammatory cells that have been attracted through the Fas-FasL signalling pathway, 
have been shown to be primarily responsible for inducing protease synthesis such as 
matrix metalloproteinases (MMPs) and aggrecanases, and subsequent cartilage matrix 
catabolism associated with OA. Therefore the up-regulation of non- or low-sulphated 
forms of lumican in arthritic diseases may directly contribute to the production of the 
cytokines and proteases responsible for cartilage degradation.
Lumican has also recently been shown to regulate keratocan gene expression in the 
mouse cornea (Carlson et al., 2005). Over expression of lumican resulted in an 
increased expression of keratocan at both the protein and mRNA levels. Analysis of 
lumican knockout models also demonstrated a decreased expression of keratocan 
compared to wild type mice (Carlson et al., 2005). These results demonstrated that 
lumican regulates keratocan expression at the transcriptional level. Perhaps this
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regulatory transcriptional role is also active in articular cartilage and the increased 
expression of lumican with pathology results in a comparable increase in keratocan 
expression.
The work carried out as part of this thesis has resulted in the generation of a range of 
useful monoclonal antibodies recognising novel KS ‘stub’ neoepitopes and lumican 
and keratocan core protein epitopes. They have proved to be important tools in the 
elucidation of the structural variations and the distribution of various matrix molecules 
in different connective tissues. Collectively, the data in this thesis provides new and 
confirmatory information regarding the heterogeneous nature of KS sulphation motif 
structure and new information about lumican and keratocan expression at the 
molecular and proteomic levels in musculoskeletal tissue. The generic structure for KS 
has been challenged and is proposed to be composed of a range of KS chain structures 
that are more heterogeneous in nature, even from within the same tissue, than 
previously thought (Oeben et al, 1987; Stuhlsatz et al, 1989). The work also suggests 
that the expression of the small leucine rich PGs, lumican and keratocan, may be 
useful biomarkers to detect cellular changes in metabolism that lead to the onset of 
degenerative joint disease.
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Appendices 
Appendix A -  List of suppliers
Supplier Materials/Equipment
Amersham Pharmacia 
Biotech, St Albans, Herts, 
UK.
UltroSpec2000 spectrophotometer; Akta explorer
Anachem Ltd. Luton, UK 0.5ml & 1.5ml eppendorf tubes
Applied Biosystems, 
Perkin-Elmer UK, 
Warrington, UK
MgCk; Gene Amp dNTPs; Gene Amp lOx PCR 
buffer; RNase inhibitor; MuLV reverse transcriptase; 
big dye terminator v 1.1 cycle sequence kit
Becton Dickenson 16 & 27.5 gauge needles
Bio-Rad Laboratories, 
Hemel Hemsted, UK
Transfer tanks; power packs; molecular weight 
protein standards
Cambio, Cambridge, UK DNA ladder (lkb); 6x tracking dye; ethidium bromide
Coming Costar Ltd., High 
Wycombe, UK
Tissue culture plastic
Elkay, UK 96 well flat bottom EIA microtitre plates
Fisher Scientific, 
Loughborough, UK
Urea; acetic acid; hydrochloric acid; sodium 
hydroxide; methanol; ethanol
Gibco Brl (now invitrogen) RPMI 1640 media; fetal bovine serum (FBS); PBS 
Dulbecco’s; L-glutamine; penicillin streptomycin, 
fungizone (PSF) & hypoxanthine (100 pM), 
aminopterin (0.4 pm), thymidine (1.6 pm) [HAT]; 
Freunds complete adjuvant & Freunds incomplete 
adjuvant
Invitrogen Pre-cast 4 - 12% and 4 - 20% Tris glycine gradient 
gels; Oligonucleotides; electrophoresis tanks
Millipore Ltd., Watford, 
UK
0.22 pM filters; milli Q Plus 185 unit; Milli RO unit;
MP Biomedical Keratanase; keratanase II; endo-p-galactosidase; Agarose 
(genetic technology grade)
National Diagnostics, 
Hessle, UK
Acrylagel and bisacrylagel
Pierce Bicinchoninic Acid (BCA) protein assay reagent kit
Promega Corporation, 
Southampton, UK
Anti-mouse IgG (H+L) alkaline phosphatase 
conjugated secondary antibody; NBT: nitro blue 
tetrazolium; BCIP: 5 -bromo-4-chloro-3 - 
indoylphosphate; Taq DNA polymerase
Qiagen Ltd., Crawley,UK RNeasy mini kit; QIA quick PCR purification kit; 
RNase free DNase set
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Roche Diagnostics Ltd., 
Lewes, UK
Digoxigenin (DIG) glycan differentiation kit
Schleicher & Schuell 
Bioscience
0.22 pm Protran BA 83 nitrocellulose membrane
Sigma- Aldrich Ltd., 
Poole, UK
General laboratory chemicals; Tri-reagent; EDGLY 
protein deglycosylation kit; Chondroitin sulphate C, 
sodium salt from shark cartilage; L-(tosylamido-2- 
phenyl) ethyl chloromethyl ketone (TPCK) treated 
trypsin; Chondroitinase ABC; Polyethylene glycol (mw 
3,000 -  3,700); dimethyl sulphoxide (DMSO); p- 
mercaptoethanol
Spectrum Laboratories, 
Rancho Dominguez, CA, 
USA
Spectra/Por dialysis membrane
Techne, Burlington, NJ, 
USA
Technegene thermal cycler
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Meek K.M., Caterson B. & Quantock A.J. (2005) Atypical composition and 
ultrastructure of proteoglycans in the mouse comeal stroma. Investigative 
Ophthalmology and Vision Science. 46(6): 1973-1978.
• Grau S., Richards P.J., K err B.C., Hughes C., Caterson B., Williams A.S., 
Junker U., Jones S.A., Clausen T., Ehrmann M. (2005) The role of human 
HtrAl in arthritic disease. Journal o f Biological Chemistry. Dec 22
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University of Manchester, UK.
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